THE 2002 OFFICIAL PATIENT’S SOURCEBOOK
on
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright Ó2002 by ICON Group International, Inc. Copyright Ó2002 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Tiffany LaRochelle Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended as a substitute for consultation with your physician. All matters regarding your health require medical supervision. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation, in close consultation with a qualified physician. The reader is advised to always check product information (package inserts) for changes and new information regarding dose and contraindications before taking any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960The 2002 Official Patient’s Sourcebook on Myopia: Revised and Updated for the Internet Age/James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary and index. ISBN: 0-597-83244-7 1. Myopia-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem or as a substitute for consultation with licensed medical professionals. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors or authors. ICON Group International, Inc., the editors, or the authors are not responsible for the content of any Web pages nor publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this sourcebook for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications are copyrighted. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs or other materials, please contact us to request permission (e-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this sourcebook.
iv
Dedication To the healthcare professionals dedicating their time and efforts to the study of myopia.
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this sourcebook which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which directly or indirectly are dedicated to myopia. All of the Official Patient’s Sourcebooks draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this sourcebook. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany LaRochelle for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for the Official Patient’s Sourcebook series published by ICON Health Publications.
Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for the Official Patient’s Sourcebook series published by ICON Health Publications.
vi
About ICON Health Publications In addition to myopia, Official Patient’s Sourcebooks are available for the following related topics: ·
The Official Patient's Sourcebook on Age-related Macular Degeneration
·
The Official Patient's Sourcebook on Astigmatism
·
The Official Patient's Sourcebook on Blepharitis
·
The Official Patient's Sourcebook on Cataract Surgery
·
The Official Patient's Sourcebook on Cataracts
·
The Official Patient's Sourcebook on Conjunctivitis
·
The Official Patient's Sourcebook on Corneal Transplant Surgery
·
The Official Patient's Sourcebook on Diabetic Retinopathy
·
The Official Patient's Sourcebook on Dry Eye
·
The Official Patient's Sourcebook on Fuchs' Dystrophy
·
The Official Patient's Sourcebook on Glaucoma
·
The Official Patient's Sourcebook on Hyperopia
·
The Official Patient's Sourcebook on Iridocorneal Endothelial Syndrome
·
The Official Patient's Sourcebook on Keratitis
·
The Official Patient's Sourcebook on Keratoconus
·
The Official Patient's Sourcebook on Lasik Surgery
·
The Official Patient's Sourcebook on Lattice Dystrophy
·
The Official Patient's Sourcebook on Macular Holes
·
The Official Patient's Sourcebook on Map-dot-fingerprint Dystrophy
·
The Official Patient's Sourcebook on Ocular Herpes
·
The Official Patient's Sourcebook on Ocular Histoplasmosis Syndrome
·
The Official Patient's Sourcebook on Presbyopia
·
The Official Patient's Sourcebook on Pterygium
·
The Official Patient's Sourcebook on Retinal Detachment
To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
Contents vii
Table of Contents INTRODUCTION ................................................................................................................. 1 Overview ................................................................................................................................. 1 Organization ......................................................................................................................... 3 Scope .......................................................................................................................................... 3 Moving Forward................................................................................................................. 4
PART I: THE ESSENTIALS ..................................................................... 7 CHAPTER 1. THE ESSENTIALS ON MYOPIA: GUIDELINES ........ 9 Overview ................................................................................................................................. 9 What Is the Cornea? ....................................................................................................... 11 What Is the Function of the Cornea? ................................................................... 13 What Are Refractive Errors? .................................................................................... 13 What Is Myopia? .............................................................................................................. 14 How Is Myopia Treated? ............................................................................................. 14 What Is LASIK? ............................................................................................................... 15 When Is LASIK Not for Me? .................................................................................... 17 What Are the Risks and How to Find the Right Doctor? ........................ 19 Additional Risks ............................................................................................................... 20 Finding the Right Doctor ............................................................................................ 22 What Should I Expect before, during, and after Surgery? ...................... 23 LASIK Surgery Checklist ............................................................................................ 27 FDA-Approved Lasers for LASIK.......................................................................... 30 FDA-Approved Lasers for PRK and Other Refractive Surgeries ....... 31 Other Resources ................................................................................................................ 32 More Guideline Sources ............................................................................................... 34 Vocabulary Builder ......................................................................................................... 37
CHAPTER 2. SEEKING GUIDANCE ................................................................. 41
Overview ............................................................................................................................... 41 Associations and Myopia ............................................................................................ 41 Finding More Associations ........................................................................................ 43 Finding an Eye Care Professional .......................................................................... 45 Selecting Your Doctor ................................................................................................... 47 Working with Your Doctor ........................................................................................ 47 Broader Health-Related Resources......................................................................... 49 Vocabulary Builder ......................................................................................................... 49
CHAPTER 3. CLINICAL TRIALS AND MYOPIA .................................... 51
viii Contents
Overview ............................................................................................................................... 51 Recent Trials on Myopia ............................................................................................. 54 Benefits and Risks ............................................................................................................ 57 Keeping Current on Clinical Trials ...................................................................... 60 General References .......................................................................................................... 61 Vocabulary Builder ......................................................................................................... 62
PART II: ADDITIONAL RESOURCES AND ADVANCED MATERIAL ....................................................................... 63 CHAPTER 4. STUDIES ON MYOPIA ................................................................ 65 Overview ............................................................................................................................... 65 The Combined Health Information Database .................................................. 65 Federally-Funded Research on Myopia............................................................... 66 The National Library of Medicine: PubMed .................................................... 80 Vocabulary Builder ......................................................................................................... 90
CHAPTER 5. PATENTS ON MYOPIA .............................................................. 95 Overview ............................................................................................................................... 95 Patents on Myopia .......................................................................................................... 96 Patent Applications on Myopia............................................................................. 108 Keeping Current ............................................................................................................. 108 Vocabulary Builder ....................................................................................................... 109
CHAPTER 6. BOOKS ON MYOPIA .................................................................. 111 Overview ............................................................................................................................. 111 The National Library of Medicine Book Index.............................................. 111 Chapters on Myopia ..................................................................................................... 115 General Home References .......................................................................................... 117 Vocabulary Builder ....................................................................................................... 118
CHAPTER 7. MULTIMEDIA ON MYOPIA................................................. 121 Overview ............................................................................................................................. 121 Bibliography: Multimedia on Myopia ............................................................... 121
CHAPTER 8. PHYSICIAN GUIDELINES AND DATABASES ....... 125 Overview ............................................................................................................................. 125 NIH Guidelines ............................................................................................................... 125 NIH Databases ................................................................................................................ 126 Other Commercial Databases ................................................................................. 129 The Genome Project and Myopia ......................................................................... 130 Specialized References ................................................................................................. 135
Contents
ix
Vocabulary Builder ....................................................................................................... 137
CHAPTER 9. DISSERTATIONS ON MYOPIA........................................... 139 Overview ............................................................................................................................. 139 Dissertations on Myopia ........................................................................................... 139 Keeping Current ............................................................................................................. 141
PART III. APPENDICES .......................................................................... 143 APPENDIX A. RESEARCHING YOUR MEDICATIONS .................. 145 Overview ............................................................................................................................. 145 Your Medications: The Basics ................................................................................ 145 Learning More about Your Medications.......................................................... 147 Commercial Databases ................................................................................................ 148 Contraindications and Interactions (Hidden Dangers) .......................... 150 A Final Warning ............................................................................................................ 150 General References ........................................................................................................ 151 Vocabulary Builder ....................................................................................................... 152
APPENDIX B. RESEARCHING ALTERNATIVE MEDICINE ........ 153
Overview ............................................................................................................................. 153 What Is CAM? ................................................................................................................ 153 What Are the Domains of Alternative Medicine?...................................... 154 Can Alternatives Affect My Treatment? ......................................................... 157 Finding CAM References on Myopia ................................................................ 158 Additional Web Resources ........................................................................................ 167 General References ........................................................................................................ 169
APPENDIX C. RESEARCHING NUTRITION ........................................... 173 Overview ............................................................................................................................. 173 Food and Nutrition: General Principles ........................................................... 173 Finding Studies on Myopia ..................................................................................... 178 Federal Resources on Nutrition............................................................................. 182 Additional Web Resources ........................................................................................ 182 Vocabulary Builder ....................................................................................................... 184
APPENDIX D. FINDING MEDICAL LIBRARIES ................................... 187
Overview ............................................................................................................................. 187 Preparation ........................................................................................................................ 187 Finding a Local Medical Library .......................................................................... 188 Medical Libraries Open to the Public ................................................................ 188
APPENDIX E. YOUR RIGHTS AND INSURANCE ............................... 195
x
Contents
Overview ............................................................................................................................. 195 Your Rights as a Patient ............................................................................................ 195 Patient Responsibilities .............................................................................................. 199 Choosing an Insurance Plan ................................................................................... 200 Medicare and Medicaid .............................................................................................. 202 Financial Aid for Eye Care ....................................................................................... 205 NORD’s Medication Assistance Programs ................................................... 207 Additional Resources ................................................................................................... 207
ONLINE GLOSSARIES............................................................................. 209 Online Dictionary Directories ............................................................................... 210
MYOPIA GLOSSARY .................................................................................. 213 General Dictionaries and Glossaries .................................................................. 223
INDEX ................................................................................................................................... 225
Introduction
1
INTRODUCTION Overview Dr. C. Everett Koop, former U.S. Surgeon General, once said, “The best prescription is knowledge.”1 The Agency for Healthcare Research and Quality (AHRQ) of the National Institutes of Health (NIH) echoes this view and recommends that every patient incorporate education into the treatment process. According to the AHRQ: Finding out more about your condition is a good place to start. By contacting groups that support your condition, visiting your local library, and searching on the Internet, you can find good information to help guide your treatment decisions. Some information may be hard to find—especially if you don't know where to look.2 As the AHRQ mentions, finding the right information is not an obvious task. Though many physicians and public officials had thought that the emergence of the Internet would do much to assist patients in obtaining reliable information, in March 2001 the National Institutes of Health issued the following warning: The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading.3
Quotation from http://www.drkoop.com. The Agency for Healthcare Research and Quality (AHRQ): http://www.ahcpr.gov/consumer/diaginfo.htm. 3 From the NIH, National Cancer Institute (NCI): http://cancertrials.nci.nih.gov/beyond/evaluating.html. 1 2
2
Myopia
Since the late 1990s, physicians have seen a general increase in patient Internet usage rates. Patients frequently enter their doctor's offices with printed Web pages of home remedies in the guise of latest medical research. This scenario is so common that doctors often spend more time dispelling misleading information than guiding patients through sound therapies. The Official Patient’s Sourcebook on Myopia has been created for patients who have decided to make education and research an integral part of the treatment process. The pages that follow will tell you where and how to look for information covering virtually all topics related to myopia, from the essentials to the most advanced areas of research. The title of this book includes the word “official.” This reflects the fact that the sourcebook draws from public, academic, government, and peerreviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on myopia. Given patients’ increasing sophistication in using the Internet, abundant references to reliable Internet-based resources are provided throughout this sourcebook. Where possible, guidance is provided on how to obtain free-ofcharge, primary research results as well as more detailed information via the Internet. E-book and electronic versions of this sourcebook are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). Hard copy users of this sourcebook can type cited Web addresses directly into their browsers to obtain access to the corresponding sites. Since we are working with ICON Health Publications, hard copy Sourcebooks are frequently updated and printed on demand to ensure that the information provided is current. In addition to extensive references accessible via the Internet, every chapter presents a “Vocabulary Builder.” Many health guides offer glossaries of technical or uncommon terms in an appendix. In editing this sourcebook, we have decided to place a smaller glossary within each chapter that covers terms used in that chapter. Given the technical nature of some chapters, you may need to revisit many sections. Building one’s vocabulary of medical terms in such a gradual manner has been shown to improve the learning process. We must emphasize that no sourcebook on myopia should affirm that a specific diagnostic procedure or treatment discussed in a research study, patent, or doctoral dissertation is “correct” or your best option. This sourcebook is no exception. Each patient is unique. Deciding on appropriate
Introduction
3
options is always up to the patient in consultation with their physician and healthcare providers.
Organization This sourcebook is organized into three parts. Part I explores basic techniques to researching myopia (e.g. finding guidelines on diagnosis, treatments, and prognosis), followed by a number of topics, including information on how to get in touch with organizations, associations, or other patient networks dedicated to myopia. It also gives you sources of information that can help you find a doctor in your local area specializing in treating myopia. Collectively, the material presented in Part I is a complete primer on basic research topics for patients with myopia. Part II moves on to advanced research dedicated to myopia. Part II is intended for those willing to invest many hours of hard work and study. It is here that we direct you to the latest scientific and applied research on myopia. When possible, contact names, links via the Internet, and summaries are provided. It is in Part II where the vocabulary process becomes important as authors publishing advanced research frequently use highly specialized language. In general, every attempt is made to recommend “freeto-use” options. Part III provides appendices of useful background reading for all patients with myopia or related disorders. The appendices are dedicated to more pragmatic issues faced by many patients with myopia. Accessing materials via medical libraries may be the only option for some readers, so a guide is provided for finding local medical libraries which are open to the public. Part III, therefore, focuses on advice that goes beyond the biological and scientific issues facing patients with myopia.
Scope While this sourcebook covers myopia, your doctor, research publications, and specialists may refer to your condition using a variety of terms. Therefore, you should understand that myopia is often considered a synonym or a condition closely related to the following: ·
Nearsightedness
·
Shortsightedness
4
Myopia
In addition to synonyms and related conditions, physicians may refer to myopia using certain coding systems. The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) is the most commonly used system of classification for the world's illnesses. Your physician may use this coding system as an administrative or tracking tool. The following classification is commonly used for myopia:4 ·
360.21 progressive high (degenerative) myopia
·
367.1 myopia
For the purposes of this sourcebook, we have attempted to be as inclusive as possible, looking for official information for all of the synonyms relevant to myopia. You may find it useful to refer to synonyms when accessing databases or interacting with healthcare professionals and medical librarians.
Moving Forward Since the 1980s, the world has seen a proliferation of healthcare guides covering most illnesses. Some are written by patients or their family members. These generally take a layperson's approach to understanding and coping with an illness or disorder. They can be uplifting, encouraging, and highly supportive. Other guides are authored by physicians or other healthcare providers who have a more clinical outlook. Each of these two styles of guide has its purpose and can be quite useful. As editors, we have chosen a third route. We have chosen to expose you to as many sources of official and peer-reviewed information as practical, for the purpose of educating you about basic and advanced knowledge as recognized by medical science today. You can think of this sourcebook as your personal Internet age reference librarian. Why “Internet age”? All too often, patients diagnosed with myopia will log on to the Internet, type words into a search engine, and receive several Web site listings which are mostly irrelevant or redundant. These patients are left to wonder where the relevant information is, and how to obtain it. Since only the smallest fraction of information dealing with myopia is even indexed in 4 This list is based on the official version of the World Health Organization's 9th Revision, International Classification of Diseases (ICD-9). According to the National Technical Information Service, “ICD-9CM extensions, interpretations, modifications, addenda, or errata other than those approved by the U.S. Public Health Service and the Health Care Financing Administration are not to be considered official and should not be utilized. Continuous maintenance of the ICD-9-CM is the responsibility of the federal government.”
Introduction
5
search engines, a non-systematic approach often leads to frustration and disappointment. With this sourcebook, we hope to direct you to the information you need that you would not likely find using popular Web directories. Beyond Web listings, in many cases we will reproduce brief summaries or abstracts of available reference materials. These abstracts often contain distilled information on topics of discussion. While we focus on the more scientific aspects of myopia, there is, of course, the emotional side to consider. Later in the sourcebook, we provide a chapter dedicated to helping you find peer groups and associations that can provide additional support beyond research produced by medical science. We hope that the choices we have made give you the most options available in moving forward. In this way, we wish you the best in your efforts to incorporate this educational approach into your treatment plan. The Editors
7
PART I: THE ESSENTIALS
ABOUT PART I Part I has been edited to give you access to what we feel are “the essentials” on myopia. The essentials of a disease typically include the definition or description of the disease, a discussion of who it affects, the signs or symptoms associated with the disease, tests or diagnostic procedures that might be specific to the disease, and treatments for the disease. Your doctor or healthcare provider may have already explained the essentials of myopia to you or even given you a pamphlet or brochure describing myopia. Now you are searching for more in-depth information. As editors, we have decided, nevertheless, to include a discussion on where to find essential information that can complement what your doctor has already told you. In this section we recommend a process, not a particular Web site or reference book. The process ensures that, as you search the Web, you gain background information in such a way as to maximize your understanding.
Guidelines
9
CHAPTER 1. THE ESSENTIALS ON MYOPIA: GUIDELINES Overview Official agencies, as well as federally-funded institutions supported by national grants, frequently publish a variety of guidelines on myopia. These are typically called “Fact Sheets” or “Guidelines.” They can take the form of a brochure, information kit, pamphlet, or flyer. Often they are only a few pages in length. The great advantage of guidelines over other sources is that they are often written with the patient in mind. Since new guidelines on myopia can appear at any moment and be published by a number of sources, the best approach to finding guidelines is to systematically scan the Internetbased services that post them.
The National Institutes of Health (NIH)5 The National Institutes of Health (NIH) is the first place to search for relatively current patient guidelines and fact sheets on myopia. Originally founded in 1887, the NIH is one of the world's foremost medical research centers and the federal focal point for medical research in the United States. At any given time, the NIH supports some 35,000 research grants at universities, medical schools, and other research and training institutions, both nationally and internationally. The rosters of those who have conducted research or who have received NIH support over the years include the world's most illustrious scientists and physicians. Among them are 97 scientists who have won the Nobel Prize for achievement in medicine.
5
Adapted from the NIH: http://www.nih.gov/about/NIHoverview.html.
10 Myopia
There is no guarantee that any one Institute will have a guideline on a specific disease, though the National Institutes of Health collectively publish over 600 guidelines for both common and rare diseases. The best way to access NIH guidelines is via the Internet. Although the NIH is organized into many different Institutes and Offices, the following is a list of key Web sites where you are most likely to find NIH clinical guidelines and publications dealing with myopia and associated conditions: ·
Office of the Director (OD); guidelines consolidated across agencies available at http://www.nih.gov/health/consumer/conkey.htm
·
National Eye Institute (NEI); guidelines available at http://www.nei.nih.gov/publications/publications.htm
·
National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines available at http://www.nlm.nih.gov/medlineplus/healthtopics.html
Among those listed above, the National Eye Institute is especially noteworthy. Established by Congress in 1968 to protect and prolong the vision of the American people, the National Eye Institute (NEI), one of the Federal government's National Institutes of Health (NIH), conducts and supports research that helps prevent and treat eye diseases and other disorders of vision.6 Vision research is supported by the NEI through approximately 1600 research grants and training awards made to scientists at more than 250 medical centers, hospitals, universities, and other institutions across the country and around the world. The NEI also conducts laboratory and patient-oriented research at its own facilities located on the NIH campus in Bethesda, Maryland. This research leads to sight-saving treatments, reduces visual impairment and blindness, and improves the quality of life for people of all ages. NEI-supported research has advanced our knowledge of how the eye functions in health and disease. Another part of the NEI mission is to conduct public and professional education programs that help prevent blindness, reduce visual impairment, and increase awareness of services and devices that are available for people with low vision. Throughout the sourcebook, some of the text has been “adapted” from various official or governmental sources. Adapted signifies “reproduced” or “reproduced with minor editorial adjustments.” This paragraph has been adapted from the NEI: http://www.nei.nih.gov/about/mission.htm; the NEI has also established the National Eye Health Education Program (NEHEP), a partnership of about 60 professional, civic, and voluntary organizations and government agencies concerned with eye health. The program represents a natural extension of the NEI's support of vision research -- a final step in the research continuum, where results are disseminated to health professionals, patients, and the public. Other NEI public education activities include a traveling exhibit, which have been viewed by more than 3.8 million people nationwide; and a school curriculum on vision for grades 4-8. 6
Guidelines 11
The National Institutes of Health has recently published the following guideline for myopia:
What Is the Cornea?7 The cornea is the eye's outermost layer. It is the clear, dome-shaped surface that covers the front of the eye. Although the cornea is clear and seems to lack substance, it is actually a highly organized group of cells and proteins. Unlike most tissues in the body, the cornea contains no blood vessels to nourish or protect it against infection. Instead, the cornea receives its nourishment from the tears and aqueous humor that fills the chamber behind it. The cornea must remain transparent to refract light properly, and the presence of even the tiniest blood vessels can interfere with this process. To see well, all layers of the cornea must be free of any cloudy or opaque areas.
The corneal tissue is arranged in five basic layers, each having an important function. These five layers are: ·
Epithelium - The epithelium is the cornea's outermost region, comprising about 10 percent of the tissue's thickness. The epithelium functions primarily to: (1) Block the passage of foreign material, such as dust,
Adapted from the National Eye Institute: http://www.nei.nih.gov/health/cornealdisease/index.htm. 7
12 Myopia
water, and bacteria, into the eye and other layers of the cornea; and (2) Provide a smooth surface that absorbs oxygen and cell nutrients from tears, then distributes these nutrients to the rest of the cornea. The epithelium is filled with thousands of tiny nerve endings that make the cornea extremely sensitive to pain when rubbed or scratched. The part of the epithelium that serves as the foundation on which the epithelial cells anchor and organize themselves is called the basement membrane. ·
Bowman's Layer - Lying directly below the basement membrane of the epithelium is a transparent sheet of tissue known as Bowman's layer. It is composed of strong layered protein fibers called collagen. Once injured, Bowman's layer can form a scar as it heals. If these scars are large and centrally located, some vision loss can occur.
·
Stroma - Beneath Bowman's layer is the stroma, which comprises about 90 percent of the cornea's thickness. It consists primarily of water (78 percent) and collagen (16 percent), and does not contain any blood vessels. Collagen gives the cornea its strength, elasticity, and form. The collagen's unique shape, arrangement, and spacing are essential in producing the cornea's light-conducting transparency.
·
Descemet's Membrane - Under the stroma is Descemet's membrane, a thin but strong sheet of tissue that serves as a protective barrier against infection and injuries. Descemet's membrane is composed of collagen fibers (different from those of the stroma) and is made by the endothelial cells that lie below it. Descemet's membrane is regenerated readily after injury.
·
Endothelium - The endothelium is the extremely thin, innermost layer of the cornea. Endothelial cells are essential in keeping the cornea clear. Normally, fluid leaks slowly from inside the eye into the middle corneal layer (stroma). The endothelium's primary task is to pump this excess fluid out of the stroma. Without this pumping action, the stroma would swell with water, become hazy, and ultimately opaque. In a healthy eye, a perfect balance is maintained between the fluid moving into the cornea and fluid being pumped out of the cornea. Once endothelium cells are destroyed by disease or trauma, they are lost forever. If too many endothelial cells are destroyed, corneal edema and blindness ensue, with corneal transplantation the only available therapy.
Guidelines 13
What Is the Function of the Cornea? Because the cornea is as smooth and clear as glass but is strong and durable, it helps the eye in two ways: ·
It helps to shield the rest of the eye from germs, dust, and other harmful matter. The cornea shares this protective task with the eyelids, the eye socket, tears, and the sclera, or white part of the eye.
·
The cornea acts as the eye's outermost lens. It functions like a window that controls and focuses the entry of light into the eye. The cornea contributes between 65-75 percent of the eye's total focusing power.
When light strikes the cornea, it bends--or refracts--the incoming light onto the lens. The lens further refocuses that light onto the retina, a layer of light sensing cells lining the back of the eye that starts the translation of light into vision. For you to see clearly, light rays must be focused by the cornea and lens to fall precisely on the retina. The retina converts the light rays into impulses that are sent through the optic nerve to the brain, which interprets them as images. The refractive process is similar to the way a camera takes a picture. The cornea and lens in the eye act as the camera lens. The retina is similar to the film. If the image is not focused properly, the film (or retina) receives a blurry image. The cornea also serves as a filter, screening out some of the most damaging ultraviolet (UV) wavelengths in sunlight. Without this protection, the lens and the retina would be highly susceptible to injury from UV radiation.
What Are Refractive Errors? About 120 million people in the United States wear eyeglasses or contact lenses to correct nearsightedness, farsightedness, or astigmatism. These vision disorders--called refractive errors-- affect the cornea and are the most common of all vision problems in this country. Refractive errors occur when the curve of the cornea is irregularly shaped (too steep or too flat). When the cornea is of normal shape and curvature, it bends, or refracts, light on the retina with precision. However, when the curve of the cornea is irregularly shaped, the cornea bends light imperfectly on the retina. This affects good vision. The refractive process is similar to the way a camera takes a picture. The cornea and lens in your eye act as the camera lens. The retina is similar
14 Myopia
to the film. If the image is not focused properly, the film (or retina) receives a blurry image. The image that your retina “sees” then goes to your brain, which tells you what the image is.
What Is Myopia? When the cornea is curved too much, or if the eye is too long, faraway objects will appear blurry because they are focused in front of the retina. This is called myopia, or nearsightedness. Myopia affects over 25 percent of all adult Americans.8 Two-thirds of Americans with myopia also have astigmatism. Astigmatism is a condition in which the uneven curvature of the cornea blurs and distorts both distant and near objects. A normal cornea is round, with even curves from side to side and top to bottom. With astigmatism, the cornea is shaped more like the back of a spoon, curved more in one direction than in another. This causes light rays to have more than one focal point and focus on two separate areas of the retina, distorting the visual image.
How Is Myopia Treated? Myopia is frequently corrected by concave-lensed eyeglasses or with contact lenses for older children and adults. Although these are safe and effective methods for treating refractive errors, refractive surgeries are becoming an increasingly popular option for some patients. LASIK eye surgery, in particular, has become an option for patients with myopia. The United States Food and Drug Administration (FDA) is the official government agency that approves medical devices and procedures. Before undergoing LASIK eye surgery, you should consider the following discussion prepared by the FDA.
8 Hyperopia, or farsightedness, is the opposite of myopia. Distant objects are clear, and close-up objects appear blurry. With hyperopia, images focus on a point beyond the retina. Hyperopia results from an eye that is too short.
Guidelines 15
What Is LASIK?9 LASIK is a surgical procedure intended to reduce a person's dependency on glasses or contact lenses. LASIK stands for Laser-Assisted In Situ Keratomileusis and is a procedure that permanently changes the shape of the cornea, the clear covering of the front of the eye, using an excimer laser. A knife, called a microkeratome, is used to cut a flap in the cornea. A hinge is left at one end of this flap. The flap is folded back revealing the stroma, the middlesection of the cornea. Pulses from a computer-controlled laser vaporize a portion of the stroma and the flap is replaced.
The Eye and Vision Errors The cornea is a part of the eye that helps focus light to create an image on the retina. It works in much the same way that the lens of a camera focuses light to create an image on film. The bending and focusing of light is also known as refraction. Usually the shape of the cornea and the eye are not perfect and the image on the retina is out-of-focus (blurred) or distorted. These imperfections in the focusing power of the eye are called refractive errors. There are three primary types of refractive errors: myopia, hyperopia and astigmatism. Persons with myopia, or nearsightedness, have more difficulty seeing distant objects as clearly as near objects. Persons with hyperopia, or farsightedness, have more difficulty seeing near objects as clearly as distant objects. Astigmatism is a distortion of the image on the retina caused by irregularities in the cornea or lens of the eye. Combinations of myopia and astigmatism or hyperopia and astigmatism are common. Glasses or contact lenses are designed to compensate for the eye's imperfections. Surgical procedures aimed at improving the focusing power of the eye are called refractive surgery. In LASIK surgery, precise and controlled removal of
9The
discussion below has been adapted from the FDA: http://www.fda.gov/cdrh/lasik/default.htm.
16 Myopia
corneal tissue by a special laser reshapes the cornea changing its focusing power.
Other Types of Refractive Surgery Radial Keratotomy or RK and Photorefractive Keratectomy or PRK are other refractive surgeries used to reshape the cornea. In RK, a very sharp knife is used to cut slits in the cornea changing its shape. PRK was the first surgical procedure developed to reshape the cornea, by sculpting, using a laser. Later, LASIK was developed. The same type of laser is used for LASIK and PRK. Often the exact same laser is used for the two types of surgery. The major difference between the two surgeries is the way that the stroma, the middle layer of the cornea, is exposed before it is vaporized with the laser. In PRK, the top layer of the cornea, called the epithelium, is scraped away to expose the stromal layer underneath. In LASIK, a flap is cut in the stromal layer and the flap is folded back. Another type of refractive surgery is thermokeratoplasty in which heat is used to reshape the cornea. The source of the heat can be a laser, but it is a different kind of laser than is used for LASIK and PRK. Other refractive devices include corneal ring segments that are inserted into the stroma and special contact lenses that temporarily reshape the cornea (orthokeratology).
What the FDA Regulates In the United States, the Food and Drug Administration (FDA) regulates the sale of medical devices such as the lasers used for LASIK. Before a medical device can be legally sold in the U.S., the person or company that wants to sell the device must seek approval from the FDA. To gain approval, they must present evidence that the device is reasonably safe and effective for a particular use, the “indication.” Once the FDA has approved a medical device, a doctor may decide to use that device for other indications if the doctor feels it is in the best interest of a patient. The use of an approved device for other than its FDA-approved indication is called “off-label use.” The FDA does not regulate the practice of medicine. The FDA does not have the authority to: ·
Regulate a doctor's practice. In other words, FDA does not tell doctors what to do when running their business or what they can or cannot tell their patients.
Guidelines 17
·
Set the amount a doctor can charge for LASIK eye surgery.
·
“Insist” the patient information booklet from the laser manufacturer be provided to the potential patient.
·
Make recommendations for individual doctors, clinics, or eye centers. FDA does not maintain nor have access to any such list of doctors performing LASIK eye surgery.
·
Conduct or provide a rating system on any medical device it regulates.
The first refractive laser systems approved by FDA were excimer lasers for use in PRK to treat myopia and later to treat astigmatism. However, doctors began using these lasers for LASIK (not just PRK), and to treat other refractive errors (not just myopia). Over the last several years, LASIK has become the main surgery doctors use to treat myopia in the United States. More recently, some laser manufacturers have gained FDA approval for laser systems for LASIK to treat myopia, hyperopia and astigmatism and for PRK to treat hyperopia and astigmatism. See the section on FDA-approved lasers for more details on which lasers have received FDA approval and the specific indications and treatment ranges for which they were approved.
When Is LASIK Not for Me? You are probably NOT a good candidate for refractive surgery if: ·
You are not a risk taker. Certain complications are unavoidable in a percentage of patients, and there are no long-term data available for current procedures.
·
It will jeopardize your career. Some jobs prohibit certain refractive procedures. Be sure to check with your employer/professional society/military service before undergoing any procedure.
·
Cost is an issue. Most medical insurance will not pay for refractive surgery. Although the cost is coming down, it is still significant.
·
You required a change in your contact lens or glasses prescription in the past year. This is called refractive instability. Patients who are: - In their early 20s or younger, - Whose hormones are fluctuating due to disease such as diabetes, - Who are pregnant or breastfeeding, or
18 Myopia
- Who are taking medications such as steroids that cause fluctuations in vision, are more likely to have refractive instability and probably should not have a refractive procedure. ·
You have a disease or are on medications that may affect wound healing. Certain conditions, such as autoimmune diseases (e.g., lupus, rheumatoid arthritis), immunodeficiency states (e.g., HIV) and diabetes, and some medications (e.g., retinoic acid and steroids) may prevent proper healing after a refractive procedure.
·
You actively participate in contact sports. You participate in boxing, wrestling, martial arts or other activities in which blows to the face and eyes are a normal occurrence.
·
You are not an adult. Currently, no lasers are approved for LASIK on persons under the age of 18.
Contraindications The safety and effectiveness of refractive procedures has not been determined in patients with some diseases. Do NOT have LASIK surgery if you have a history of any of the following: ·
Herpes simplex or Herpes zoster (shingles) involving the eye area.
·
Glaucoma, glaucoma suspect, or ocular hypertension.
·
Eye diseases, such as uveitis/iritis (inflammations of the eye) and blepharitis (inflammation of the eyelids with crusting of the eyelashes).
·
Eye injuries or previous eye surgeries.
·
Keratoconus. Other Risk Factors
Your doctor should screen you for the following conditions or indicators of risk: ·
Large pupils. Make sure this evaluation is done in a dark room. Younger patients and patients on certain medications may be prone to having large pupils under dim lighting conditions. This can cause symptoms such as glare, halos, starbursts, and ghost images (double vision) after surgery. In some patients these symptoms may be debilitating. For example, a patient may no longer be able to drive a car at night or in certain weather conditions, such as fog.
Guidelines 19
·
Thin Corneas. The cornea is the thin clear covering of the eye that is over the iris, the colored part of the eye. Most refractive procedures change the eye’s focusing power by reshaping the cornea (for example, by removing tissue). Performing a refractive procedure on a cornea that is too thin or has too few cells lining the back surface (endothelial cells) may result in blinding complications.
·
Previous refractive surgery (e.g., RK, PRK, LASIK). Additional refractive surgery may not be recommended. The decision to have additional refractive surgery must be made in consultation with your doctor after careful consideration of your unique situation.
·
Dry Eyes. LASIK surgery tends to aggravate this condition.
What Are the Risks and How to Find the Right Doctor? Most patients are very pleased with the results of their refractive surgery. However, like any other medical procedure, there are risks involved. That's why it is important for you to understand the limitations and possible complications of refractive surgery. Before undergoing a refractive procedure, you should carefully weigh the risks and benefits based on your own personal value system, and try to avoid being influenced by friends that have had the procedure or doctors encouraging you to do so. ·
You may be undertreated or overtreated. Only a certain percent of patients achieve 20/20 vision without glasses or contacts. You may require additional treatment, but additional treatment may not be possible. You may still need glasses or contact lenses after surgery. This may be true even if you only required a very weak prescription before surgery. If you used reading glasses before surgery, you will still need reading glasses after surgery.
·
Results are generally not as good in patients with very small amounts of astigmatism or very large refractive errors of any type. You should discuss your expectations with your doctor and realize that you may still require glasses or contacts after the surgery.
·
Results may not be lasting. The level of improved vision you experience after surgery may be temporary, especially if you are farsighted or currently need reading glasses. It is especially important for farsighted individuals to have a cycloplegic refraction (a vision exam with lenses after dilating drops) as part of the screening process. Patients whose manifest refraction (a vision exam with lenses before dilating drops) is
20 Myopia
very different from their cycloplegic refraction are more likely to have temporary results. ·
Some patients lose vision. Some patients lose lines of vision on the vision chart that cannot be corrected with glasses, contact lenses, or surgery as a result of treatment. There is little known about how refractive procedures affect other aspects of vision, such as contrast sensitivity (the ability to see objects clearly against a similar background or in dim lighting conditions). Some studies suggest that patients do not see as well in situations of low contrast, such as at night or in fog, after treatment as compared to before treatment. Therefore, patients with low contrast sensitivity to begin with probably should not have a refractive procedure. It is important for you to know that not all eye centers test contrast sensitivity, and that when it is tested, it should be done in a dark room.
·
Some patients may develop severe dry eye syndrome. As a result of surgery, your eye may not be able to produce enough tears to keep the eye moist and comfortable. This condition may be permanent. Intensive drop therapy and the use of plugs or other procedures may be required.
Additional Risks Monovision Monovision is one clinical technique used to deal with the correction of presbyopia, the gradual loss of the ability of the eye to change focus for close-up tasks that progresses with age. The intent of monovision is for the presbyopic patient to use one eye for distance viewing and one eye for near viewing. This practice was first applied to fit contact lens wearers and more recently to LASIK and other refractive surgeries. With contact lenses, a presbyopic patient has one eye fit with a contact lens to correct distance vision, and the other eye fit with a contact lens to correct near vision. In the same way, with LASIK, a presbyopic patient has one eye operated on to correct the distance vision, and the other operated on to correct the near vision. In other words, the goal of the surgery is for one eye to have vision worse than 20/20, the commonly referred to goal for LASIK surgical correction of distance vision. Since one eye is corrected for distance viewing and the other eye is corrected for near viewing, the two eyes no longer work together. This results in poorer quality vision and a decrease in depth perception. These effects of monovision are most noticeable in low lighting conditions and when performing tasks requiring very sharp vision. Therefore, you may need to wear glasses or contact lenses to fully correct
Guidelines 21
both eyes for distance or near when performing visually demanding tasks, such as driving at night, operating dangerous equipment, or performing occupational tasks requiring very sharp close vision (e.g., reading small print for long periods of time). Many patients cannot get used to having one eye blurred at all times. The difference between monovision with contact lenses and monovision with LASIK is that you can always take contact lenses out or have them changed (the treatment is reversible and adjustable) as opposed to LASIK, where the result of the surgery is not reversible or adjustable. Therefore, if you are considering monovision with LASIK, make sure you go through a trial period with contact lenses to see if you can tolerate monovision, before having the irreversible surgery performed on your eyes. Just before this trial period starts, find out if you pass your state's driver's license requirements with monovision, or if you need supplemental glasses to drive. In addition, you should consider how much your presbyopia is expected to increase in the future. Ask your doctor when you should expect the results of your monovision surgery to no longer be enough for you to see near-by objects clearly without the aid of glasses or contacts, or when a second surgery might be required to further correct your near vision.
Bilateral Simultaneous Treatment You may choose to have LASIK surgery on both eyes at the same time or to have surgery on one eye at a time. Although the convenience of having surgery on both eyes on the same day is attractive, this practice is riskier than having two separate surgeries. The second eye may have a higher risk of developing an inflammation if surgery is done on the same day than if surgery is performed on separate days. If a malfunction of the laser or microkeratome occurs causing a complication with the first eye, the second eye is more likely to also experience the same complication if the surgery is performed on the same day rather than on separate days. If you decide to have one eye done at a time, you and your doctor will decide how long to wait before having surgery on the other eye. If both eyes are treated at the same time or before one eye has a chance to fully heal, you and your doctor do not have the advantage of being able to see how the first eye responds to surgery before the second eye is treated. Another disadvantage to having surgery on both eyes at the same time is that the vision in both eyes may be blurred after surgery until the initial
22 Myopia
healing process is over, rather than being able to rely on clear vision in at least one eye at all times.
Finding the Right Doctor If you are considering refractive surgery, make sure you: ·
Compare. The levels of risk and benefit vary slightly not only from procedure to procedure, but from device to device depending on the manufacturer, and from surgeon to surgeon depending on their level of experience with a particular procedure.
·
Don't base your decision simply on cost and don't settle for the first eye center, doctor, or procedure you investigate. Remember that the decisions you make about your eyes and refractive surgery will affect you for the rest of your life.
·
Be wary of eye centers that advertise, “20/20 vision or your money back” or “package deals.” There are never any guarantees in medicine.
·
Read. It is important for you to read the patient handbook provided to your doctor by the manufacturer of the device used to perform the refractive procedure. Your doctor should provide you with this handbook and be willing to discuss his/her outcomes (successes as well as complications) compared to the results of studies outlined in the handbook.
Even the best screened patients under the care of most skilled surgeons can experience serious complications. ·
During surgery. Malfunction of a device or other error, such as cutting a flap of cornea through and through instead of making a hinge during LASIK surgery, may lead to discontinuation of the procedure or irreversible damage to the eye.
·
After surgery. Some complications, such as migration of the flap, inflammation or infection, may require another procedure and/or intensive treatment with drops. Even with aggressive therapy, such complications may lead to temporary loss of vision or even irreversible blindness.
Guidelines 23
Under the care of an experienced doctor, carefully screened candidates with reasonable expectations and a clear understanding of the risks and alternatives are likely to be happy with the results of their refractive procedure. Advertising Be cautious about “slick” advertising and/or deals that sound “too good to be true.” Remember, they usually are. There is a lot of competition resulting in a great deal of advertising and bidding for your business. Do your homework. If you want to know more about advertising ethics, do's and don'ts, or want to report on false advertising, explore the following Web sites: ·
http://www.ftc.gov/bcp/menu-ads.htm
·
http://www.ftc.gov/bcp/menu-health.htm
What Should I Expect before, during, and after Surgery? What to expect before, during, and after surgery will vary from doctor to doctor and patient to patient. This section is a compilation of patient information developed by manufacturers and healthcare professionals, but cannot replace the dialogue you should have with your doctor. Read this information carefully and with the checklist, discuss your expectations with your doctor. Before Surgery If you decide to go ahead with LASIK surgery, you will need an initial or baseline evaluation by your eye doctor to determine if you are a good candidate. This is what you need to know to prepare for the exam and what you should expect. If you wear contact lenses, it is a good idea to stop wearing them before your baseline evaluation and switch to wearing your glasses full-time. Contact lenses change the shape of your cornea for up to several weeks after you have stopped using them depending on the type of contact lenses you wear. Not leaving your contact lenses out long enough for your cornea to assume its natural shape before surgery can have negative consequences. These
24 Myopia
consequences include inaccurate measurements and a poor surgical plan, resulting in poor vision after surgery. These measurements, which determine how much corneal tissue to remove, may need to be repeated at least a week after your initial evaluation and before surgery to make sure they have not changed, especially if you wear RGP or hard lenses. If you wear: ·
Soft contact lenses, you should stop wearing them for 2 weeks before your initial evaluation.
·
Toric soft lenses or rigid gas permeable (RGP) lenses, you should stop wearing them for at least 3 weeks before your initial evaluation.
·
Hard lenses, you should stop wearing them for at least 4 weeks before your initial evaluation.
You should tell your doctor: ·
About your past and present medical and eye conditions
·
About all the medications you are taking, including over-the-counter medications and any medications you may be allergic to
Your doctor should perform a thorough eye exam and discuss: ·
Whether you are a good candidate
·
What the risks, benefits, and alternatives of the surgery are
·
What you should expect before, during, and after surgery
·
What your responsibilities will be before, during, and after surgery
You should have the opportunity to ask your doctor questions during this discussion. Give yourself plenty of time to think about the risk/benefit discussion, to review any informational literature provided by your doctor, and to have any additional questions answered by your doctor before deciding to go through with surgery and before signing the informed consent form. You should not feel pressured by your doctor, family, friends, or anyone else to make a decision about having surgery. Carefully consider the pros and cons. The day before surgery, you should stop using: ·
Creams
·
Lotions
·
Makeup
Guidelines 25
·
Perfumes
These products as well as debris along the eyelashes may increase the risk of infection during and after surgery. Your doctor may ask you to scrub your eyelashes for a period of time before surgery to get rid of residues and debris along the lashes. Also before surgery, arrange for transportation to and from your surgery and your first follow-up visit. On the day of surgery, your doctor may give you some medicine to make you relax. Because this medicine impairs your ability to drive and because your vision may be blurry, even if you don't drive make sure someone can bring you home after surgery.
During Surgery The surgery should take less than 30 minutes. You will lie on your back in a reclining chair in an exam room containing the laser system. The laser system includes a large machine with a microscope attached to it and a computer screen. A numbing drop will be placed in your eye, the area around your eye will be cleaned, and an instrument called a lid speculum will be used to hold your eyelids open. A ring will be placed on your eye and very high pressures will be applied to create suction to the cornea. Your vision will dim while the suction ring is on and you may feel the pressure and experience some discomfort during this part of the procedure. The microkeratome, a cutting instrument, is attached to the suction ring. Your doctor will use the blade of the microkeratome to cut a flap in your cornea. The microkeratome and the suction ring are then removed. You will be able to see, but you will experience fluctuating degrees of blurred vision during the rest of the procedure. The doctor will then lift the flap and fold it back on its hinge, and dry the exposed tissue. The laser will be positioned over your eye and you will be asked to stare at a light. This is not the laser used to remove tissue from the cornea. This light is to help you keep your eye fixed on one spot once the laser comes on. NOTE: If you cannot stare at a fixed object for at least 60 seconds, you may not be a good candidate for this surgery. When your eye is in the correct position, your doctor will start the laser. At this point in the surgery, you may become aware of new sounds and smells.
26 Myopia
The pulse of the laser makes a ticking sound. As the laser removes corneal tissue, some people have reported a smell similar to burning hair. A computer controls the amount of laser delivered to your eye. Before the start of surgery, your doctor will have programmed the computer to vaporize a particular amount of tissue based on the measurements taken at your initial evaluation. After the pulses of laser energy vaporize the corneal tissue, the flap is put back into position. A shield should be placed over your eye at the end of the procedure as protection, since no stitches are used to hold the flap in place. It is important for you to wear this shield to prevent you from rubbing your eye and putting pressure on your eye while you sleep, and to protect your eye from accidentally being hit or poked until the flap has healed.
After Surgery Immediately after the procedure, your eye may burn, itch, or feel like there is something in it. You may experience some discomfort, or in some cases, mild pain and your doctor may suggest you take a mild pain reliever. Both your eyes may tear or water. Your vision will probably be hazy or blurry. You will instinctively want to rub your eye, but don't! Rubbing your eye could dislodge the flap, requiring further treatment. In addition, you may experience sensitivity to light, glare, starbursts or haloes around lights, or the whites of your eye may look red or bloodshot. These symptoms should improve considerably within the first few days after surgery. You should plan on taking a few days off from work until these symptoms subside. You should contact your doctor immediately and not wait for your scheduled visit, if you experience severe pain, or if your vision or other symptoms get worse instead of better. You should see your doctor within the first 24 to 48 hours after surgery and at regular intervals after that for at least the first six months. At the first postoperative visit, your doctor will remove the eye shield, test your vision, and examine your eye. Your doctor may give you one or more types of eye drops to take at home to help prevent infection and/or inflammation. You may also be advised to use artificial tears to help lubricate the eye. Do not resume wearing a contact lens in the operated eye, even if your vision is blurry. You should wait one to three days following surgery before beginning any non-contact sports, depending on the amount of activity required, how you feel, and your doctor's instructions.
Guidelines 27
To help prevent infection, you may need to wait for up to two weeks after surgery or until your doctor advises you otherwise before using lotions, creams, or make-up around the eye. Your doctor may advise you to continue scrubbing your eyelashes for a period of time after surgery. You should also avoid swimming and using hot tubs or whirlpools for 1-2 months. Strenuous contact sports such as boxing, football, karate, etc. should not be attempted for at least four weeks after surgery. It is important to protect your eyes from anything that might get in them and from being hit or bumped. During the first few months after surgery, your vision may fluctuate: ·
It may take up to three to six months for your vision to stabilize after surgery.
·
Glare, haloes, difficulty driving at night, and other visual symptoms may also persist during this stabilization period. If further correction or enhancement is necessary, you should wait until your eye measurements are consistent for two consecutive visits at least 3 months apart before reoperation.
·
It is important to realize that although distance vision may improve after re-operation, it is unlikely that other visual symptoms such as glare or haloes will improve.
·
It is also important to note that no laser company has presented enough evidence for the FDA to make conclusions about the safety or effectiveness of enhancement surgery.
Contact your eye doctor immediately, if you develop any new, unusual or worsening symptoms at any point after surgery. Such symptoms could signal a problem that, if not treated early enough, may lead to a loss of vision.
LASIK Surgery Checklist Know what makes you a poor candidate: ·
Career impact - does your job prohibit refractive surgery?
·
Cost - can you really afford this procedure?
·
Medical conditions - e.g., do you have an autoimmune disease or other major illness? Do you have a chronic illness that might slow or alter healing?
28 Myopia
·
Eye conditions - do you have or have you ever had any problems with your eyes other than needing glasses or contacts?
·
Medications - do you take steroids or other drugs that might prevent healing?
·
Stable refraction - has your prescription changed in the last year?
·
High or low refractive error - do you use glasses/contacts only some of the time? Do you need an unusually strong prescription?
·
Pupil size - are your pupils extra large in dim conditions?
·
Corneal thickness - do you have thin corneas?
Know all the risks and procedure limitations: ·
Overtreatment or undertreatment - are you willing and able to have more than one surgery to get the desired result?
·
May still need reading glasses - do you have presbyopia?
·
Results may not be lasting - do you think this is the last correction you will ever need? Do you realize that long-term results are not known?
·
May permanently lose vision - do you know some patients may lose some vision or experience blindness?
·
Development of visual symptoms - do you know about glare, halos, starbursts, etc. and that night driving might be difficult?
·
Contrast sensitivity - do you know your vision could be significantly reduced in dim light conditions?
·
Bilateral treatment - do you know the additional risks of having both eyes treated at the same time?
·
Patient information - have you read the patient information booklet about the laser being used for your procedure?
Know how to find the right doctor: ·
Experienced - how many eyes has your doctor performed LASIK surgery on with the same laser?
·
Equipment - does your doctor use an FDA-approved laser for the procedure you need?
·
Informative - is your doctor willing to spend the time to answer all your questions?
Guidelines 29
·
Long-term Care - does your doctor encourage follow-up and management of you as a patient? Your preop and postop care may be provided by a doctor other than the surgeon.
·
Be Comfortable - do you feel you know your doctor and are comfortable with an equal exchange of information?
Know preoperative, operative, and postoperative expectations: ·
No contact lenses prior to evaluation and surgery - can you go for an extended period of time without wearing contact lenses?
·
Have a thorough exam - have you arranged not to drive or work after the exam?
·
Read and understand the informed consent - has your doctor given you an informed consent form to take home and answered all your questions?
·
No makeup before surgery - can you go 24-36 hours without makeup prior to surgery?
·
Arrange for transportation - can someone drive you home after surgery?
·
Plan to take a few days to recover - can you take time off to take it easy for a couple of days if necessary?
·
Expect not to see clearly for a few days - do you know you will not see clearly immediately?
·
Know sights, smells, sounds of surgery - has your doctor made you feel comfortable with the actual steps of the procedure?
·
Be prepared to take drops/medications- are you willing and able to put drops in your eyes at regular intervals?
·
Be prepared to wear an eye shield - do you know you need to protect the eye for a period of time after surgery to avoid injury?
·
Expect some pain/discomfort - do you know how much pain to expect?
·
Know when to seek help - do you understand what problems could occur and when to seek medical intervention?
·
Know when to expect your vision to stop changing - are you aware that final results could take months?
·
Make sure your refraction is stable before any further surgery - if you don't get the desired result, do you know not to have an enhancement until the prescription stops changing?
30 Myopia
FDA-Approved Lasers for LASIK Company and model
Approval number and date
Autonomous Technology - LADARVision Patient information
P970043/S5 5/9/00
Myopia less than -9.0D with or without astigmatism from -0.5 to 3.0D
Bausch & Lomb Surgical - Technolas 217a Patient booklet (PDF)
P990027 2/23/00
Myopia from -1.0 to -7.0D with or without astigmatism less than -3.0D
Dishler
P970049 12/16/99
Myopia from -0.5 to -13.0D with or without astigmatism between -0.5 to 4.0D
Kremer
P970005 7/30/98
Myopia from -1.0 to -15.0D with or without astigmatism less then -5.0D
Nidek - EC5000
P970053/S2 4/14/00
Myopia from -1.0 to -14.0D with or without astigmatism less than 4.0D
Summit - Apex Plus
P930034/S13 Myopia less than -14.0D with or 10/21/99 without astigmatism from 0.5 to 5.0D
Summit Autonomous - LADARVision
P970043/S7 9/22/00
VISX - Star S2 & S3
P930016/S12 Hyperopia between +0.5 and +5.0D 4/27/01 with or without astigmatism up to +3.0D
VISX - Star S2
P990010 11/19/99
Myopia less than -14.0D with or without astigmatism between -0.5 and -5.0D
VISX - Star S3 (EyeTracker)
P990010/S1 4/20/00
Same as S2, except with eye tracker
Approved indications (D = diopters)
Hyperopia less than 6.0D with or without astigmatism less than -6.0D
Guidelines 31
FDA-Approved Lasers for PRK and Other Refractive Surgeries Company and model
Approval number and date
Approved indications (D = diopters)
Autonomous Technology - LADARVision
P970043 11/2/98
PRK; Myopia from -1.0 to -10.0D with or without astigmatism less than -4.0D
Bausch & Lomb Surgical - KERACOR 116
P970056 9/28/99
PRK; Myopia from -1.5 to -7.0D with or without astigmatism less than -4.5D
LaserSight - LaserScan LSX
P980008 11/12/99
PRK; Myopia from -1.0 to -6.0D with or without astigmatism less than 1.0D
Nidek - EC5000
P970053 12/17/98
PRK; Myopia from -0.75 to -13.0D
Nidek - EC5000
P970053/S1 9/29/99
PRK; Myopia from -1.0 to -8.0D with or without astigmatism from -0.5 to -4.0D
Summit - Apex & Apex Plus
P930034 10/25/95
PRK; Myopia from -1.5 to -7.0D
Summit - Apex Plus
P930034/S9 3/11/98
PRK; Myopia from -1.0 to -6.0D with or without astigmatism from -1.0 to -4.0D
Summit - Apex Plus
P930034/S12 10/21/99
PRK; Hyperopia from +1.5 to +4.0D with or without astigmatism less than -1.0D
Summit Autonomous - LADARVision
P970043/S8 7/11/00
Name Change Only
Sunrise - Hyperion
P990078 6/30/00
Laser Thermokeratoplasty (LTK); Hyperopia from +0.75 to +2.5D with or without astigmatism less than 0.75D
32 Myopia
VISX - Model B & C (Star & Star S2)
P930016 3/27/96
PRK; Myopia from 0 to -6.0D
VISX - Model B & C (Star & Star S2)
P930016/S3 4/24/97
PRK; Myopia from 0 to -6.0D with or without astigmatism from -0.75 to -4.0D
VISX - Model B & C (Star & Star S2)
P930016/S5 1/29/98
PRK; Myopia from 0 to -12.0D with or without astigmatism from 0 to -4.0D
VISX - Star S2
P930016/S7 11/2/98
PRK; Hyperopia from +1.0 to +6.0D
VISX - Star S2 & S3
P930016/S10 10/18/00
PRK; Hyperopia from +0.5 to +5.0D with or without astigmatism +0.5 to +4.0D
VISX - Star S2 & S3
P930016/S13 3/19/01
Add myopia blend zone; increase overall ablation zone from 6.5 to 8.0mm
Other Resources10 Links to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by FDA or the federal government. FDA is not responsible for the content of the Web pages found at these links.
FDA Web Resources Food and Drug Administration 5600 Fishers Lane (HFE-88) Rockville, MD 20852 Toll free: 1-888-463-6332 Telephone: (301) 827-4420 www.fda.gov This section includes information from the FDA: http://www.ftc.gov/bcp/conline/pubs/health/lasik.htm. 10
Guidelines 33
The FDA oversees the safety of food, cosmetics, medicines, medical devices, and radiation- emitting products and provides information on contact lenses, intraocular lenses, refractive surgery, and corneal implants for myopia. Additional web resources from the FDA include: ·
FDA CDRH documents regarding Manufacturers and Users of Lasers for Refractive Surgery; http://www.fda.gov/cdrh/ode/laser.html
·
CDRH directory of contacts for consumer and manufacturer calls; http://www.fda.gov/cdrh/dsma/dsmastaf.html
·
FDA web site for general consumer information on medical devices and radiation-emitting products; http://www.fda.gov/cdrh/consumer/index.shtml
·
The FDA MEDWATCH site: Safety information on drugs and other medical products; http://www.fda.gov/medwatch
Web Sites of Professional Opthalmology Societies American Academy of Ophthalmology P.O. Box 7424 San Francisco, CA 94120-7424 www.eyenet.org The AAO works to advance the lifelong learning and professional interests of ophthalmologists to ensure that the public can obtain the best possible eye care. American Society of Cataract and Refractive Surgery 4000 Legato Road, Suite 850 Fairfax, VA 22033 www.ascrs.org The ASCRS works to raise the standards and skills of anterior segment surgeons through clinical and practice management education. The Society also works with patients, government and the medical community to promote delivery of quality eye care. International Society of Refractive Surgery 1180 Springs Centre So. Blvd. #116 Altamonte Springs, FL www.LocateAnEyeDoc.com The ISRS provides scientific research, knowledge and information to all individuals who are interested in refractive surgery.
34 Myopia
National Eye Institute 31 Center Drive MSC 2510 Bethesda, MD 20892-2510 301-496-5248 www.nei.nih.gov The NEI conducts and supports research on eye diseases and vision disorders, and offers free publications for the general public and patients.
Other Links ·
Hardin MD list of eye diseases & other opthalmological topics: http://www.lib.uiowa.edu/hardin/md/ophth.html
·
Basic information from the United States Federal Trade Commission about LASIK surgery: http://www.ftc.gov/bcp/conline/pubs/health/lasik.htm
More Guideline Sources The guideline above on myopia is only one example of the kind of material that you can find online and free of charge. The remainder of this chapter will direct you to other sources which either publish or can help you find additional guidelines on topics related to myopia. Many of the guidelines listed below address topics that may be of particular relevance to your specific situation or of special interest to only some patients with myopia. Due to space limitations these sources are listed in a concise manner. Do not hesitate to consult the following sources by either using the Internet hyperlink provided, or, in cases where the contact information is provided, contacting the publisher or author directly.
Topic Pages: MEDLINEplus For patients wishing to go beyond guidelines published by specific Institutes of the NIH, the National Library of Medicine has created a vast and patientoriented healthcare information portal called MEDLINEplus. Within this Internet-based system are “health topic pages.” You can think of a health topic page as a guide to patient guides. To access this system, log on to http://www.nlm.nih.gov/medlineplus/healthtopics.html. From there you can either search using the alphabetical index or browse by broad topic areas.
Guidelines 35
If you do not find topics of interest when browsing health topic pages, then you can choose to use the advanced search utility of MEDLINEplus at the following:http://www.nlm.nih.gov/medlineplus/advancedsearch.html. This utility is similar to the NIH Search Utility, with the exception that it only includes material linked within the MEDLINEplus system (mostly patientoriented information). It also has the disadvantage of generating unstructured results. We recommend, therefore, that you use this method only if you have a very targeted search. The National Guideline Clearinghouse™ The National Guideline Clearinghouse™ offers hundreds of evidence-based clinical practice guidelines published in the United States and other countries. You can search their site located at http://www.guideline.gov by using the keyword “myopia” or synonyms. The following was recently posted: ·
Care of the patient with myopia. Source: American Optometric Association.; 1997 (reviewed 2001); 75 pages http://www.guideline.gov/FRAMESETS/guideline_fs.asp?guideline=00 1224&sSearch_string=myopia
Healthfinder™ Healthfinder™ is an additional source sponsored by the U.S. Department of Health and Human Services which offers links to hundreds of other sites that contain healthcare information. This Web site is located at http://www.healthfinder.gov. Again, keyword searches can be used to find guidelines. The following was recently found in this database: ·
FAQ - About LASIK Summary: Answers to commonly asked questions about LASIK -- a surgical procedure used in correcting a wide range of nearsightedness (myopia), farsightedness (hyperopia) and astigmatism. Source: LASIK Institute http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&R ecordID=5299
36 Myopia
·
LASIK Glossary of Terms Summary: Definitions of medical terms commonly used in eye diseases treatments and procedures, specifically LASIK -- a surgical procedure used in correcting a wide range of nearsightedness (myopia), Source: LASIK Institute http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&R ecordID=5301
·
LASIK Risk & Complications Summary: Information that provides patients with an understanding of the risks and complications of LASIK -- a surgical procedure used in correcting a wide range of nearsightedness (myopia), farsightedness Source: LASIK Institute http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&R ecordID=5300
·
Tips on Selecting a Surgeon for the LASIK Procedure Summary: This web site presents criteria and suggested reading that will help you select a surgeon to perform the LASIK procedure -- surgery used in correcting a wide range of nearsightedness (myopia), Source: LASIK Institute http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&R ecordID=5302
The NIH Search Utility After browsing the references listed at the beginning of this chapter, you may want to explore the NIH Search Utility. This allows you to search for documents on over 100 selected Web sites that comprise the NIH-WEBSPACE. Each of these servers is “crawled” and indexed on an ongoing basis. Your search will produce a list of various documents, all of which will relate in some way to myopia. The drawbacks of this approach are that the information is not organized by theme and that the references are often a mix of information for professionals and patients. Nevertheless, a large number of the listed Web sites provide useful background information. We can only recommend this route, therefore, for relatively rare or specific disorders, or when using highly targeted searches. To use the NIH search utility, visit the following Web page: http://search.nih.gov/index.html.
Guidelines 37
Additional Web Sources A number of Web sites that often link to government sites are available to the public. These can also point you in the direction of essential information. The following is a representative sample: ·
AOL: http://search.aol.com/cat.adp?id=168&layer=&from=subcats
·
drkoop.comÒ: http://www.drkoop.com/conditions/ency/index.html
·
Family Village: http://www.familyvillage.wisc.edu/specific.htm
·
Google: http://directory.google.com/Top/Health/Conditions_and_Diseases/
·
Med Help International: http://www.medhelp.org/HealthTopics/A.html
·
Open Directory Project: http://dmoz.org/Health/Conditions_and_Diseases/
·
Yahoo.com: http://dir.yahoo.com/Health/Diseases_and_Conditions/
·
WebMDÒHealth: http://my.webmd.com/health_topics
Vocabulary Builder The material in this chapter may have contained a number of unfamiliar words. The following Vocabulary Builder introduces you to terms used in this chapter that have not been covered in the previous chapter: Aqueous: Watery; prepared with water. [EU] Astigmatism: A condition in which the surface of the cornea is not spherical; causes a blurred image to be received at the retina. [NIH] Bacteria: Unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. [NIH] Bilateral: Having two sides, or pertaining to both sides. [EU] Blepharitis: Inflammation of the eyelids. [EU] Cataract: An opacity, partial or complete, of one or both eyes, on or in the lens or capsule, especially an opacity impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). [EU] Chronic: Persisting over a long period of time. [EU]
38 Myopia
Collagen: The protein substance of the white fibres (collagenous fibres) of skin, tendon, bone, cartilage, and all other connective tissue; composed of molecules of tropocollagen (q.v.), it is converted into gelatin by boiling. collagenous pertaining to collagen; forming or producing collagen. [EU] Cornea: The outer, transparent, dome-like structure that covers the iris, pupil, and anterior chamber; part of eye's focusing system. [NIH] Diopter: The measurement of refractive error. A negative diopter value signifies an eye with myopia and positive diopter value signifies an eye with hyperopia. [NIH] Edema: Excessive amount of watery fluid accumulated in the intercellular spaces, most commonly present in subcutaneous tissue. [NIH] Elasticity: Resistance and recovery from distortion of shape. [NIH] Endothelium: The inner layer of cells on the inside surface of the cornea. [NIH]
Epithelium: The outermost layer of cells of the cornea and the eye's first defense against infection. [NIH] Farsightedness: The common term for hyperopia. [NIH] Glare: Scatter from bright light that decreases vision. [NIH] Halos: Rings around lights due to optical imperfections in or in front of the eye. [NIH] Herpes: Any inflammatory skin disease caused by a herpesvirus and characterized by the formation of clusters of small vesicles. When used alone, the term may refer to herpes simplex or to herpes zoster. [EU] Hormones: Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various endocrine glands and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. [NIH] Hyperopia: Farsightedness; ability to see distant objects more clearly than close objects; may be corrected with glasses or contact lenses. [NIH] Hypertension: Persistently high arterial blood pressure. Various criteria for its threshold have been suggested, ranging from 140 mm. Hg systolic and 90 mm. Hg diastolic to as high as 200 mm. Hg systolic and 110 mm. Hg diastolic. Hypertension may have no known cause (essential or idiopathic h.) or be associated with other primary diseases (secondary h.). [EU] Inflammation: The body's reaction to trauma, infection, or a foreign substance, often associated with pain, heat, redness, swelling, and/or loss of function. [NIH]
Guidelines 39
Intraocular: Within the eye. [EU] Iris: The colored ring of tissue suspended behind the cornea and immediately in front of the lens; regulates the amount of light entering the eye by adjusting the size of the pupil. [NIH] Iritis: Inflammation of the iris, usually marked by pain, congestion in the ciliary region, photophobia, contraction of the pupil, and discoloration of the iris. [EU] Keratectomy: The surgical removal of corneal tissue. [NIH] Keratoconus: A disorder characterized by an irregular corneal surface (cone-shaped) resulting in blurred and distorted images. [NIH] Keratomileusis: Carving of the cornea to reshape it. [NIH] Keratotomy: A surgical incision (cut) of the cornea. [NIH] LASIK: The acronym for laser assisted in situ keratomileusis which refers to creating a flap in the cornea with a microkeratome and using a laser to reshape the underlying cornea. [NIH] Lens: The transparent, double convex (outward curve on both sides) structure suspended between the aqueous and vitreous; helps to focus light on the retina. [NIH] Lupus: A form of cutaneous tuberculosis. It is seen predominantly in women and typically involves the nasal, buccal, and conjunctival mucosa. [NIH]
Manifest: Being the part or aspect of a phenomenon that is directly observable : concretely expressed in behaviour. [EU] Membrane: A thin layer of tissue which covers a surface, lines a cavity or divides a space or organ. [EU] Microkeratome: A surgical device that is affixed to the eye by use of a vacuum ring. When secured, a very sharp blade cuts a layer of the cornea at a predetermined depth. [NIH] Monovision: The purposeful adjustment of one eye for near vision and the other eye fordistance vision. [NIH] Myopia: Nearsightedness; ability to see close objects more clearly than distant objects; may be corrected with glasses or contact lenses. [NIH] Nearsightedness: The common term for myopia. [NIH] Ocular: 1. of, pertaining to, or affecting the eye. 2. eyepiece. [EU] Ophthalmologist: A medical doctor specializing in the diagnosis and medical or surgical treatment of visual disorders and eye disease. [NIH] Ophthalmology: A surgical specialty concerned with the structure and function of the eye and the medical and surgical treatment of its defects and
40 Myopia
diseases. [NIH] Optic: Of or pertaining to the eye. [EU] Postoperative: Occurring after a surgical operation. [EU] Preoperative: Preceding an operation. [EU] Presbyopia: The gradual loss of the eye's ability to change focus (accommodation) for seeing near objects caused by the lens becoming less elastic; associated with aging; occurs in almost all people over age 45. [NIH] PRK: The acronym for photorefractive keratectomy which is a procedure involving the removal of the surface layer of the cornea (epithelium) by gentle scraping and use of a computer-controlled excimer laser to reshape the stroma. [NIH] Proteins: Polymers of amino acids linked by peptide bonds. The specific sequence of amino acids determines the shape and function of the protein. [NIH]
Pupil: The adjustable opening at the center of the iris that allows varying amounts of light to enter the eye. [NIH] Refraction: A test to determine the best eyeglasses or contact lenses to correct a refractive error (myopia, hyperopia, or astigmatism). [NIH] Retina: The light-sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. [NIH] Rheumatoid: Resembling rheumatism. [EU] Sclera: The tough, white, outer layer (coat) of the eyeball; with the cornea, it protects the entire eyeball. [NIH] Stabilization: The creation of a stable state. [EU] Steroid: A group name for lipids that contain a hydrogenated cyclopentanoperhydrophenanthrene ring system. Some of the substances included in this group are progesterone, adrenocortical hormones, the gonadal hormones, cardiac aglycones, bile acids, sterols (such as cholesterol), toad poisons, saponins, and some of the carcinogenic hydrocarbons. [EU] Stroma: The middle, thickest layer of tissue in the cornea. [NIH] Suction: The removal of secretions, gas or fluid from hollow or tubular organs or cavities by means of a tube and a device that acts on negative pressure. [NIH] Transplantation: The grafting of tissues taken from the patient's own body or from another. [EU] Uveitis: An inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (the sclera and cornea, and the retina). [EU]
Seeking Guidance 41
CHAPTER 2. SEEKING GUIDANCE Overview Some patients are comforted by the knowledge that a number of organizations dedicate their resources to helping people with myopia. These associations can become invaluable sources of information and advice. Many associations offer aftercare support, financial assistance, and other important services. Furthermore, healthcare research has shown that support groups often help people to better cope with their conditions.11 In addition to support groups, your physician can be a valuable source of guidance and support. Therefore, finding a physician that can work with your unique situation is a very important aspect of your care. In this chapter, we direct you to resources that can help you find patient organizations and medical specialists. We begin by describing how to find associations and peer groups that can help you better understand and cope with myopia. The chapter ends with a discussion on how to find a doctor that is right for you.
Associations and Myopia As mentioned by the Agency for Healthcare Research and Quality, sometimes the emotional side of an illness can be as taxing as the physical side.12 You may have fears or feel overwhelmed by your situation. Everyone has different ways of dealing with disease or physical injury. Your attitude, your expectations, and how well you cope with your condition can all Churches, synagogues, and other houses of worship might also have groups that can offer you the social support you need. 12 This section has been adapted from http://www.ahcpr.gov/consumer/diaginf5.htm. 11
42 Myopia
influence your well-being. This is true for both minor conditions and serious illnesses. For example, a study on female breast cancer survivors revealed that women who participated in support groups lived longer and experienced better quality of life when compared with women who did not participate. In the support group, women learned coping skills and had the opportunity to share their feelings with other women in the same situation. In addition to associations or groups that your doctor might recommend, we suggest that you consider the following list (if there is a fee for an association, you may want to check with your insurance provider to find out if the cost will be covered): ·
International Myopia Prevention Association Address: 1054 Gravel Hill Road Ligonier, PA 15658 Email:
[email protected] Web Site: http://www.myopia.org Background: The International Myopia Prevention Association (IMPA) was founded in 1974 by Donald Rehm to promote the prevention and control of myopia through public and professional education efforts. IMPA promotes the concept that acquired myopia is caused by excessive close work and is not an inherited condition. Publication(s): The Myopia Myth: The Truth About Nearsightedness and How to Prevent It; The Facts on Eye Disease; The Prevention of Acquired Myopia. Relevant area(s) of interest: Myopia; Visual impairment
·
Prevent Blindness America Address: Prevent Blindness America 500 East Remington Road, Schaumberg, IL 60173 Telephone: (847) 843-2020 Toll-free: (800) 331-2020 Fax: (847) 843- 8458 Email:
[email protected] Web Site: http://www.preventblindness.org Background: Prevent Blindness America is a nonprofit voluntary organization dedicated to fighting blindness and saving sight. Established in 1908, Prevent Blindness America and its nationwide network of affiliates, divisions, and chapters serve millions of people each year through public and professional education, community and patient service programs, and research. Consisting of 35,000 volunteers and 43 chapters, the organization produces educational materials
Seeking Guidance 43
including brochures entitled 'Age-Related Macular Degeneration,' 'Signs of Possible Eye Trouble in Adults,' and 'Your Child's Sight.' The organization also produces videos, posters, and brochures. Program activities include support groups, patient advocacy, referrals, and a tollfree help line. Relevant area(s) of interest: Cataracts, Conjunctivitis, Diabetic Retinopathy, Dry Eye, Glaucoma, Hyperopia, Keratoconus, Myopia, Presbyopia, Retinal Detachment
Finding More Associations There are a number of directories that list additional medical associations that you may find useful. While not all of these directories will provide different information than what is listed above, by consulting all of them, you will have nearly exhausted all sources for patient associations.
The National Health Information Center (NHIC) The National Health Information Center (NHIC) offers a free referral service to help people find organizations that provide information about myopia. For more information, see the NHIC’s Web site at http://www.health.gov/NHIC/ or contact an information specialist by calling 1-800-336-4797.
DIRLINE A comprehensive source of information on associations is the DIRLINE database maintained by the National Library of Medicine. The database comprises some 10,000 records of organizations, research centers, and government institutes and associations which primarily focus on health and biomedicine. DIRLINE is available via the Internet at the following Web site: http://dirline.nlm.nih.gov/. Simply type in “myopia” (or a synonym) or the name of a topic, and the site will list information contained in the database on all relevant organizations.
44 Myopia
The Combined Health Information Database Another comprehensive source of information on healthcare associations is the Combined Health Information Database. Using the “Detailed Search” option, you will need to limit your search to “Organizations” and “myopia”. Type the following hyperlink into your Web browser: http://chid.nih.gov/detail/detail.html. To find associations, use the drop boxes at the bottom of the search page where “You may refine your search by.” For publication date, select “All Years.” Then, select your preferred language and the format option “Organization Resource Sheet.” By making these selections and typing in “myopia” (or synonyms) into the “For these words:” box, you will only receive results on organizations dealing with myopia. You should check back periodically with this database since it is updated every 3 months. The National Organization for Rare Disorders, Inc. The National Organization for Rare Disorders, Inc. has prepared a Web site that provides, at no charge, lists of associations organized by specific diseases. You can access this database at the following Web site: http://www.rarediseases.org/cgi-bin/nord/searchpage. Select the option called “Organizational Database (ODB)” and type “myopia” (or a synonym) in the search box.
Online Support Groups In addition to support groups, commercial Internet service providers offer forums and chat rooms for people with different illnesses and conditions. WebMDÒ, for example, offers such as service at their Web site: http://boards.webmd.com/roundtable. These online self-help communities can help you connect with a network of people whose concerns are similar to yours. Online support groups are places where people can talk informally. If you read about a novel approach, consult with your doctor or other healthcare providers, as the treatments or discoveries you hear about may not be scientifically proven to be safe and effective.
Seeking Guidance 45
Finding an Eye Care Professional13 The National Eye Institute does not provide referrals nor recommend specific eye care professionals. However, you may wish to consider the following ways of finding a professional to provide your eye care. You can: ·
Ask family members and friends about eye care professionals they use.
·
Ask your family doctor for the name of a local eye care specialist.
·
Call the department of ophthalmology or optometry at a nearby hospital or university medical center.
·
Contact a state or county association of ophthalmologists or optometrists. These groups, usually called academies or societies, may have lists of eye care professionals with specific information on specialty and experience.
·
Contact your insurance company or health plan to learn whether it has a list of eye care professionals that are covered under your plan.
·
At a bookstore or library, check on available journals and books about choosing physicians and medical treatments. Here are some examples: -
Most large libraries have the reference set The ABMS Compendium of Certified Medical Professionals, which lists board-certified ophthalmologists, each with a small amount of biographical information. A library reference specialist can also help you identify other books on finding healthcare professionals or help you seek additional information about local eye physicians using the Internet.
Each year, usually in August, the magazine U.S. News and World Report features an article that rates hospitals in the United States. For more specific information, the following sources may prove useful: -
·
The American Academy of Ophthalmology coordinates an online listing called Find an Ophthalmologist that contains information on member ophthalmologists practicing in the United States and abroad. This service is designed to help the general public locate ophthalmologists within a specific region. Web site: http://www.eyenet.org/.
·
The International Society of Refractive Surgery maintains a comprehensive directory of surgeons around the world who are currently performing refractive surgery. Telephone: (407) 786-7446. E-mail:
[email protected]. Web site: http://www.isrs.org.
·
The Blue Book of Optometrists and the Red Book of Ophthalmologists, now available online, can be used to find doctors in the U.S., Puerto Rico,
13
This section has been adapted from http://www.nei.nih.gov/health/findprofessional.htm.
46 Myopia
and Canada. This resource is helpful when you know the doctor's name, but need contact information. Web site: http://www.eyefind.com/. ·
Administrators in Medicine and the Association of State Medical Board Executive Directors have launched DocFinder, an online database that helps consumers learn whether any malpractice actions have been taken against a particular doctor. The site provides links to the licensing boards in the participating states. Web site: http://www.docboard.org/.
·
The American Association of Eye and Ear Hospitals (AAEEH) is comprised of the premier centers for specialized eye and ear procedures in the world. Association members are major referral centers that offer some of the most innovative teaching programs, and routinely treat the most severely ill eye and ear patients. Telephone: (202) 347-1993. Web site: http://www.aaeeh.org/locations.html.
Additional steps you can take to locate doctors include the following: ·
Check with the associations listed earlier in this chapter.
·
Information on doctors in some states is available on the Internet at http://www.docboard.org. This Web site is run by “Administrators in Medicine,” a group of state medical board directors.
·
The American Board of Medical Specialties can tell you if your doctor is board certified. “Certified” means that the doctor has completed a training program in a specialty and has passed an exam, or “board,” to assess his or her knowledge, skills, and experience to provide quality patient care in that specialty. Primary care doctors may also be certified as specialists. The AMBS Web site is located at 14 http://www.abms.org/newsearch.asp. You can also contact the ABMS by phone at 1-866-ASK-ABMS.
·
You can call the American Medical Association (AMA) at 800-665-2882 for information on training, specialties, and board certification for many licensed doctors in the United States. This information also can be found in “Physician Select” at the AMA's Web site: http://www.amaassn.org/aps/amahg.htm.
If the previous sources did not meet your needs, you may want to log on to the Web site of the National Organization for Rare Disorders (NORD) at http://www.rarediseases.org/. NORD maintains a database of doctors with expertise in various rare diseases. The Metabolic Information Network (MIN), 800-945-2188, also maintains a database of physicians with expertise in various metabolic diseases. While board certification is a good measure of a doctor's knowledge, it is possible to receive quality care from doctors who are not board certified. 14
Seeking Guidance 47
Selecting Your Doctor15 When you have compiled a list of prospective doctors, call each of their offices. First, ask if the doctor accepts your health insurance plan and if he or she is taking new patients. If the doctor is not covered by your plan, ask yourself if you are prepared to pay the extra costs. The next step is to schedule a visit with your chosen physician. During the first visit you will have the opportunity to evaluate your doctor and to find out if you feel comfortable with him or her. Ask yourself, did the doctor: ·
Give me a chance to ask questions about myopia?
·
Really listen to my questions?
·
Answer in terms I understood?
·
Show respect for me?
·
Ask me questions?
·
Make me feel comfortable?
·
Address the health problem(s) I came with?
·
Ask me my preferences about different kinds of treatments for myopia?
·
Spend enough time with me?
Trust your instincts when deciding if the doctor is right for you. But remember, it might take time for the relationship to develop. It takes more than one visit for you and your doctor to get to know each other.
Working with Your Doctor16 Research has shown that patients who have good relationships with their doctors tend to be more satisfied with their care and have better results. Here are some tips to help you and your doctor become partners: ·
You know important things about your symptoms and your health history. Tell your doctor what you think he or she needs to know.
·
It is important to tell your doctor personal information, even if it makes you feel embarrassed or uncomfortable.
15 This
section has been adapted from the AHRQ: www.ahrq.gov/consumer/qntascii/qntdr.htm. 16 This section has been adapted from the AHRQ: www.ahrq.gov/consumer/qntascii/qntdr.htm.
48 Myopia
·
Bring a “health history” list with you (and keep it up to date).
·
Always bring any medications you are currently taking with you to the appointment, or you can bring a list of your medications including dosage and frequency information. Talk about any allergies or reactions you have had to your medications.
·
Tell your doctor about any natural or alternative medicines you are taking.
·
Bring other medical information, such as x-ray films, test results, and medical records.
·
Ask questions. If you don't, your doctor will assume that you understood everything that was said.
·
Write down your questions before your visit. List the most important ones first to make sure that they are addressed.
·
Consider bringing a friend with you to the appointment to help you ask questions. This person can also help you understand and/or remember the answers.
·
Ask your doctor to draw pictures if you think that this would help you understand.
·
Take notes. Some doctors do not mind if you bring a tape recorder to help you remember things, but always ask first.
·
Let your doctor know if you need more time. If there is not time that day, perhaps you can speak to a nurse or physician assistant on staff or schedule a telephone appointment.
·
Take information home. Ask for written instructions. Your doctor may also have brochures and audio and videotapes that can help you.
·
After leaving the doctor's office, take responsibility for your care. If you have questions, call. If your symptoms get worse or if you have problems with your medication, call. If you had tests and do not hear from your doctor, call for your test results. If your doctor recommended that you have certain tests, schedule an appointment to get them done. If your doctor said you should see an additional specialist, make an appointment.
By following these steps, you will enhance the relationship you will have with your physician.
Seeking Guidance 49
Broader Health-Related Resources In addition to the references above, the NIH has set up guidance Web sites that can help patients find healthcare professionals. These include:17 ·
Caregivers: http://www.nlm.nih.gov/medlineplus/caregivers.html
·
Choosing a Doctor or Healthcare Service: http://www.nlm.nih.gov/medlineplus/choosingadoctororhealthcareserv ice.html
·
Hospitals and Health Facilities: http://www.nlm.nih.gov/medlineplus/healthfacilities.html
Vocabulary Builder The following vocabulary builder provides definitions of words used in this chapter that have not been defined in previous chapters: Conjunctivitis: Inflammation of the conjunctiva, generally consisting of conjunctival hyperaemia associated with a discharge. [EU] Optometrist: A primary eye care provider who diagnoses, manages, and treats disorders of the visual system and eye diseases. [NIH] Optometry: The professional practice of primary eye and vision care that includes the measurement of visual refractive power and the correction of visual defects with lenses or glasses. [NIH] Retinopathy: 1. retinitis (= inflammation of the retina). 2. retinosis (= degenerative, noninflammatory condition of the retina). [EU]
You can access this information at: http://www.nlm.nih.gov/medlineplus/healthsystem.html.
17
Clinical Trials 51
CHAPTER 3. CLINICAL TRIALS AND MYOPIA Overview Very few medical conditions have a single treatment. The basic treatment guidelines that your physician has discussed with you, or those that you have found using the techniques discussed in Chapter 1, may provide you with all that you will require. For some patients, current treatments can be enhanced with new or innovative techniques currently under investigation. In this chapter, we will describe how clinical trials work and show you how to keep informed of trials concerning myopia.
What Is a Clinical Trial?18 Clinical trials involve the participation of people in medical research. Most medical research begins with studies in test tubes and on animals. Treatments that show promise in these early studies may then be tried with people. The only sure way to find out whether a new treatment is safe, effective, and better than other treatments for myopia is to try it on patients in a clinical trial.
What Kinds of Clinical Trials Are There? Clinical trials are carried out in three phases:
The discussion in this chapter has been adapted from the NIH and the NEI: www.nei.nih.gov/netrials/ctivr.htm.
18
52 Myopia
·
Phase I. Researchers first conduct Phase I trials with small numbers of patients and healthy volunteers. If the new treatment is a medication, researchers also try to determine how much of it can be given safely.
·
Phase II. Researchers conduct Phase II trials in small numbers of patients to find out the effect of a new treatment on myopia.
·
Phase III. Finally, researchers conduct Phase III trials to find out how new treatments for myopia compare with standard treatments already being used. Phase III trials also help to determine if new treatments have any side effects. These trials--which may involve hundreds, perhaps thousands, of people--can also compare new treatments with no treatment. How Is a Clinical Trial Conducted?
Various organizations support clinical trials at medical centers, hospitals, universities, and doctors' offices across the United States. The “principal investigator” is the researcher in charge of the study at each facility participating in the clinical trial. Most clinical trial researchers are medical doctors, academic researchers, and specialists. The “clinic coordinator” knows all about how the study works and makes all the arrangements for your visits. All doctors and researchers who take part in the study on myopia carefully follow a detailed treatment plan called a protocol. This plan fully explains how the doctors will treat you in the study. The “protocol” ensures that all patients are treated in the same way, no matter where they receive care. Clinical trials are controlled. This means that researchers compare the effects of the new treatment with those of the standard treatment. In some cases, when no standard treatment exists, the new treatment is compared with no treatment. Patients who receive the new treatment are in the treatment group. Patients who receive a standard treatment or no treatment are in the “control” group. In some clinical trials, patients in the treatment group get a new medication while those in the control group get a placebo. A placebo is a harmless substance, a “dummy” pill, that has no effect on myopia. In other clinical trials, where a new surgery or device (not a medicine) is being tested, patients in the control group may receive a “sham treatment.” This treatment, like a placebo, has no effect on myopia and does not harm patients. Researchers assign patients “randomly” to the treatment or control group. This is like flipping a coin to decide which patients are in each group. If you
Clinical Trials 53
choose to participate in a clinical trial, you will not know which group you will be appointed to. The chance of any patient getting the new treatment is about 50 percent. You cannot request to receive the new treatment instead of the placebo or sham treatment. Often, you will not know until the study is over whether you have been in the treatment group or the control group. This is called a “masked” study. In some trials, neither doctors nor patients know who is getting which treatment. This is called a “double masked” study. These types of trials help to ensure that the perceptions of the patients or doctors will not affect the study results. Natural History Studies Unlike clinical trials in which patient volunteers may receive new treatments, natural history studies provide important information to researchers on how myopia develops over time. A natural history study follows patient volunteers to see how factors such as age, sex, race, or family history might make some people more or less at risk for myopia. A natural history study may also tell researchers if diet, lifestyle, or occupation affects how a disease or disorder develops and progresses. Results from these studies provide information that helps answer questions such as: How fast will a disease or disorder usually progress? How bad will the condition become? Will treatment be needed? What Is Expected of Patients in a Clinical Trial? Not everyone can take part in a clinical trial for a specific disease or disorder. Each study enrolls patients with certain features or eligibility criteria. These criteria may include the type and stage of disease or disorder, as well as, the age and previous treatment history of the patient. You or your doctor can contact the sponsoring organization to find out more about specific clinical trials and their eligibility criteria. If you are interested in joining a clinical trial, your doctor must contact one of the trial's investigators and provide details about your diagnosis and medical history. If you participate in a clinical trial, you may be required to have a number of medical tests. You may also need to take medications and/or undergo surgery. Depending upon the treatment and the examination procedure, you may be required to receive inpatient hospital care. Or, you may have to return to the medical facility for follow-up examinations. These exams help find out how well the treatment is working. Follow-up studies can take months or years. However, the success of the clinical trial often depends on
54 Myopia
learning what happens to patients over a long period of time. Only patients who continue to return for follow-up examinations can provide this important long-term information.
Recent Trials on Myopia The National Institutes of Health and other organizations sponsor trials on various diseases and disorders. Because funding for research goes to the medical areas that show promising research opportunities, it is not possible for the NIH or others to sponsor clinical trials for every disease and disorder at all times. The following lists recent trials dedicated to myopia.19 If the trial listed by the NIH is still recruiting, you may be eligible. If it is no longer recruiting or has been completed, then you can contact the sponsors to learn more about the study and, if published, the results. Further information on the trial is available at the Web site indicated. Please note that some trials may no longer be recruiting patients or are otherwise closed. Before contacting sponsors of a clinical trial, consult with your physician who can help you determine if you might benefit from participation. ·
The Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study Condition(s): Myopia Study Status: This study is currently recruiting patients. Sponsor(s): National Eye Institute (NEI) Purpose - Excerpt: To compare and contrast normal eye growth, ocular component development, and refractive error development in Hispanic, African-American, and Asian schoolchildren with what happens in Caucasian children from the Orinda Longitudinal Study of Myopia. To investigate risk factors for the development of myopia. To conduct DNAbased studies on nearsighted children and their families. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/c/w1b/show/NCT00000169
·
A Trial of Bifocals in Myopic Children With Esophoria Condition(s): Myopia; Strabismus; Esophoria Study Status: This study is no longer recruiting patients. Sponsor(s): National Eye Institute (NEI)
19
These are listed at www.ClinicalTrials.gov.
Clinical Trials 55
Purpose - Excerpt: To test the hypothesis that correction with bifocal spectacle lenses rather than single-vision lenses will slow the progression of myopia in children with near-point esophoria. The primary outcome variable is cycloplegic refraction as measured with an automated refractor. Axial length is measured with ultrasound in order to test the corollary hypothesis that use of bifocals will slow ocular growth in these myopic children. We will also examine the amount of close work performed by subjects and the degree of parental myopia as factors that may influence myopia progression. Phase(s): Phase III Study Type: Interventional Contact(s): Oklahoma; The Office of Billie Walsh, O.D, Tulsa, Oklahoma, United States; Oklahoma; Tahlequah College of Optometry, Northeastern State University, Tahlequah, Oklahoma, United States Web Site: http://clinicaltrials.gov/ct/gui/c/w1b/show/NCT00000128 ·
Correction of Myopia Evaluation Trial (COMET) Condition(s): Myopia Study Status: This study is no longer recruiting patients. Sponsor(s): National Eye Institute (NEI) Purpose - Excerpt: To evaluate whether progressive addition lenses (PALs) slow the rate of progression of juvenile-onset myopia (nearsightedness) when compared with single vision lenses, as measured by cycloplegic autorefraction. An additional outcome measure is axial length, as measured by A-scan ultrasonography. To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses). Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/c/w1b/show/NCT00000113
·
The Contact Lens and Myopia Progression (CLAMP) Study Condition(s): Myopia Study Status: This study is no longer recruiting patients. Sponsor(s): National Eye Institute (NEI) Purpose - Excerpt: To examine the effects of rigid gas permeable contact lenses on the progression of myopia (nearsightedness) in children To
56 Myopia
determine what changes in the eyes cause certain eyes to progress in nearsightedness more slowly Study Type: Observational Contact(s): Ohio; The Ohio State University College of Optometry, Columbus, Ohio, 43210, United States; Jeffery J Walline, OD,MS 614-2926603
[email protected] Web Site: http://clinicaltrials.gov/ct/gui/c/w1b/show/NCT00009529 ·
Prospective Evaluation of Radial Keratotomy (PERK) Study Condition(s): Myopia Study Status: This study is completed. Sponsor(s): National Eye Institute (NEI) Purpose - Excerpt: To determine whether radial keratotomy is effective in reducing myopia. To detect complications of the surgery. To discover patient characteristics and surgical factors affecting the results. To determine the long-term safety and efficacy of the procedure. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/c/w1b/show/NCT00000129
·
The Berkeley Orthokeratology Study Condition(s): Astigmatism; Myopia Study Status: This study is completed. Sponsor(s): National Eye Institute (NEI) Purpose - Excerpt: To evaluate the relative efficacy of orthokeratology, primarily by assessment of changes in central corneal thickness, astigmatism, visual acuity, endothelial cell density, and corneal curvature. To evaluate the relative safety of orthokeratology, primarily by assessment of changes in central corneal thickness, astigmatism, visual acuity, endothelial cell density, induced corneal edema, and epithelial staining. To assess the duration of any orthokeratology treatment effect. To study the mechanisms by which refractive error and visual acuity changes occur, in particular the contribution that comes from changes in corneal curvature and shape. To determine whether there were any predisposing ocular factors that could be used to predict which subjects will experience changes or complications. Phase(s): Phase III
Clinical Trials 57
Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/gui/c/w1b/show/NCT00000123
Benefits and Risks20 What Are the Benefits of Participating in a Clinical Trial? If you are interested in a clinical trial, it is important to realize that your participation can bring many benefits to you and society at large: ·
A new treatment could be more effective than the current treatment for myopia. Although only half of the participants in a clinical trial receive the experimental treatment, if the new treatment is proved to be more effective and safer than the current treatment, then those patients who did not receive the new treatment during the clinical trial may be among the first to benefit from it when the study is over.
·
If the treatment is effective, then it may improve health or prevent diseases or disorders.
·
Clinical trial patients receive the highest quality of medical care. Experts watch them closely during the study and may continue to follow them after the study is over.
·
People who take part in trials contribute to scientific discoveries that may help other people with myopia. In cases where certain diseases or disorders run in families, your participation may lead to better care or prevention for your family members. The Informed Consent
Once you agree to take part in a clinical trial, you will be asked to sign an “informed consent.” This document explains a clinical trial's risks and benefits, the researcher’s expectations of you, and your rights as a patient.
This section has been adapted from ClinicalTrials.gov, a service of the National Institutes of Health: http://www.clinicaltrials.gov/ct/gui/c/a1r/info/whatis?JServSessionIdzone_ct=9jmun6f291. 20
58 Myopia
What Are the Risks? Clinical trials may involve risks as well as benefits. Whether or not a new treatment will work cannot be known ahead of time. There is always a chance that a new treatment may not work better than a standard treatment. There is also the possibility that it may be harmful. The treatment you receive may cause side effects that are serious enough to require medical attention.
How Is Patient Safety Protected? Clinical trials can raise fears of the unknown. Understanding the safeguards that protect patients can ease some of these fears. Before a clinical trial begins, researchers must get approval from their hospital's Institutional Review Board (IRB), an advisory group that makes sure a clinical trial is designed to protect patient safety. During a clinical trial, doctors will closely watch you to see if the treatment is working and if you are experiencing any side effects. All the results are carefully recorded and reviewed. In many cases, experts from the Data and Safety Monitoring Committee carefully monitor each clinical trial and can recommend that a study be stopped at any time. You will only be asked to take part in a clinical trial as a volunteer giving informed consent.
What Are a Patient's Rights in a Clinical Trial? If you are eligible for a clinical trial, you will be given information to help you decide whether or not you want to participate. As a patient, you have the right to: ·
Information on all known risks and benefits of the treatments in the study.
·
Know how the researchers plan to carry out the study, for how long, and where.
·
Know what is expected of you.
·
Know any costs involved for you or your insurance provider.
·
Know before any of your medical or personal information is shared with other researchers involved in the clinical trial.
·
Talk openly with doctors and ask any questions.
Clinical Trials 59
After you join a clinical trial, you have the right to: ·
Leave the study at any time. Participation is strictly voluntary. However, you should not enroll if you do not plan to complete the study.
·
Receive any new information about the new treatment.
·
Continue to ask questions and get answers.
·
Maintain your privacy. Your name will not appear in any reports based on the study.
·
Know whether you participated in the treatment group or the control group (once the study has been completed). What about Costs?
In some clinical trials, the research facility pays for treatment costs and other associated expenses. You or your insurance provider may have to pay for costs that are considered standard care. These things may include inpatient hospital care, laboratory and other tests, and medical procedures. You also may need to pay for travel between your home and the clinic. You should find out about costs before committing to participation in the trial. If you have health insurance, find out exactly what it will cover. If you don't have health insurance, or if your insurance company will not cover your costs, talk to the clinic staff about other options for covering the cost of your care. What Should You Ask before Deciding to Join a Clinical Trial? Questions you should ask when thinking about joining a clinical trial include the following: ·
What is the purpose of the clinical trial?
·
What are the standard treatments for myopia? Why do researchers think the new treatment may be better? What is likely to happen to me with or without the new treatment?
·
What tests and treatments will I need? Will I need surgery? Medication? Hospitalization?
·
How long will the treatment last? How often will I have to come back for follow-up exams?
·
What are the treatment's possible benefits to my condition? What are the short- and long-term risks? What are the possible side effects?
60 Myopia
·
Will the treatment be uncomfortable? Will it make me feel sick? If so, for how long?
·
How will my health be monitored?
·
Where will I need to go for the clinical trial? How will I get there?
·
How much will it cost to be in the study? What costs are covered by the study? How much will my health insurance cover?
·
Will I be able to see my own doctor? Who will be in charge of my care?
·
Will taking part in the study affect my daily life? Do I have time to participate?
·
How do I feel about taking part in a clinical trial? Are there family members or friends who may benefit from my contributions to new medical knowledge?
Keeping Current on Clinical Trials Various government agencies maintain databases on trials. The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and physicians with current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to their Web site (www.clinicaltrials.gov) and search by “myopia” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: ·
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
Clinical Trials 61
·
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
·
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
General References The following references describe clinical trials and experimental medical research. They have been selected to ensure that they are likely to be available from your local or online bookseller or university medical library. These references are usually written for healthcare professionals, so you may consider consulting with a librarian or bookseller who might recommend a particular reference. The following includes some of the most readily available references (sorted alphabetically by title; hyperlinks provide rankings, information and reviews at Amazon.com): ·
A Guide to Patient Recruitment : Today's Best Practices & Proven Strategies by Diana L. Anderson; Paperback - 350 pages (2001), CenterWatch, Inc.; ISBN: 1930624115; http://www.amazon.com/exec/obidos/ASIN/1930624115/icongroupinterna
·
A Step-By-Step Guide to Clinical Trials by Marilyn Mulay, R.N., M.S., OCN; Spiral-bound - 143 pages Spiral edition (2001), Jones & Bartlett Pub; ISBN: 0763715697; http://www.amazon.com/exec/obidos/ASIN/0763715697/icongroupinterna
·
The CenterWatch Directory of Drugs in Clinical Trials by CenterWatch; Paperback - 656 pages (2000), CenterWatch, Inc.; ISBN: 0967302935; http://www.amazon.com/exec/obidos/ASIN/0967302935/icongroupinterna
·
The Complete Guide to Informed Consent in Clinical Trials by Terry Hartnett (Editor); Paperback - 164 pages (2000), PharmSource Information Services, Inc.; ISBN: 0970153309; http://www.amazon.com/exec/obidos/ASIN/0970153309/icongroupinterna
·
Dictionary for Clinical Trials by Simon Day; Paperback - 228 pages (1999), John Wiley & Sons; ISBN: 0471985961; http://www.amazon.com/exec/obidos/ASIN/0471985961/icongroupinterna
·
Extending Medicare Reimbursement in Clinical Trials by Institute of Medicine Staff (Editor), et al; Paperback 1st edition (2000), National Academy Press; ISBN: 0309068886; http://www.amazon.com/exec/obidos/ASIN/0309068886/icongroupinterna
62 Myopia
·
Handbook of Clinical Trials by Marcus Flather (Editor); Paperback (2001), Remedica Pub Ltd; ISBN: 1901346293; http://www.amazon.com/exec/obidos/ASIN/1901346293/icongroupinterna
Vocabulary Builder The following vocabulary builder gives definitions of words used in this chapter that have not been defined in previous chapters: Acuity: Clearness, or sharpness of vision. [NIH] Progressive: Advancing; going forward; going from bad to worse; increasing in scope or severity. [EU] Strabismus: Deviation of the eye which the patient cannot overcome. The visual axes assume a position relative to each other different from that required by the physiological conditions. The various forms of strabismus are spoken of as tropias, their direction being indicated by the appropriate prefix, as cyclo tropia, esotropia, exotropia, hypertropia, and hypotropia. Called also cast, heterotropia, manifest deviation, and squint. [EU] Ultrasonography: The visualization of deep structures of the body by recording the reflections of echoes of pulses of ultrasonic waves directed into the tissues. Use of ultrasound for imaging or diagnostic purposes employs frequencies ranging from 1.6 to 10 megahertz. [NIH]
63
PART II: ADDITIONAL RESOURCES AND ADVANCED MATERIAL
ABOUT PART II In Part II, we introduce you to additional resources and advanced research on myopia. All too often, patients who conduct their own research are overwhelmed by the difficulty in finding and organizing information. The purpose of the following chapters is to provide you an organized and structured format to help you find additional information resources on myopia. In Part II, as in Part I, our objective is not to interpret the latest advances on myopia or render an opinion. Rather, our goal is to give you access to original research and to increase your awareness of sources you may not have already considered. In this way, you will come across the advanced materials often referred to in pamphlets, books, or other general works. Once again, some of this material is technical in nature, so consultation with a professional familiar with myopia is suggested.
Studies 65
CHAPTER 4. STUDIES ON MYOPIA Overview Every year, academic studies are published on myopia or related conditions. Broadly speaking, there are two types of studies. The first are peer reviewed. Generally, the content of these studies has been reviewed by scientists or physicians. Peer-reviewed studies are typically published in scientific journals and are usually available at medical libraries. The second type of studies is non-peer reviewed. These works include summary articles that do not use or report scientific results. These often appear in the popular press, newsletters, or similar periodicals. In this chapter, we will show you how to locate peer-reviewed references and studies on myopia. We will begin by discussing research that has been summarized and is free to view by the public via the Internet. We then show you how to generate a bibliography on myopia and teach you how to keep current on new studies as they are published or undertaken by the scientific community.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and myopia, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the
66 Myopia
format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type in “myopia” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is a sample of what you can expect from this type of search: ·
Relieving Visual Stress With Massage and Self-Care Source: Massage Therapy Journal. 37(4): 34-36, 38, 40, 44. Winter 1999. Summary: This journal article describes an approach to improving vision through massage and eye movements. According to the author, many cases of poor eyesight are caused by visual stress, and habitual straining to see produces muscle tension and contorted posture, which further contribute to visual problems. Two components of visual stress, prolonged near-focusing and tasks with high-level cognitive demand, have been shown to result in myopia. At Meir Schneider's School for SelfHealing in San Francisco, California, massage therapists learn how to treat these problems using a combination of massage of the face and upper body, eye and body movement exercises, and other techniques. This article describes 13 massage techniques Mr. Schneider recommends to improve or maintain vision. It also provides instructions for self-care exercises, including palming, sunning, blinking, extending the periphery, and shifting, which can help reduce visual stress and improve eyesight. It has 5 references.
Federally-Funded Research on Myopia The U.S. Government supports a variety of research studies relating to myopia and associated conditions. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.21 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally-funded biomedical research projects conducted at universities, hospitals, and other institutions. Visit the CRISP Web site at http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket. You can 21 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies 67
perform targeted searches by various criteria including geography, date, as well as topics related to myopia and related conditions. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally-funded studies use animals or simulated models to explore myopia and related conditions. In some cases, therefore, it may be difficult to understand how some basic or fundamental research could eventually translate into medical practice. The following sample is typical of the type of information found when searching the CRISP database for myopia: ·
Project Title: Accomodation and the Development of Refractive State Principal Investigator & Institution: Troilo, David B.; Associate Professor; Biosciences and Disease; New England College of Optometry 424 Beacon St Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 1-JUL-1995; Project End 1-MAR2005 Summary: (adapted from applicant's abstract): Myopia (nearsightedness) is on the rise around the world and in the United States. It affects tens of millions of Americans and, in progressive forms, is a leading cause of blindness. Earlier research with humans and experimental animal models has made it clear that the postnatal development of the eye and refractive state involves a combination of genetic and visual factors. The rise in incidence of human myopia has been associated with increases in literacy and levels of education, although the nature of the relationship is unclear. Research using animal models has established that visual stimuli related to retinal defocus regulate eye growth and refractive state. The studies described in this proposal use various visual manipulations to explore the temporal integration of visual stimuli that affect eye growth and the biochemical mechanisms that may underlie these changes. The following questions are asked: (1) How does the eye temporally integrate different visual stimuli for the regulation of eye growth? To answer this, the investigators will contrast the effects of different states of defocus or deprivation with corrected or clear vision and examine the stimulus durations necessary to elicit different ocular growth responses. (2) Do ocular circadian rhythms in IOP, axial length and choroid thickness play a role in the regulation of ocular growth? Specifically, the investigators will examine the phase relationships between these different rhythms during induced changes in ocular growth rate. (3) How do the temporal pattern and accuracy of accommodation affect the degree of blur experienced during near work tasks and when viewing through negative power spectacle lenses? These measures of accommodative behavior will
68 Myopia
then be correlated with the degree of experimental myopia induced. (4) What are the changes in scleral extracellular matrix during experimentally induced changes in ocular growth, and how are they controlled? Using ocular tissues from the other experiments, the investigators will quantify changes in scleral extracellular components and correlate them with visually induced increases and decreases in ocular growth rate. In addition, the possibility that retinoic acid synthesis by the choroids/RPE plays a role in the signal cascade from retina to sclera will be explored. This project will bring together several lines of investigation to help answer important questions relating to how myopia develops in response to altered visual experience. These studies will provide new information for understanding the association of near work, such as reading, and the development of myopia in humans. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Contact Lenses and Myopia (CLAMP) Study Principal Investigator & Institution: Walline, Jeffrey J.; None; Ohio State University Columbus, Oh 43210 Timing: Fiscal Year 2000; Project Start 1-DEC-1997; Project End 0-NOV2002 Summary: The Contact Lenses and Myopia Progression (CLAMP) Study will serve two purposes: 1) it will provide the training mechanism for Jeffrey J. Walline, O.D. to become a successful independent investigator and 2) it will evaluate the effect of rigid contact lenses on myopia progression in children. The CLAMP Study applies itself very well to furthering Dr. Walline's education and clinical experience. The CLAMP Study will generate the basis for Dr. Walline's qualifying examinations and his doctoral thesis, which will focus on his coursework in Physiological Optics and Preventive Medicine. Dr. Walline will serve as Principal Investigator and will gain valuable experience in all aspects of clinical research. He will be responsible for the recruitment, retention, ocular examination, and contact lens fitting of 110 children, most data collection, all data input and analysis, and the administrative functions of the entire study. The training plan, combined with the wide range of responsibilities in conducting this small-scale study, will produce an independent clinician-scientist who has learned the trials and tribulations of clinical research by direct application of his training and by personal experience. The CLAMP Study will examine the effects of rigid contact lenses on myopia progression in nearsighted children over a three-year period and will attempt to determine the mechanism of treatment effect if one exists. We will conduct a single-masked, randomized clinical trial on 110 children ages 8 to 11 years old who have between -1.00 D and -3.00 D
Studies 69
(spherical component) of myopia in each eye, less than 1.00 D of astigmatism in both eyes, less than 1.00 D of anisometropia, no ocular or systemic health problems that may affect vision, and at least 20/20 best corrected visual acuity in both eyes. All subjects will be given a comprehensive baseline examination and fitted with rigid contact lenses; those who meet the minimum requirements for rigid contact lens adaptation will be randomized to the experimental group (rigid contact lenses) or to the control group (soft contact lenses). Annual examinations will be given to all children to determine their myopic progression, and to measure their ocular components. Their vision correction will be updated every six months. The CLAMP Study is the ideal scope and size of study to train Dr. Walline to become an independent investigator and has the potential to change the standard of care for young children who become nearsighted. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Correction of Myopia Evaluation Trial (COMET) Principal Investigator & Institution: Scheiman, Mitchell M.; Pediatrics; Pennsylvania College of Optometry 8360 Old York Rd Elkins Park, Pa 19027 Timing: Fiscal Year 2000; Project Start 1-MAR-1997; Project End 8-FEB2002 Summary: (Applicant's Abstract) This proposal is for the Pennsylvania College of Optometry (PCO) to serve as one of four clinical centers in the Correction of Myopia Evaluation Trial (COMET). COMET is a prospective, randomized clinical trial designed to assess whether progressive addition lenses (PAL's) slow the progression of juvenileonset myopia, compared to conventional single vision lenses (SV). Seven hundred fifty children 6-12 years old with myopia (-1.25 to -4.5 D) in both eyes, who meet specific inclusion and exclusion criteria will be enrolled. They will be identified primarily from elementary school vision screenings and School of Optometry clinical patient records. All eligible children will be examined at baseline and at six-month intervals for at least three years to measure changes in refractive error and to update prescriptions. A standardized, common protocol will be used at all four centers. The primary outcome measure is progression of myopia, as measured by cycloplegic autorefraction. An additional outcome measure is axial elongation as measured by A-scan ultrasonography. These will be obtained by masked examiners. This application documents the ability of PCO to screen 7500 children for possible eligibility, to recruit at least 188 children within on academic year, and to retain them for at least three years. Documentation is also provided that PCO has the personnel,
70 Myopia
equipment, and facilities to conduct the study in accordance with the COMET Manual of Procedures (MOP). Complete details of the COMET rationale, design, and methods are contained in the MOP, which is submitted separately with the Study Chair and Coordinating Center applications. In addition to PCO, the other clinical centers are located at Colleges of Optometry in Boston, Houston, and Birmingham, with the Study Chair in Boston and the Coordinating Center at Stony Brook. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Correction of Myopia Evaluation Trial--Clinical Center Principal Investigator & Institution: Kurtz, Daniel; None; New England College of Optometry 424 Beacon St Boston, Ma 02115 Timing: Fiscal Year 2000; Project Start 1-MAR-1997; Project End 8-FEB2002 Summary: (Applicant's Abstract) This proposal is for the New England College of Optometry (NEWENCO) to serve as a clinical center in the Correction of Myopia Evaluation Trial (COMET). COMET is a prospective, randomized clinical trial designed to assess whether progressive addition lenses (PALs) slow the progression of juvenile-onset myopia, compared to conventional single vision lenses (SV). Seven hundred fifty children 6-12 years old with myopia (-1.25 to -4.5 D) in both eyes, who meet specific inclusion criteria and lack specific exclusion criteria will be enrolled. They will be identified primarily from elementary school vision screenings. All eligible children will be examined at baseline and at six-month intervals for at least three years of follow up to measure changes in refractive error and to update prescriptions. A standardized, common protocol will be used at all four centers. The primary outcome measure is progression of myopia, as measured by cycloplegic autorefraction. An additional outcome measure is axial elongation as measured by A-scan ultrasonography. These will be obtained by masked examiners. This application documents the ability of NEWENCO to screen about 7700 children for possible eligibility, to recruit at least 188 children within one academic year and to retain them for at least three years of follow up. Documentation is also provided that NEWENCO has the personnel, equipment, and facilities to conduct the study in accordance with the COMET Manual of Procedures (MOP). Complete details of the COMET rationale, design, and methods are contained in the MOP, which is submitted separately with the study chair and coordinating center applications. In addition to NEWENCO, the other clinical centers are located at Colleges of Optometry in Birmingham, Houston, and Philadelphia, with the Study Chair in Boston and the Coordinating Center at Stony Brook, NY.
Studies 71
Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Correction of Myopia Trial--Clinical Center Principal Investigator & Institution: Manny, Ruth E.; Chair; Clinical Optometric Sciences; University of Houston-University Park 4800 Calhoun Blvd Houston, Tx 77004 Timing: Fiscal Year 2000; Project Start 1-MAR-1997; Project End 8-FEB2002 Summary: (Applicant's Abstract) This proposal is for the University of Houston, College of Optometry (UHCO) to serve as one of four clinical centers in the Correction of Myopia Evaluation Trial (COMET). COMET is a prospective, randomized clinical trial designed to assess whether progressive addition lenses (PAL's) slow the progression of juvenileonset myopia, compared to conventional single vision lenses (SV). A total of four hundred children, 6-12 years of age with myopia (-1.25 to -4.50 D) in both eyes, who meet specific inclusion and exclusion criteria will be enrolled in the 4 participating centers. One hundred twelve children will be identified in Houston. These children will be recruited primarily from the University Eye Institute (UEI - the Clinic at UHCO). All eligible children will be examined at baseline and at six-month intervals for at least three years to measure changes in refractive error and to update prescriptions. A standardized, common protocol will be used at all four centers. The primary outcome measure is progression of myopia, as measured by cycloplegic autorefraction. A additional outcome measure is axial elongation as measured by A-scan ultrasonography. These outcome measures will be obtained by masked examiners. This application documents the ability of UHCO to recruit at least 112 children within one academic year, and to retain them for at least three years. Documentation is also provided that UHCO has the personnel, equipment, and facilities to conduct the study in accordance with the COMET Manual of Procedures (MOP). Complete details of the COMET rationale, design, and methods are contained in the MOP, which is submitted separately with the Study Chair and Coordinating Center applications. In addition to UHCO, the other clinical centers are located at Colleges of Optometry in Boston, Birmingham, and Philadelphia, with the Study Chair in Boston and the Coordinating Center at Stony Brook NY. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
72 Myopia
·
Project Title: Emmetropization and Development of Myopia in Children Principal Investigator & Institution: Gwiazda, Jane E.; Associate Professor; None; New England College of Optometry 424 Beacon St Boston, Ma 02115 Timing: Fiscal Year 2000; Project Start 1-SEP-1980; Project End 1-JUL-2004 Summary: The primary goal of the proposed research is increased understanding of the interacting environmental and hereditary factors which underlie the normal emmetropization process and which may produce abnormal growth of the eye eventuating in myopia in school-age children. Emerging from consideration of studies of humans and animals is the consensus that retinal defocus is a precursor to the development of myopia. A primary emphasis of the next phase of this research effort is an investigation of factors that induce retinal defocus in children. Some of the factors, such as accommodation, have been studied in the last project period, while others, such as ocular aberrations, are only now being investigated with the advent of new techniques. Genetics studies will investigate what factors may be inherited. Results from this multi-faceted investigation will be combined into an integrated account of myopization. In the process, risk factors for the development of myopia will be identified. The main hypothesis driving this research is that retinal defocus contributes to continued growth of the eye and consequent myopia in susceptible children. The projects as three specific aims: Specific Aim 1: To continue to delineate the time course of development of coordinated accommodation, convergence, and pupillary constriction, and compare it to the onset, progression, and stabilization of myopia. Dynamics of accommodation when children are engaged in near work activities will be investigated, to determine the extent to which retinal defocus may be experienced under conditions which approximate their daily close work habits. The hypothesis to be tested is that children engaged in close work experience retinal defocus that produces myopia. Specific Aim 2: To investigate the role of ocular aberrations, including astigmatism, in the etiology of myopia. Aberrations will be measured under different accommodative demands know to exacerbate aberrations. The hypothesis to be tested is that aberrations degrade retinal images and thereby produce myopia. Specific Aim 3: To complete the collection and ascertainment of a cohort of pedigrees affected by juvenile onset myopia and to begin genetic studies designed to identify genes responsible for overall myopia susceptibility and myopia related specific factors identified in Aims 1 and 2. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
Studies 73
·
Project Title: Genetics Studies of Myopia Principal Investigator & Institution: Stambolian, Dwight E.; Assoicate Professor; Ophthalmology; University of Pennsylvania 1 College Hall Philadelphia, Pa 19104 Timing: Fiscal Year 2000; Project Start 1-AUG-1999; Project End 1-JUL2004 Summary: Myopia is a disorder in which the eye is relatively long for the power of the cornea and lens resulting in blurred vision. Because myopia is the most common eye condition in the world, it is an enormous public health problem with a large economic impact on the population at large. Its contribution to acquired blindness varies from 3-19% depending on the study. Although very common, nothing secure is known about its pathogenesis despite studies of various animal models. A number of different studies provide compelling evidence indicating that myopia is inherited. The complexity of the genetics of this disorder requires a broad based collaborative effort to adequately locate the gene(s) for this disorder. The goal of this proposal is to contain the loci responsible for this disorder. Using uniform clinical criteria, pedigrees affected with myopia will be collected from two separate geographic regions. Blood samples from suitable families will be collected for DNA extraction which will be used for genetic mapping. Microsatellite repeat markers located at 10 cM intervals through the genome will be used for genotype generation. The genotype data will be utilized to create databases for linkage analysis. Potential areas suggestive of linkage will be further examined with additional markers from the potential region. The results of this investigation will (1) identify specific genetic loci for myopia, (2) permit an estimate of the relative importance of environmental exposure on myopia, and (3) provide a more rational framework for the classification of myopia based on genetic locus. Findings from this study may also provide further understanding of the pathogenesis of myopia and may have public health implications if there are some segments of the population in which preventing environmental exposures may alter the onset of disease or its further progression. This will have an even greater relevance if we are successful at defining the refractive component(s) of the eye which is responsible for the development of myopia. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
·
Project Title: Mechanisms of Ocular Development Principal Investigator & Institution: Norton, Thomas T.; Professor; Physiological Optics; University of Alabama at Birmingham Uab Station Birmingham, Al 35294
74 Myopia
Timing: Fiscal Year 2000; Project Start 1-APR-1986; Project End 1-MAR2002 Summary: The goal of this project is to understand the visually-guided regulation of axial length in juvenile eyes. Evidence from animal models strongly suggests that visual signals are used to match the developing eye s length to its optical power to produce eyes that are in good focus (e.g., the eyes become emmetropic.) Some aspects of the visual images on the retina, such as the amount of hyperopic defocus, stimulates eyes to elongate. As young eyes move from hyperopia toward emmetropia, the visual stimulus for elongation is reduced and the axial elongation rate is slowed, keeping the retina in the focal plane. Visual/neural control of scleral extensibility may be a key component in regulating the elongation rate of mammalian eyes during emmetropization. Our studies in tree shrews (small mammals closely related to primates) have found that the extensibility of the sclera is regulated by the visual environment. The sclera becomes more extensible in eyes with an environmentally-induced increase in elongation rate and less extensible in eyes with a decreased elongation rate. A detailed understanding of the spatial location and temporal pattern of changes within the sclera is needed to 1) determine how specific changes in scleral components produce changes in extensibility, and 2) help define the latency and signaling pathway(s) by which signals of retinal origin reach the sclera via the choroid. There are two broad objectives for this project period: First, Specific Aim 1 is to better define the visual stimuli that increase and decrease axial elongation rate. This will be accomplished by manipulating and measuring the amount and sign of defocus during the development of induced myopia. Second, Specific Aims 2 and 3 are to understand in detail the remodeling of the scleral matrix that controls axial elongation, learning what changes, where the changes occur and when the changes occur relative to changes in the visual environment and changes in axial elongation. Specific Aim 2 is to define and localize the specific changes in collagen and proteoglycans in the scleral extracellular matrix that occur during the development of induced myopia and during recovery from an induced myopia; Specific Aim 3 is to measure the time-course and latency of changes in scleral fibroblast gene expression for synthesis and degradation of scleral extracellular matrix during the development of induced myopia and recovery. The proposed experiments will significantly advance our understanding of the mammalian emmetropization mechanism. This, in turn, will help us to learn how human eyes normally control their elongation, and how interactions with the visual environment can lead to myopia (nearsightedness) in children. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
Studies 75
·
Project Title: Molecular Genetics of Myopia Principal Investigator & Institution: Young, Terri L.; Associate Professor; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, Pa 19104 Timing: Fiscal Year 2000; Project Start 1-AUG-1998; Project End 1-JUL2003 Summary: Dr. Terri Young is a pediatric ophthalmologist and Assistant Professor of Ophthalmology at the University of Minnesota. This award will enhance the candidate's potential for success by providing support for investigations into the molecular genetics of exaggerate eye growth, or myopia. Myopia, or nearsightedness is a refractive condition of the eyes with high incidence in the United States and one of the leading causes of blindness. Severe myopia predisposes the eye to glaucoma, macular degeneration, and retinal detachment. Genetic and environmental influences have been implicated, but specific factors responsible for myopia in humans have not bee identified. Several studies support the hypothesis that heredity is a major factor. In order to better understand the molecular genetics of myopia, we propose to characterize potential genetic factors of myopia through family studies with genome screening and linkage analysis. The overall goal of this proposal is to map genes responsible for familial severe myopia. Currently, 51 families have been recruited with an autosomal dominant pattern of inheritance of severe myopia (refractive error less than or equal to -6.00 diopters). Highly informative short tandem repeat polymorphisms have been utilized to confirm linkage and subsequently narrow the chromosomal region of interest. Significant linkage (Lod score= 6.24) has been identified at a locus on chromosome 18 in 8 families. Recently, significant linkage has been identified at a second locus on chromosome 12 (Lod score = 3.01) in one large multigeneration family. These potential candidate regions for myopia, as well as others that may be identified with the genome screen will be examined for mutations. This project is important to further our understanding of the molecular genetics of myopia, and may be generalized to enhance out understanding of the mechanisms of eye growth, whether normal, diminished, or excessive. Dr. Young's career goal is to flourish as a clinical scientist, with an established independent laboratory program in ophthalmic genetics. Dr. Richard king, the proposed sponsor, has extensive experience in the genetic analysis of complex diseases. The cosponsors in this proposal will provide expertise in molecular genetics, ophthalmic genetics, and statistical analysis and epidemiology. With the support of the Mentored Clinical Scientist Development Award, the candidate will obtain a solid foundation in molecular genetics.
76 Myopia
Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Myopia Development in Children Principal Investigator & Institution: Zadnik, Karla S.; Associate Professor; None; Ohio State University Columbus, Oh 43210 Timing: Fiscal Year 2000; Project Start 1-JUL-1991; Project End 0-JUN2001 Summary: The Orinda Longitudinal Study of Myopia (OLSM) was started in 1989 and has investigated normal eye growth and the development =of myopia in over 1,200 school-aged children to date. In the next five years of this project, we propose to conduct three parallel study phases. Phase I will investigate additional factors that may predict the onset of juvenile myopia (accommodative function, peripheral refractive error, intraocular pressure, and school achievement). Phase 2 will compare and contrast the optical ocular components and refractive error profiles of other ethnic groups with the predominantly Caucasian Orinda database. Phase 3 will initiate DNA- based studies on the prevalent OLSM myopes and their families to use these phenotypically well-characterized children and a panel of candidate genes to look for evidence of genetic factors. In parallel with the candidate gene association, family material will be used in an allele sharing approach to identify loci using highly variable, PCR-based markers. In Phase 1 we will continue to examine Orinda Union School District children in grades 1 through 8 (ages 6 through 14 years) annually. The measurement of accommodative response, accommodative lag, phoria, response AC/A ratio, peripheral refractive error, pushup accommodative amplitude, and intraocular pressure will be added to the existing protocol. Parents of children in the study will be contacted for their permission to release school achievement data (Iowa Test of Basic Skills). Phase 2 will add a major component to assess the influence of ethnicity on normal ocular and refractive error development. We propose to identify three participating sites with access to their local school districts that are predominantly African-American, Hispanic, and Asian, Children in the school districts associated with these sites will be examined annually with initial enrollment in all grades from 1 through 8 using the revised OLSM protocol as described above. Increased prevalence of myopia among children of myopic parents, twin studies, segregation analysis, and our own preliminary analyses from OLSM support a genetic etiologic component for myopia. In phase 3, we will use the phenotypic characterization of children in the Orinda Longitudinal Study of Myopia to identify prevalent cases of myopia and their families. These welldefined phenotypic myopes and non-myopic siblings and their parents
Studies 77
will be explored, seeking to develop a panel of candidate genes for myopia and to conduct an allele sharing analysis in these families. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Regulation of Scleral Growth and Remodelling Principal Investigator & Institution: Rada, Jody A.; Associate Professor; Anatomy and Cell Biology; University of North Dakota Grand Forks, Nd 58201 Timing: Fiscal Year 2000; Project Start 1-JAN-1992; Project End 1-JUL2001 Summary: The sclera, a connective tissue consisting of proteoglycans and collagen, provides the structural integrity that defines the shape and focal length of the eye. Therefore, alterations in the synthesis, degradation and net accumulation of these extracellular matrix components are likely to lead to significant changes in eye shape and severely affect vision. High myopia is a common condition characterized by excessive lengthening of the eye, primarily due to elongation of the vitreous chamber. Generally, myopia develops before puberty, and then stabilizes. If axial elongation fails to stabilize, an individual has an increased risk of retinal detachment, glaucoma, and blindness. This proposal examines the hypothesis that myopia is a connective tissue disorder in which the scleral extracellular matrix components are inappropriately remodeled. The objective of this proposal is to characterize the biochemical events which lead to scleral elongation and to identify regulatory mechanisms that govern these events. The well established model of myopia in chicks (form deprivation myopia) will be used to determine whether: 1) proteoglycan accumulation within the chick sclera is directly responsible for normal and myopic scleral growth, 2) changes in the fibrous sclera of form-deprived chick eyes parallel changes observed in myopic mammalian sclera 3) regional extracellular matrix turnover is mediated by the regulation of the 72 kDa gelatinase (MMP-2) and its associated inhibitors (TIMP-1 and TIMP-2) in the normal and form-deprived sclera, and 4) changes in the visual environment trigger the differential expression of genes within the eye which regulate scleral growth. Additionally, we propose to characterize the extracellular matrix of the human sclera from donors ranging in age from fetal - 90 years, in order to identify structural and biochemical differences which would predispose children to the development of myopia. Together, this information will serve as a basis for understanding the mechanisms by which myopia develops in chicks as well as in humans. Ultimately, this information may lead to the development of an anti-myopia therapy in children which
78 Myopia
would slow the progression of myopia by altering scleral metabolism and growth. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: The Myopia of Adulthood Principal Investigator & Institution: Bullimore, Mark A.; None; Ohio State University Columbus, Oh 43210 Timing: Fiscal Year 2001; Project Start 1-MAY-2001; Project End 0-APR2006 Summary: (Applicant's Abstract) Significant myopia progression occurs in over 40 percent of adults in their thirties. It has been proposed that the amount of near work performed places an individual at risk. There is also evidence that characteristics of a patient's accommodation and vergence system may predispose them to myopic changes. Nonetheless, there has been no systematic evaluation of the risk factors for adult myopia progression. We propose a five-year cohort study to determine the risk factors associated with adult myopia progression. The risk factors to be evaluated include: a. A greater proportion of time spent performing near tasks at home and at work. b. Performing near tasks at a closer distance. c. A higher accommodative convergence/accommodation (AC/A) ratio. d. A higher accommodative lag. Five hundred myopic subjects between 25 and 35 years of age will be recruited from the faculty and staff of The Ohio State University. Myopia progression is operationally defined as an increase in myopia of at least -0.75 D spherical equivalent as determined by cycloplegic auto-refraction. Subjects will be divided into progressors and non-progressors for data analysis based on this criterion. Subjects will be tested annually using the following methods: visual acuity, noncycloplegic auto-refraction and auto-keratometry, phoria, accommodative lag, response AC/A ratio, cycloplegic auto-refraction, videophakometry, and partial coherence interferometry (axial ocular dimensions). Participants' near work will be assessed using a novel technique known as the Experience Sampling Method. Subjects carry a portable electronic pager for two one-week periods and are paged randomly throughout the day. Each time they are paged, they dial into an automated telephone survey and report their activity at that time. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
·
Project Title: Trial of Bifocals in Myopic Children with Esophoria Principal Investigator & Institution: Fulk, George W.; None; Northeastern Oklahoma State University Tahlequah, Ok 74464
Studies 79
Timing: Fiscal Year 2000; Project Start 1-JUN-1996; Project End 1-MAY2002 Summary: (Applicant's Abstract) This clinical trial will test the hypothesis that correcting a specific group of myopic children with bifocals, instead of with single-vision spectacles, will reduce the rate of myopic progression. The specific group of myopic children to be included in the trial are those who show near-point esophoria, a tendency to overconverge while reading. Such children constitute about 30 percent of all myopic children. Support for the effectiveness of bifocals in esophoric children comes from three sources: a retrospective study, a secondary analysis of a clinical trial designed for another purpose, and pilot data collected by the applicants. These studies suggest that bifocals reduce the rate of myopic progression by 50 percent in esophoria children. The proposed study will be the first clinical trial of bifocals in myopic children with esophoria. Eighty myopic children with near-point esophoria will be divided randomly into two treatment groups: correction with single-vision lenses or with bifocal lenses containing a +1.50 D add. For 30 months, myopia will be measured every 6 months by means of automated, cycloplegic refraction. The long-term objective of the study is to find a method of reducing the final amount of myopia in a significant portion of all myopic persons. About 25 percent of all Americans are myopic. The correction of myopia and the treatment of myopia-associated diseases accounts for a significant proportion of health care costs. Substantial savings could be achieved if this study is successful. Many children, who are in phase of rapid myopia progression, would have to change prescriptions less often. Many adults would have better vision without glasses, thinner lenses, and a lower risk of retinal detachment. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket ·
Project Title: Vision and Etiology of Axial Myopia Principal Investigator & Institution: Wallmann, Josh; Professor; Biology; City College of New York 138Th St and Convent Ave New York, Ny 10031 Timing: Fiscal Year 2000; Project Start 1-DEC-1978; Project End 1-MAR2002 Summary: (Investigator's Abstract): This project seeks to contribute to the understanding of the etiology of myopia, a leading cause of blindness, by studying the severe myopia produced by deprivation of form vision in chickens. This animal model has three important features: the visual deprivation of one part of the retina produces myopia of only that part of the eye, and the scleral growth can be modulated up or down as
80 Myopia
necessary to compensate for myopia or hyperopia, suggesting that the eye can sense its refractive error and compensate for it. This has important implications in understanding how the eye grows and how it can go awry in clinical myopia.Three sets of experiments are proposed: (i) To study the cellular basis of myopia and emmetropization, the bidirectional modulation of scleral growth will be investigated in an in vitro system as assessed by incorporation of radiolabeled sulfur into in organ cultures and in dissociated cell cultures. The increase in proteoglycan synthesis in myopic scleras and cells of myopic eyes, and the decrease in those of recovering eyes will be studied to determine whether the modulation is achieved via a growth factor continuously or transiently released. Conditioned medium experiments will investigate the experiments will investigate the roles of he retinal pigment epithelium, choroid and retina as sources of relevant growth factors. Finally, different known growth factors will be added to the cultures to determine their effect on scleral growth in vitro. (ii) By in vivo studies, evidence will be sought that the recognized role of dopamine in the amelioration in form deprivation myopia represents a specific inhibition of the deprivation effect by using agonists on partially occluded eyes.In addition, scleras of tree shrews, which provide a mammalian model for myopia, will be studied to determine whether the myopia in these animals is also largely due to enhanced growth of the posterior sclera. (iii) The nature of the emmetropization process will be explored with experiments directed at determining the roles of the choroid and sclera in compensating for myopia or hyperopia. Website: http://commons.cit.nih.gov/crisp3/CRISP.Generate_Ticket
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine. The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to the public.22 If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
22
Studies 81
some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with myopia, simply go to the PubMed Web site at www.ncbi.nlm.nih.gov/pubmed. Type “myopia” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for “myopia” (hyperlinks lead to article summaries): ·
Biofeedback training for myopia control. Author(s): Trachtman JN, Giambalvo V, Dippner RF. Source: Optom Vis Sci. 1992 March; 69(3): 252-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=1520360&dopt=Abstract
·
Induced myopia associated with increased scleral creep in chick and tree shrew eyes. Author(s): Phillips JR, Khalaj M, McBrien NA. Source: Investigative Ophthalmology & Visual Science. 2000 July; 41(8): 2028-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10892839&dopt=Abstract
·
Inhibition of myopia development in chicks using himbacine: a role for M(4) receptors? Author(s): Cottriall CL, Truong HT, McBrien NA. Source: Neuroreport. 2001 August 8; 12(11): 2453-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=11496128&dopt=Abstract
·
Lacquer crack lesions in experimental chick myopia. Author(s): Hirata A, Negi A. Source: Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 1998 February; 236(2): 138-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9498125&dopt=Abstract
·
Lid-suture myopia in tree shrews with retinal ganglion cell blockade. Author(s): Norton TT, Essinger JA, McBrien NA.
82 Myopia
Source: Visual Neuroscience. 1994 January-February; 11(1): 143-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8011577&dopt=Abstract ·
Long-term changes in retinal contrast sensitivity in chicks from frosted occluders and drugs: relations to myopia? Author(s): Diether S, Schaeffel F. Source: Vision Research. 1999 July; 39(15): 2499-510. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10396619&dopt=Abstract
·
Melatonin and deprivation myopia in chickens. Author(s): Hoffmann M, Schaeffel F. Source: Neurochemistry International. 1996 January; 28(1): 95-107. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8746769&dopt=Abstract
·
Modulation of scleral DNA synthesis in development of and recovery from induced axial myopia in the tree shrew. Author(s): Gentle A, McBrien NA. Source: Experimental Eye Research. 1999 February; 68(2): 155-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10068481&dopt=Abstract
·
Morphological changes of choriocapillaris in experimentally induced chick myopia. Author(s): Hirata A, Negi A. Source: Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 1998 February; 236(2): 132-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9498124&dopt=Abstract
·
Morphology of the recovery from form deprivation myopia in the chick. Author(s): Liang H, Crewther SG, Crewther DP, Pirie B. Source: Australian and New Zealand Journal of Ophthalmology. 1996 May; 24(2 Suppl): 41-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8811241&dopt=Abstract
Studies 83
·
Myopia in the eye of developing chicks following monocular and binocular lid closure. Author(s): Yinon U, Rose L, Shapiro A. Source: Vision Research. 1980; 20(2): 137-41. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7434574&dopt=Abstract
·
Myopia in the lid-sutured tree shrew (Tupaia glis). Author(s): Sherman SM, Norton TT, Casagrande VA. Source: Brain Research. 1977 March 18; 124(1): 154-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=843938&dopt=Abstract
·
Myopia induced in cats deprived of distance vision during development. Author(s): Rose L, Yinon U, Belkin M. Source: Vision Research. 1974 October; 14(10): 1029-32. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=4432382&dopt=Abstract
·
Myopia. Author(s): Schaeffel F, Howland HC. Source: Vision Research. 1995 May; 35(9): 1135-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7610574&dopt=Abstract
·
Myopia. The nature versus nurture debate goes on. Author(s): Mutti DO, Zadnik K, Adams AJ. Source: Investigative Ophthalmology & Visual Science. 1996 May; 37(6): 952-7. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8631638&dopt=Abstract
·
Myopia: what can we do about it clinically? Author(s): Grosvenor T. Source: Optom Vis Sci. 1989 July; 66(7): 415-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=2671846&dopt=Abstract
84 Myopia
·
New approach in strabismus surgery in high myopia. Author(s): Krzizok TH, Kaufmann H, Traupe H. Source: The British Journal of Ophthalmology. 1997 August; 81(8): 625-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9349146&dopt=Abstract
·
N-methyl-D-aspartate-induced excitotoxicity causes myopia in hatched chicks. Author(s): Fischer AJ, Seltner RL, Stell WK. Source: Can J Ophthalmol. 1997 October; 32(6): 373-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9363340&dopt=Abstract
·
Nuclear cataract and myopia during hyperbaric oxygen therapy. Author(s): Palmquist BM, Philipson B, Barr PO. Source: The British Journal of Ophthalmology. 1984 February; 68(2): 1137. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=6691953&dopt=Abstract
·
Ocular development and visual deprivation myopia in the common marmoset (Callithrix jacchus). Author(s): Troilo D, Judge SJ. Source: Vision Research. 1993 July; 33(10): 1311-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8333155&dopt=Abstract
·
Opiate and N-methyl-D-aspartate receptors in form-deprivation myopia. Author(s): Fischer AJ, Seltner RL, Stell WK. Source: Visual Neuroscience. 1998 November-December; 15(6): 1089-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9839973&dopt=Abstract
·
Optical correction of induced axial myopia in the tree shrew: implications for emmetropization. Author(s): McBrien NA, Gentle A, Cottriall C. Source: Optom Vis Sci. 1999 June; 76(6): 419-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10416937&dopt=Abstract
Studies 85
·
Persistent hyperplastic primary vitreous with myopia: a case study. Author(s): Steele G, Peters R. Source: J Am Optom Assoc. 1999 September; 70(9): 593-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10547975&dopt=Abstract
·
Photorefractive keratectomy to correct astigmatism with myopia or hyperopia. Author(s): Dausch D, Klein R, Landesz M, Schroder E. Source: Journal of Cataract and Refractive Surgery. 1994 March; 20 Suppl: 252-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8006796&dopt=Abstract
·
Pirenzepine prevents form deprivation myopia in a dose dependent manner. Author(s): Leech EM, Cottriall CL, McBrien NA. Source: Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists). 1995 September; 15(5): 351-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8524553&dopt=Abstract
·
Prevention of collagen crosslinking increases form-deprivation myopia in tree shrew. Author(s): McBrien NA, Norton TT. Source: Experimental Eye Research. 1994 October; 59(4): 475-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7859823&dopt=Abstract
·
Prevention of form-deprivation myopia with pirenzepine: a study of drug delivery and distribution. Author(s): Cottriall CL, McBrien NA, Annies R, Leech EM. Source: Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists). 1999 July; 19(4): 327-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=10645389&dopt=Abstract
·
Reduced extracellular matrix in mammalian sclera with induced myopia. Author(s): Norton TT, Rada JA.
86 Myopia
Source: Vision Research. 1995 May; 35(9): 1271-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7610587&dopt=Abstract ·
Reduction in choroidal blood flow occurs in chicks wearing goggles that induce eye growth toward myopia. Author(s): Shih YF, Fitzgerald ME, Norton TT, Gamlin PD, Hodos W, Reiner A. Source: Current Eye Research. 1993 March; 12(3): 219-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8482110&dopt=Abstract
·
Refractive changes in chicks with form-deprivation myopia. Author(s): Wang F, Chu T, Zhang W. Source: Yan Ke Xue Bao. 1996 September; 12(3): 138-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9639839&dopt=Abstract
·
Retinal dopamine in the recovery from experimental myopia. Author(s): Pendrak K, Nguyen T, Lin T, Capehart C, Zhu X, Stone RA. Source: Current Eye Research. 1997 February; 16(2): 152-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9068946&dopt=Abstract
·
Retinal function with lens-induced myopia compared with formdeprivation myopia in chicks. Author(s): Fujikado T, Kawasaki Y, Suzuki A, Ohmi G, Tano Y. Source: Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 1997 May; 235(5): 320-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9176681&dopt=Abstract
·
Retinoic acid increases in the retina of the chick with form deprivation myopia. Author(s): Seko Y, Shimizu M, Tokoro T. Source: Ophthalmic Research. 1998; 30(6): 361-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9731117&dopt=Abstract
Studies 87
·
Scleral remodeling during the development of and recovery from axial myopia in the tree shrew. Author(s): McBrien NA, Lawlor P, Gentle A. Source: Investigative Ophthalmology & Visual Science. 2000 November; 41(12): 3713-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=11053267&dopt=Abstract
·
Sex differences in chick eye growth and experimental myopia. Author(s): Zhu X, Lin T, Stone RA, Laties AM. Source: Experimental Eye Research. 1995 August; 61(2): 173-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7556481&dopt=Abstract
·
Steady state mRNA levels in tree shrew sclera with form-deprivation myopia and during recovery. Author(s): Siegwart JT Jr, Norton TT. Source: Investigative Ophthalmology & Visual Science. 2001 May; 42(6): 1153-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=11328721&dopt=Abstract
·
Stimulation of dopaminergic amacrine cells by stroboscopic illumination or fibroblast growth factor (bFGF, FGF-2) injections: possible roles in prevention of form-deprivation myopia in the chick. Author(s): Rohrer B, Iuvone PM, Stell WK. Source: Brain Research. 1995 July 24; 686(2): 169-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7583283&dopt=Abstract
·
Stimulus deprivation myopia in human congenital ptosis: a preliminary report of 50 unilateral cases. Author(s): Gusek-Schneider GC, Martus P. Source: Strabismus. 2000 September; 8(3): 169-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=11035559&dopt=Abstract
·
Stimulus deprivation myopia in human congenital ptosis: a study of 95 patients. Author(s): Gusek-Schneider GC, Martus P.
88 Myopia
Source: J Pediatr Ophthalmol Strabismus. 2001 November-December; 38(6): 340-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=11759772&dopt=Abstract ·
Structural and ultrastructural changes to the sclera in a mammalian model of high myopia. Author(s): McBrien NA, Cornell LM, Gentle A. Source: Investigative Ophthalmology & Visual Science. 2001 September; 42(10): 2179-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=11527928&dopt=Abstract
·
Surgically-induced astigmatism after laser in situ keratomileusis for spherical myopia. Author(s): Huang D, Sur S, Seffo F, Meisler DM, Krueger RR. Source: J Refract Surg. 2000 September-October; 16(5): 515-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=11019865&dopt=Abstract
·
The amelioration of myopia using biofeedback of accommodation: a review. Author(s): Gilmartin B, Gray LS, Winn B. Source: Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists). 1991 October; 11(4): 30413. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=1771067&dopt=Abstract
·
The development of experimental myopia and ocular component dimensions in monocularly lid-sutured tree shrews (Tupaia belangeri) Author(s): McBrien NA, Norton TT. Source: Vision Research. 1992 May; 32(5): 843-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=1604853&dopt=Abstract
·
The duration of normal visual exposure necessary to prevent form deprivation myopia in chicks. Author(s): Napper GA, Brennan NA, Barrington M, Squires MA, Vessey GA, Vingrys AJ.
Studies 89
Source: Vision Research. 1995 May; 35(9): 1337-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7610595&dopt=Abstract ·
The effect of an interrupted daily period of normal visual stimulation on form deprivation myopia in chicks. Author(s): Napper GA, Brennan NA, Barrington M, Squires MA, Vessey GA, Vingrys AJ. Source: Vision Research. 1997 June; 37(12): 1557-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9231222&dopt=Abstract
·
The effect of nitric oxide synthase inhibitor on form-deprivation myopia. Author(s): Fujikado T, Kawasaki Y, Fujii J, Taniguchi N, Okada M, Suzuki A, Ohmi G, Tano Y. Source: Current Eye Research. 1997 October; 16(10): 992-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=9330850&dopt=Abstract
·
The effect of vasoactive intestinal peptide on development of form deprivation myopia in the chick: a pharmacological and immunocytochemical study. Author(s): Seltner RL, Stell WK. Source: Vision Research. 1995 May; 35(9): 1265-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7610586&dopt=Abstract
·
The effects of blockade of retinal cell action potentials on ocular growth, emmetropization and form deprivation myopia in young chicks. Author(s): McBrien NA, Moghaddam HO, Cottriall CL, Leech EM, Cornell LM. Source: Vision Research. 1995 May; 35(9): 1141-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=7610575&dopt=Abstract
·
The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew. Author(s): Cottriall CL, McBrien NA.
90 Myopia
Source: Investigative Ophthalmology & Visual Science. 1996 June; 37(7): 1368-79. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=8641840&dopt=Abstract ·
The mechanism of lid-suture myopia. Author(s): Raviola E, Wiesel TN. Source: Acta Ophthalmol Suppl. 1988; 185: 91-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db= PubMed&list_uids=2853550&dopt=Abstract
Vocabulary Builder Accommodation: The ability of the eye to change its focus from distant to near objects; process achieved by the lens changing its shape. [NIH] Agonist: In anatomy, a prime mover. In pharmacology, a drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances. [EU] Anisometropia: A condition of an inequality of refractive power of the two eyes. [NIH] Anxiety: The unpleasant emotional state consisting of psychophysiological responses to anticipation of unreal or imagined danger, ostensibly resulting from unrecognized intrapsychic conflict. Physiological concomitants include increased heart rate, altered respiration rate, sweating, trembling, weakness, and fatigue; psychological concomitants include feelings of impending danger, powerlessness, apprehension, and tension. [EU] Ascariasis: Infection by nematodes of the genus ASCARIS. Ingestion of infective eggs causes diarrhea and pneumonitis. Its distribution is more prevalent in areas of poor sanitation and where human feces are used for fertilizer. [NIH] Auricular: Pertaining to an auricle or to the ear, and, formerly, to an atrium of the heart. [EU] Biochemical: Relating to biochemistry; characterized by, produced by, or involving chemical reactions in living organisms. [EU] Cardiovascular: Pertaining to the heart and blood vessels. [EU] Choroid: The layer filled with blood vessels that nourishes the retina; part of the uvea. [NIH] Chromosomal: Pertaining to chromosomes. [EU] Criterion: A standard by which something may be judged. [EU]
Studies 91
Degenerative: Undergoing degeneration : tending to degenerate; having the character of or involving degeneration; causing or tending to cause degeneration. [EU] Deprivation: Loss or absence of parts, organs, powers, or things that are needed. [EU] Dysplasia: Abnormality of development; in pathology, alteration in size, shape, and organization of adult cells. [EU] Epidemic: Occurring suddenly in numbers clearly in excess of normal expectancy; said especially of infectious diseases but applied also to any disease, injury, or other health-related event occurring in such outbreaks. [EU] Epiphyseal: Pertaining to or of the nature of an epiphysis. [EU] Extracellular: Outside a cell or cells. [EU] Extraction: The process or act of pulling or drawing out. [EU] Ganglion: 1. a knot, or knotlike mass. 2. a general term for a group of nerve cell bodies located outside the central nervous system; occasionally applied to certain nuclear groups within the brain or spinal cord, e.g. basal ganglia. 3. a benign cystic tumour occurring on a aponeurosis or tendon, as in the wrist or dorsum of the foot; it consists of a thin fibrous capsule enclosing a clear mucinous fluid. [EU] Gastroenteritis: An acute inflammation of the lining of the stomach and intestines, characterized by anorexia, nausea, diarrhoea, abdominal pain, and weakness, which has various causes, including food poisoning due to infection with such organisms as Escherichia coli, Staphylococcus aureus, and Salmonella species; consumption of irritating food or drink; or psychological factors such as anger, stress, and fear. Called also enterogastritis. [EU] Genotype: The genetic constitution of the individual; the characterization of the genes. [NIH] Habitual: Of the nature of a habit; according to habit; established by or repeated by force of habit, customary. [EU] Hepatitis: Inflammation of the liver. [EU] Heredity: 1. the genetic transmission of a particular quality or trait from parent to offspring. 2. the genetic constitution of an individual. [EU] Hyperbaric: Characterized by greater than normal pressure or weight; applied to gases under greater than atmospheric pressure, as hyperbaric oxygen, or to a solution of greater specific gravity than another taken as a standard of reference. [EU] Hypoplasia: Incomplete development or underdevelopment of an organ or tissue. [EU]
92 Myopia
Immunization: The induction of immunity. [EU] Induction: The act or process of inducing or causing to occur, especially the production of a specific morphogenetic effect in the developing embryo through the influence of evocators or organizers, or the production of anaesthesia or unconsciousness by use of appropriate agents. [EU] Intestinal: Pertaining to the intestine. [EU] function of a part. [EU] Molecular: Of, pertaining to, or composed of molecules : a very small mass of matter. [EU] Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. [NIH] Neural: 1. pertaining to a nerve or to the nerves. 2. situated in the region of the spinal axis, as the neutral arch. [EU] Ophthalmic: Pertaining to the eye. [EU] Opiate: A remedy containing or derived from opium; also any drug that induces sleep. [EU] Optician: An expert in the art and science of making and fitting glasses and may also dispense contact lenses. [NIH] Oral: Pertaining to the mouth, taken through or applied in the mouth, as an oral medication or an oral thermometer. [EU] Pediatrics: A medical specialty concerned with maintaining health and providing medical care to children from birth to adolescence. [NIH] Pneumonia: Inflammation of the lungs with consolidation. [EU] Polydipsia: Chronic excessive thirst, as in diabetes mellitus or diabetes insipidus. [EU] Posterior: Situated in back of, or in the back part of, or affecting the back or dorsal surface of the body. In lower animals, it refers to the caudal end of the body. [EU] Postnatal: Occurring after birth, with reference to the newborn. [EU] Precursor: Something that precedes. In biological processes, a substance from which another, usually more active or mature substance is formed. In clinical medicine, a sign or symptom that heralds another. [EU] Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from incidence, which refers to the number of new cases in the population at a given time. [NIH] Prostaglandins: A group of compounds derived from unsaturated 20carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase
Studies 93
pathway. They are extremely potent mediators of a diverse group of physiological processes. [NIH] Proteoglycans: content. [NIH]
Glycoproteins which have a very high polysaccharide
Ptosis: 1. prolapse of an organ or part. 2. drooping of the upper eyelid from paralysis of the third nerve or from sympathetic innervation. [EU] Puberty: The period during which the secondary sex characteristics begin to develop and the capability of sexual reproduction is attained. [EU] Sanitation: The development and establishment of environmental conditions favorable to the health of the public. [NIH] Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight 32.066. It is found in the amino acids cysteine and methionine. [NIH] Systemic: Pertaining to or affecting the body as a whole. [EU] Trachoma: A chronic infectious disease of the conjunctiva and cornea, producing photophobia, pain, and lacrimation, caused by an organism once thought to be a virus but now classified as a strain of the bacteria Chlamydia trachomatis. [EU] Tuberculosis: Any of the infectious diseases of man and other animals caused by species of mycobacterium. [NIH] Tupaia: A genus of tree shrews of the family TUPAIIDAE which consists of about 12 species. One of the most frequently encountered species is T. glis. Members of this genus inhabit rain forests and secondary growth areas in southeast Asia. [NIH] Vasoactive: Exerting an effect upon the calibre of blood vessels. [EU] Vitreous: Glasslike or hyaline; often used alone to designate the vitreous body of the eye (corpus vitreum). [EU]
Patents 95
CHAPTER 5. PATENTS ON MYOPIA Overview You can learn about innovations relating to myopia by reading recent patents and patent applications. Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.23 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available to patients with myopia within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available to patients with myopia. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information.
23Adapted
from The U. S. Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
96 Myopia
Patents on Myopia By performing a patent search focusing on myopia, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an example of the type of information that you can expect to obtain from a patent search on myopia: ·
Myopia lens Inventor(s): Kris; Dimitrios Jack (South Autralia, AU), Edwards; Simon John (South Australia, AU), Fisher; Scott Warren (South Australia, AU), Pavy; Simon John (South Australia, AU), Varnas; Saulius Raymond (South Australia, AU), Kris; Dimitrios Jack (South Autralia, AU), Edwards; Simon John (South Australia, AU), Fisher; Scott Warren (South Australia, AU), Pavy; Simon John (South Australia, AU), Varnas; Saulius Raymond (South Australia, AU) Assignee(s): Sola International Holdings, Ltd. (Lonsdale, AU), Sola International Holdings, Ltd. (Lonsdale, AU) Patent Number: 6,343,861 Date filed: February 26, 2001 Abstract: A progressive ophthalmic lens element including a lens surface having an upper viewing zone having a surface to achieve a refracting power corresponding to distance vision, a lower viewing zone having a greater surface power than the upper viewing zone to achieve a refracting power corresponding to near vision, and an intermediate zon extending across the lens element having a surface power varying from that of the upper viewing zone to that of the lower viewing zone and including a corridor of relatively low surface astigmatism, the progressive ophthalmic lens element including progressive design elements selected to reduce myopia progression. Excerpt(s): The present invention relates to a progressive ophthalmic lens and in particular to a progressive ophthalmic lens designed to reduce the rate of juvenile myopia progression, and to a process for producing such lenses. ... The present invention relates to a progressive ophthalmic lens and in particular to a progressive ophthalmic lens designed to reduce the rate of juvenile myopia progression, and to a process for producing such
Patents 97
lenses. ... Myopia, or short-sightedness, is a condition of the eye in which parallel rays of light come to a focus in front of the retina. The condition is generally corrected utilising a diverging lens. In many countries, particularly those in the Asian region, the rate of myopia progression is significant, particularly in children, with a rate between -1.25 Dioptre (D)/yr to -2.00 D/yr. This results in a very high proportion of the population with high levels of myopia. Many countries have accordingly embarked on research programs to determine suitable methods of reducing the rate of myopia progression, but with limited success. ... Myopia, or short-sightedness, is a condition of the eye in which parallel rays of light come to a focus in front of the retina. The condition is generally corrected utilising a diverging lens. In many countries, particularly those in the Asian region, the rate of myopia progression is significant, particularly in children, with a rate between -1.25 Dioptre (D)/yr to -2.00 D/yr. This results in a very high proportion of the population with high levels of myopia. Many countries have accordingly embarked on research programs to determine suitable methods of reducing the rate of myopia progression, but with limited success. ... Numerous progressive lenses are known in the prior art. Progressive lenses have heretofore been designed on the basis that they have distance, near and intermediate viewing zones. The intermediate zone joins the near and distance zones in a cosmetically acceptable way, in the sense that no discontinuities in the lens should be visible to people observing the lens of the wearer. The design of the intermediate zone is based on a line called the "eye path" along which the optical power of the lens increases more or less uniformly. However, progressive lens designs, whilst in certain cases tailored for wearers suffering from myopia (see International Patent Application PCT/EP97/00105 to Applicants) have heretofore not been applied to juvenile wearers, nor to the problem of juvenile myopia progression. ... Numerous progressive lenses are known in the prior art. Progressive lenses have heretofore been designed on the basis that they have distance, near and intermediate viewing zones. The intermediate zone joins the near and distance zones in a cosmetically acceptable way, in the sense that no discontinuities in the lens should be visible to people observing the lens of the wearer. The design of the intermediate zone is based on a line called the "eye path" along which the optical power of the lens increases more or less uniformly. However, progressive lens designs, whilst in certain cases tailored for wearers suffering from myopia (see International Patent Application PCT/EP97/00105 to Applicants) have heretofore not been applied to juvenile wearers, nor to the problem of juvenile myopia progression. Web site: http://www.delphion.com/details?pn=US06343861__
98 Myopia
·
Corneal contact lens and method for treating myopia Inventor(s): Stoyan; Nick (3841 Diamante Pl., Encino, CA 91436) Assignee(s): none reported Patent Number: 5,191,365 Date filed: August 23, 1991 Abstract: A corneal contact lens for use in treating myopia by controlled corneal molding. The lens includes a central zone having a central zone radius of curvature and a tear zone. The tear zone is located concentrically around the central zone and has a radius of curvature which is smaller than the central zone. A transition zone is provided between the central zone and the tear zone wherein the transition zone has at least one transition ring. The lens may also include a peripheral zone which is located concentrically around the tear zone wherein the peripheral zone includes multiple peripheral curves having radii of curvature equal to or greater than the central zone. Excerpt(s): The present invention relates generally to corneal contact lenses and their use in treating myopia. More particularly, the present invention is directed to corneal contact lenses which are shaped to provide gradual altering of the patient's cornea during continued wear to reshape the cornea to reduce the myopic condition. ... Myopia, also known as nearsightedness, is a condition where the radius of curvature of the cornea is smaller than normal. Individuals with this condition have difficulty in focusing on distant objects because the cornea is curved too sharply to provide adequate focusing. Myopia is a common condition for which no entirely suitable permanent treatment has been developed. ... One approach to correcting myopia is through surgical reshaping of the cornea. However, such surgical procedures have not been entirely proven and there is some question as to the permanency of the surgically altered lens shape. Web site: http://www.delphion.com/details?pn=US05191365__
Patents 99
·
Composition for treatment of progressive myopia Inventor(s): Avetisov; Eduard S. (ulitsa Ramenki, II, korpus 3, kv. 629, Moscow, SU), Vinetskaya; Maya I. (I6 Parkovaya ulitsa, 49, korpus I, kv. 8, Moscow, SU), Iomdina; Elena N. (I Parkovaya ulitsa, I/5I, kv. 34, Moscow, SU), Boltaeva; Zulfia K. (ulitsa Druzhby narodov, 8a, kv. 27, Tashkent, SU), Khromov; Gennady L. (2-aya Frunzenskaya ulitsa, I0, kv. I00, Moscow, SU), Dolgopyatova; Antonina A. (ulitsa Karla Marxa, 20, kv. I78, Moscow, SU), Davydov; Anatoly B. (ulitsa Krasny Kazanets, I9, korpus I, kv. 283, Moscow, SU), Tarutta; Elena P. (ulitsa Volgina, I9, kv. 28, Moscow, SU), Andreeva; Ljudmila D. (Nagatinskaya naberezhnaya, 34, kv. I89, Moscow, SU), Avetisov; Eduard S. (ulitsa Ramenki, II, korpus 3, kv. 629, Moscow, SU), Vinetskaya; Maya I. (I6 Parkovaya ulitsa, 49, korpus I, kv. 8, Moscow, SU), Iomdina; Elena N. (I Parkovaya ulitsa, I/5I, kv. 34, Moscow, SU), Boltaeva; Zulfia K. (ulitsa Druzhby narodov, 8a, kv. 27, Tashkent, SU), Khromov; Gennady L. (2-aya Frunzenskaya ulitsa, I0, kv. I00, Moscow, SU), Dolgopyatova; Antonina A. (ulitsa Karla Marxa, 20, kv. I78, Moscow, SU), Davydov; Anatoly B. (ulitsa Krasny Kazanets, I9, korpus I, kv. 283, Moscow, SU), Tarutta; Elena P. (ulitsa Volgina, I9, kv. 28, Moscow, SU), Andreeva; Ljudmila D. (Nagatinskaya naberezhnaya, 34, kv. I89, Moscow, SU) Assignee(s): none reported, none reported Patent Number: 5,075,105 Date filed: April 23, 1991 Abstract: The invention relates to medicine.A composition for treatment of progressive myopia is composed of the following constituents, taken in mass percent: Excerpt(s): The present invention relates to medicine and more specifically a composition for treatment of progressive myopia. ... The present invention relates to medicine and more specifically a composition for treatment of progressive myopia. ... At present a complex of therapeutic measures applied against progressive myopia involves various methods aimed at reinforcing the posterior pole of the eyeball. Alongside with conventional surgical methods search for new methods and means for operationless effects upon the sclera aimed at directional correction of the myopic process proves to be the currently central problem. ... At present a complex of therapeutic measures applied against progressive myopia involves various methods aimed at reinforcing the posterior pole of the eyeball. Alongside with conventional surgical methods search for new methods and means for operationless effects upon the sclera aimed at directional correction of the myopic process proves to be the currently central problem. ... One state-of-the-art
100 Myopia
medicinal agent for treatment of progressive myopia (SU, A, 1,156,680; Ophthalmological Herald, 1985, Moscow, Meditsina Publishers, vol. 101, No. 2, pp. 31-36) is known to appear as a foaming gel-like composition, incorporating a dry mixture of polyvinylpyrrolidone, acrylamidehydrazide, and ethylacrylate, and a dissolving mixture, consisting of ferrous chloride, cupric citrate, boric acid, hydrochloric acid, and distilled water, as well as an activator, i.e., a 3-percent hydrogen peroxide that promotes foaming of the composition. The aforesaid composition is injected under the Tenon's capsule to establish an elastic foamed gel on the scleral surface, which while being gradually replaced by the freshly formed connective tissue, adds to the strength characteristics of the sclera. However, the studies performed have demonstrated that formation of a connective capsule on the scleral surface and a process of its reinforcing occur at a relative slow rate, which is accounted for by a definite formulation of said composition, whose active components stimulate the synthesis of collagen and provide for its structural stability. ... One state-of-the-art medicinal agent for treatment of progressive myopia (SU, A, 1,156,680; Ophthalmological Herald, 1985, Moscow, Meditsina Publishers, vol. 101, No. 2, pp. 31-36) is known to appear as a foaming gel-like composition, incorporating a dry mixture of polyvinylpyrrolidone, acrylamide-hydrazide, and ethylacrylate, and a dissolving mixture, consisting of ferrous chloride, cupric citrate, boric acid, hydrochloric acid, and distilled water, as well as an activator, i.e., a 3-percent hydrogen peroxide that promotes foaming of the composition. The aforesaid composition is injected under the Tenon's capsule to establish an elastic foamed gel on the scleral surface, which while being gradually replaced by the freshly formed connective tissue, adds to the strength characteristics of the sclera. However, the studies performed have demonstrated that formation of a connective capsule on the scleral surface and a process of its reinforcing occur at a relative slow rate, which is accounted for by a definite formulation of said composition, whose active components stimulate the synthesis of collagen and provide for its structural stability. Web site: http://www.delphion.com/details?pn=US05075105__
Patents 101
·
Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin Inventor(s): Lee; Yong-Hee (Daejeon, KR), Choi; Yun-Jeong (Daejeon, KR), Seo; Mi-Kyeong (Daejeon, KR), Lee; Chang-Ho (Daejeon, KR), Kim; In-Chull (Daejeon, KR) Assignee(s): LG Chemical Ltd. (Seoul, KR) Patent Number: 5,814,638 Date filed: October 2, 1996 Abstract: An ophthalmic formulation for treating myopia, which comprises a dopamine agonist and cyclodextrin or its derivative in combination with a pharmaceutically acceptable carrier. Excerpt(s): The present invention relates to an ophthalmic formulation for treating myopia, which comprises a dopamine agonist and cyclodextrin or its derivative in combination with a pharmaceutically acceptable carrier. ... It has been estimated that about every fourth person on earth suffers from myopia and that about one-half or more of those are axial myopia caused by elongation of the eye along the visual axis. At birth, the human eye is about two-thirds the adult size and is relatively short in the axial direction. As a consequence, young children tend to be farsighted. As the eye grows during childhood, there occurs compensatory fine tuning of the optical properties of the cornea and lens to the increasing ocular length. Often the entire process takes place virtually flawlessly and the eye becomes emmetropic. When this fine tuning process fails, it usually brings about a lengthened eye. As a result, distant images get focused in front of the plane of the retina and axial myopia results(Josh Wallman, Retinal Control of Eye Growth and Refraction, Progress in Retinal Research, 12, 133-153(1993); and R. A. Stone et al., U.S. Pat. No. 5,284,843, filed on Apr. 10, 1991). ... Hitherto, many theories have been put forth to explain the development of myopia. There is now a substantial evidence to link the function of the posterior part of the eye, especially image quality at the retina and hence the nervous system, to the postnatal regulation of ocular growth(R. A. Stone et al., Postnatal Control of Ocular Growth: Dopaminergic Mechanisms, Ciba Foundation Symposium 155, 45-62(1990)). For example, there is an evidence that myopia develops in an eye when it is subjected to retinal image degradation; Josh Wallman has reported that axial myopia can be experimentally induced in either birds or primates, when the retina is deprived of formed images, e.g., by suturing eyelids(Progress in Retinal Research, 12, 133-153(1993)). The experimental myopia induced in primates such as monkeys precisely mimics human axial myopia. Thus,
102 Myopia
the vision process is apparently involved in the feedback mechanism which regulates the postnatal ocular growth. Web site: http://www.delphion.com/details?pn=US05814638__ ·
High myopia anterior chamber lens with anti-glare mask Inventor(s): Kelman; Charles D. (721 Fifth Ave., New York, NY 10022) Assignee(s): none reported Patent Number: 5,769,889 Date filed: September 5, 1996 Abstract: A two piece anterior chamber artificial intraocular lens for treating high myopia conditions by implantation in an eye after extracapsular removal of the natural eye lens is disclosed. The two-piece assembly is inserted through a minimum size incision in the eye. The lens includes a lens body or optic and a separate ring-shaped tension frame therefor containing light masking means for inhibiting light rays directed toward the outer edge portions of the lens body from being scattered thereby toward the retina after the assembled lens has been inserted into the eye. The lens body or optic is generally circular and conveniently made of shape retaining plastic. The optic is generally smaller than the diameter of a pupil dilated for night vision, and is surrounded by a snugly fitting annular opaque or semi-opaque ring or frame having a Cshaped cross section and a peripherally extending fin of the same material. The fin is preferably formed of flexible material which is bent during insertion to allow insertion of the two-piece assembly through a minimal size corneal incision. The lens is also provided with position fixation means, such as haptics, which are integrally formed with the lens body and extend outward in the generally horizontal plane of the lens body for seating the lens in the eye. The ring-shaped frame is preferably mated with the lens during manufacturing. Excerpt(s): Intraocular lenses for high myopia conditions generally have a thickened peripheral portion. However, as the diameter of the lens is increased so as to avoid glare conditions, there is a danger that the thickened peripheral portion will come in contact with the inner surface of the cornea, resulting in potential injury. Alternatively, the diameter of the optic or lens body may be reduced in order to avoid the abovementioned peripheral contact. However, in this latter situation, the optic will be smaller than the pupil in its dilated condition, resulting in glare caused by the light being reflected from the edge of the smaller diameter optic. ... It is yet another object of the present invention to provide a two piece anterior chamber intraocular lens for treating high myopia
Patents 103
conditions, and which does not present the danger of contacting the inner surface of the cornea, while at the same time not causing any glare. ... The present invention relates to a two piece anterior chamber intraocular lens, and more particularly to an artificial intraocular lens for treating high myopia conditions by implantation in an eye, such as in the anterior chamber, after extracapsular removal of the natural eye lens. The twopiece assembly is inserted through a minimum size incision in the eye. The lens includes a lens body or optic and a separate ring-shaped tension frame therefor containing light masking means for inhibiting light rays directed toward the outer edge portions of the lens body from being scattered thereby toward the retina after the assembled lens has been inserted into the eye. Web site: http://www.delphion.com/details?pn=US05769889__ ·
Method for treating myopia with an aspheric corneal contact lens Inventor(s): Stoyan; Nick (3841 Diamante Pl., Encino, CA 91436) Assignee(s): none reported Patent Number: 5,428,412 Date filed: August 17, 1993 Abstract: Aspheric corneal contact lenses are used to treat myopia by controlled corneal molding. In one embodiment of the method, the lens includes an asymmetric central zone which provides multiple focusing capability to correct both near and far vision. A tear zone is located concentrically around the central zone. The tear zone is integral with the central zone and has a radius of curvature which is smaller than the central zone. The lens also includes a peripheral zone located concentrically around the tear zone wherein the peripheral zone has a radius of curvature equal to or greater than the central zone. Excerpt(s): The present invention relates generally to corneal contact lenses and their use in treating myopia. More particularly, the present invention is directed to corneal contact lenses which are shaped to provide gradual altering of the patient's cornea during continued wear to reshape the cornea to reduce the myopic condition. ... Myopia, also known as nearsightedness, is a condition where the radius of curvature of the cornea is smaller than normal. Individuals with this condition have difficulty in focusing on distant objects because the cornea the curved too sharply to provide adequate focusing. Myopia is a common condition for which no entirely suitable permanent treatment has been developed. ... One approach to correcting myopia is through surgical reshaping of the cornea. However, such surgical procedures have not been entirely proven
104 Myopia
and there is some question as to the permanency of the surgically altered lens shape. Web site: http://www.delphion.com/details?pn=US05428412__ ·
Multiple focus corneal contact lens and method for treating myopia Inventor(s): Stoyan; Nick (3841 Diamante Pl., Encino, CA 91436) Assignee(s): none reported Patent Number: 5,349,395 Date filed: January 26, 1993 Abstract: A multiple focus corneal contact lens for use in treating myopia by controlled corneal molding. The lens includes an asymmetric central zone which provides multiple focusing capability to correct both near and far vision. The tear zone is located concentrically around the central zone. The tear zone is integral with the central zone and has a radius of curvature which is smaller than the central zone. The lens also includes a peripheral zone located concentrically around the tear zone wherein the peripheral zone has a radius of curvature equal to or greater than the central zone. Excerpt(s): The present invention relates generally to corneal contact lenses and their use in treating myopia. More particularly, the present invention is directed to corneal contact lenses which are shaped to provide gradual altering of the patient's cornea during continued wear to reshape the cornea to reduce the myopic condition. ... Myopia, also known as nearsightedness, is a condition where the radius of curvature of the cornea is smaller than normal. Individuals with this condition have difficulty in focusing on distant objects because the cornea the curved too sharply to provide adequate focusing. Myopia is a common condition for which no entirely suitable permanent treatment has been developed. ... One approach to correcting myopia is through surgical reshaping of the cornea. However, such surgical procedures have not been entirely proven and there is some question as to the permanency of the surgically altered lens shape. Web site: http://www.delphion.com/details?pn=US05349395__
Patents 105
·
Corneal contact lens and method for treating myopia Inventor(s): Stoyan; Nick (3841 Diamante Pl., Encino, CA 91436) Assignee(s): none reported Patent Number: 5,191,365 Date filed: August 23, 1991 Abstract: A corneal contact lens for use in treating myopia by controlled corneal molding. The lens includes a central zone having a central zone radius of curvature and a tear zone. The tear zone is located concentrically around the central zone and has a radius of curvature which is smaller than the central zone. A transition zone is provided between the central zone and the tear zone wherein the transition zone has at least one transition ring. The lens may also include a peripheral zone which is located concentrically around the tear zone wherein the peripheral zone includes multiple peripheral curves having radii of curvature equal to or greater than the central zone. Excerpt(s): The present invention relates generally to corneal contact lenses and their use in treating myopia. More particularly, the present invention is directed to corneal contact lenses which are shaped to provide gradual altering of the patient's cornea during continued wear to reshape the cornea to reduce the myopic condition. ... Myopia, also known as nearsightedness, is a condition where the radius of curvature of the cornea is smaller than normal. Individuals with this condition have difficulty in focusing on distant objects because the cornea is curved too sharply to provide adequate focusing. Myopia is a common condition for which no entirely suitable permanent treatment has been developed. ... One approach to correcting myopia is through surgical reshaping of the cornea. However, such surgical procedures have not been entirely proven and there is some question as to the permanency of the surgically altered lens shape. Web site: http://www.delphion.com/details?pn=US05191365__
106 Myopia
·
Composition for treatment of progressive myopia Inventor(s): Avetisov; Eduard S. (ulitsa Ramenki, II, korpus 3, kv. 629, Moscow, SU), Vinetskaya; Maya I. (I6 Parkovaya ulitsa, 49, korpus I, kv. 8, Moscow, SU), Iomdina; Elena N. (I Parkovaya ulitsa, I/5I, kv. 34, Moscow, SU), Boltaeva; Zulfia K. (ulitsa Druzhby narodov, 8a, kv. 27, Tashkent, SU), Khromov; Gennady L. (2-aya Frunzenskaya ulitsa, I0, kv. I00, Moscow, SU), Dolgopyatova; Antonina A. (ulitsa Karla Marxa, 20, kv. I78, Moscow, SU), Davydov; Anatoly B. (ulitsa Krasny Kazanets, I9, korpus I, kv. 283, Moscow, SU), Tarutta; Elena P. (ulitsa Volgina, I9, kv. 28, Moscow, SU), Andreeva; Ljudmila D. (Nagatinskaya naberezhnaya, 34, kv. I89, Moscow, SU) Assignee(s): none reported Patent Number: 5,075,105 Date filed: April 23, 1991 Abstract: The invention relates to medicine.A composition for treatment of progressive myopia is composed of the following constituents, taken in mass percent: Excerpt(s): The present invention relates to medicine and more specifically a composition for treatment of progressive myopia. ... At present a complex of therapeutic measures applied against progressive myopia involves various methods aimed at reinforcing the posterior pole of the eyeball. Alongside with conventional surgical methods search for new methods and means for operationless effects upon the sclera aimed at directional correction of the myopic process proves to be the currently central problem. ... One state-of-the-art medicinal agent for treatment of progressive myopia (SU, A, 1,156,680; Ophthalmological Herald, 1985, Moscow, Meditsina Publishers, vol. 101, No. 2, pp. 31-36) is known to appear as a foaming gel-like composition, incorporating a dry mixture of polyvinylpyrrolidone, acrylamide-hydrazide, and ethylacrylate, and a dissolving mixture, consisting of ferrous chloride, cupric citrate, boric acid, hydrochloric acid, and distilled water, as well as an activator, i.e., a 3-percent hydrogen peroxide that promotes foaming of the composition. The aforesaid composition is injected under the Tenon's capsule to establish an elastic foamed gel on the scleral surface, which while being gradually replaced by the freshly formed connective tissue, adds to the strength characteristics of the sclera. However, the studies performed have demonstrated that formation of a connective capsule on the scleral surface and a process of its reinforcing occur at a relative slow rate, which is accounted for by a definite formulation of said composition, whose active components stimulate the synthesis of collagen and provide for its structural stability.
Patents 107
Web site: http://www.delphion.com/details?pn=US05075105__ ·
Method and artificial intraocular lens device for the phakic treatment of myopia Inventor(s): Praeger; Donald (41 Yates Blvd., Poughkeepsie, NY 12601) Assignee(s): none reported Patent Number: 4,676,792 Date filed: November 10, 1986 Abstract: The placing of an artificial intraocular lens device (IOL) in the anterior chamber of the eye (in front of the iris) for treating myopia. The intraocular lens device includes a meniscus style lens which has a plano anterior surface and a concave posterior surface. The edges of the lens are rounded off and the peripheral portion of the lens is considerably thicker than the central portion of the lens. The lens is a minus (negative) refracting lens. The lens is suspended in the anterior chamber by three or four carrying angles or haptics having solid footplates at their ends for anchoring the device in the anatomic angle of the eye. The solid footplates are sized to prevent tissue overgrowth and resulting synechia after placement, additionally facilitating subsequent removal of the lens device from the anterior chamber if necessary. A ridges lens glide is also provided to facilitate insertion of the lens device into the anterior chamber during implantation. This lens device is utilized in the phakic state (the state of the natural lens being retained). With the patient's natural crystalline lens being retained, the natural crystalline lens is located in the posterior chamber behind the iris and the artificial intraocular lens of negative power is located in the anterior chamber in front of the iris. The presence of the phakic state allows for accommodation to occur. The intended age range for applicability of the device is approximately from age 20-50. Excerpt(s): Presently, the standard technique for the surgical treatment of myopia is a keratorefractive procedure wherein either the shape of the cornea is altered or the refractive index of the cornea is surgically altered. There are many problems associated with this procedure. While many physicians are trained in keratorefaction, relatively few ever perform them and then not often. It thus becomes an intimidating procedure when performed. There are technical difficulties resulting from the microkeratome, the computer and the cryolathe, and many problems in learning to use the cryolathe. Additionally, there are possible complications such as infection, loss of endothelial cells, penetration and perforation. Moreover, in the best of hands, the predictability rate is only
108 Myopia
about 55 to 65 percent to plus or minus 2 diopters. ... Implantation of an intraocular lens is a general procedure practiced in one form or another by probably 90 percent of the present ophthalmologists. It is a procedure in which they are experienced. Thus, if a successful lens and method for the phakic treatment of myopia could be developed, the incidence of eyes that would be lost or damaged in treating myopia would clearly be reduced. ... Additionally, if a successful lens and method for the phakic treatment of myopia could be developed, the patients would retain their power of accommodation. A 20 year old has an average range of accommodation of about 10 diopters; a 50 year old might have a range of accommodation of about 2.0 diopters. With most accommodation occurring in the anterior lens capsule and with the synkinetic reflex of internal rectus convergence and myosis, a properly vaulted lens would allow for adequate accommodation. Web site: http://www.delphion.com/details?pn=US04676792__
Patent Applications on Myopia As of December 2000, U.S. patent applications are open to public viewing.24 Applications are patent requests which have yet to be granted (the process to achieve a patent can take several years).
Keeping Current In order to stay informed about patents and patent applications dealing with myopia, you can access the U.S. Patent Office archive via the Internet at no cost to you. This archive is available at the following Web address: http://www.uspto.gov/main/patents.htm. Under “Services,” click on “Search Patents.” You will see two broad options: (1) Patent Grants, and (2) Patent Applications. To see a list of granted patents, perform the following steps: Under “Patent Grants,” click “Quick Search.” Then, type “myopia” (or synonyms) into the “Term 1” box. After clicking on the search button, scroll down to see the various patents which have been granted to date on myopia. You can also use this procedure to view pending patent applications concerning myopia. Simply go back to the following Web address: http://www.uspto.gov/main/patents.htm. Under “Services,” click on “Search Patents.” Select “Quick Search” under “Patent Applications.” Then proceed with the steps listed above. 24
This has been a common practice outside the United States prior to December 2000.
Patents 109
Vocabulary Builder Acrylamide: A colorless, odorless, highly water soluble vinyl monomer formed from the hydration of acrylonitrile. It is primarily used in research laboratories for electrophoresis, chromatography, and electron microscopy and in the sewage and wastewater treatment industries. [NIH] Implantation: The insertion or grafting into the body of biological, living, inert, or radioactive material. [EU] Incision: 1. cleft, cut, gash. 2. an act or action of incising. [EU] Perforation: 1. the act of boring or piercing through a part. 2. a hole made through a part or substance. [EU] Reflex: 1; reflected. 2. a reflected action or movement; the sum total of any particular involuntary activity. [EU]
Books 111
CHAPTER 6. BOOKS ON MYOPIA Overview This chapter provides bibliographic book references relating to myopia. You have many options to locate books on myopia. The simplest method is to go to your local bookseller and inquire about titles that they have in stock or can special order for you. Some patients, however, feel uncomfortable approaching their local booksellers and prefer online sources (e.g. www.amazon.com and www.bn.com). In addition to online booksellers, excellent sources for book titles on myopia include the Combined Health Information Database and the National Library of Medicine. Once you have found a title that interests you, visit your local public or medical library to see if it is available for loan.
The National Library of Medicine Book Index The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, http://locatorplus.gov/, and then select “Search LOCATORplus.” Once you are in the search area, simply type “myopia” (or synonyms) into the search box, and select “books only.” From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine:25 In addition to LOCATORPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a “Books” button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also
25
112 Myopia
·
Accommodation, nearwork, and myopia. Author: Editha Ong, Kenneth J. Ciuffreda; Year: 1997; Santa Ana, CA: Optometric Extension Program Foundation, c1997; ISBN: 0943599881 (alk. paper) http://www.amazon.com/exec/obidos/ASIN/0943599881/icongroupin terna
·
Art of LASIK. Author: [edited by] Jeffrey J. Machat, Stephen G. Slade, Louis E. Probst; Year: 1999; Thorofare, NJ: SLACK, Inc., c1999; ISBN: 1556423861 (alk. paper) http://www.amazon.com/exec/obidos/ASIN/1556423861/icongroupin terna
·
Atlas of posterior fundus changes in pathologic myopia. Author: Takashi Tokoro; Year: 1998; Tokyo; New York: Springer, c1998; ISBN: 4431702253 (hard: alk. paper) http://www.amazon.com/exec/obidos/ASIN/4431702253/icongroupin terna
·
Care of the patient with myopia: reference guide for clinicians. Author: prepared by the American Optometric Association, Consensus Panel on Care of the Patient with Myopia; David A. Goss, principal author ... [et al.]; Year: 1997; St. Louis, MO: American Optometric Association, [1997?]
·
Clinical management of myopia. Author: Theodore Grosvenor, David A. Goss; with a foreword by Henry W Hofstetter; Year: 1999; Boston: Butterworth-Heinemann, c1999; ISBN: 0750670606 (alk. paper) http://www.amazon.com/exec/obidos/ASIN/0750670606/icongroupin terna
·
Complex cases with LASIK: advanced techniques and complication management. Author: [edited by] Louis E. Probst; Year: 2000; Thorofare, NJ: SLACK, c2000; ISBN: 1556424043 http://www.amazon.com/exec/obidos/ASIN/1556424043/icongroupin terna
·
Excimer laser in ophthalmology: a state-of-knowledge update. Author: Conseil d'évaluation des technologies de la santé du Québec; Year: 2000; Montréal, Québec: The Conseil, [2000]; ISBN: 2550370287
·
Excimer laser photorefractive keratectomy: the correction of myopia and astigmatism; report submitted to the Minister of Health and Social Services of Québec. Author: Grosvenor, Theodore P; Year: 1997;
found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. Currently, the majority of the links are between the books and PubMed. In the future, more links will be created between the books and other types of information, such as gene and protein sequences and macromolecular structures. See http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.
Books 113
Montréal, Québec: Conseil d'évaluation des technologies de la santé du Québec, [1997]; ISBN: 2550326105 ·
Excimer laser refractive surgery: practice and principles. Author: [edited by] Jeffery J. Machat; Year: 1996; Thorofare, NJ: Slack, c1996; ISBN: 15556422741 (alk. paper)
·
Fourth International Conference on Myopia, March 14, 15, and 16, 1990. Author: sponsored by the Myopia International Research Foundation, Inc; Year: 1990; New York, NY, USA: The Foundation, c1990; ISBN: 1879037009
·
Guide to the optometric training of myopia control. Author: Sonja Collier-Vanhimbeeck; Year: 1997; Santa Ana, CA: Optometric Extension Program Foundation, c1997; ISBN: 0943599946 http://www.amazon.com/exec/obidos/ASIN/0943599946/icongroupin terna
·
Help for progressive myopes: the result of forty-six years ophthalmic research into causes and nutritional management of progressive myopia. Author: by Stanley C. Evans; Year: 1990; Suffolk: Teecoll Publications, 1990; ISBN: 0710900279
·
Myopia: prevalence and progression. Author: Working Group on Myopia Prevalence and Progression, Committee on Vision, Commission on Behavioral and Social Sciences and Education, National Research Council; Year: 1989; Washington, D.C.: National Academy Press, 1989; ISBN: 0309040817 http://www.amazon.com/exec/obidos/ASIN/0309040817/icongroupin terna
·
Myopia and nearwork. Author: [edited by] Mark Rosenfield, Bernard Gilmartin; with a foreword by Ernst Goldsmith; Year: 1998; Oxford; Boston: Butterworth-Heinemann, 1998; ISBN: 0750637846 http://www.amazon.com/exec/obidos/ASIN/0750637846/icongroupin terna
·
Myopia and the control of eye growth. Author: Waring, George O., 1941-; Year: 1990; Chichester; New York: Wiley, 1990; ISBN: 0471926922 http://www.amazon.com/exec/obidos/ASIN/0471926922/icongroupin terna
·
Myopia surgery: anterior and posterior segments. Author: editor, Frank B. Thompson; Year: 1990; New York: Macmillan Pub. Co., c1990 [1989 printing]; ISBN: 0024206105 http://www.amazon.com/exec/obidos/ASIN/0024206105/icongroupin terna
114 Myopia
·
Myopia updates: proceedings of the 6th International Conference on Myopia. Author: T. Tokoro (ed.); Year: 1998; Tokyo; New York: Springer, c1998; ISBN: 4431701990 (hardcover: alk. paper) http://www.amazon.com/exec/obidos/ASIN/4431701990/icongroupin terna
·
Myopia updates II: proceedings of the 7th International Conference on Myopia, 1998. Author: L.L.-K. Lin, Y.-F. Shih, P.T. Hung (eds); Year: 2000; Tokyo; New York: Springer, c2000; ISBN: 443170275X (soft cover: alk. paper) http://www.amazon.com/exec/obidos/ASIN/443170275X/icongroupi nterna
·
Myopias: basic science and clinical management. Author: Brian J. Curtin; Year: 1985; Philadelphia: Harper & Row, c1985; ISBN: 0061406724 http://www.amazon.com/exec/obidos/ASIN/0061406724/icongroupin terna
·
Near sight, treated by atropia: with tables. Author: by Hasket Derby ..; Year: 1875; New York: [s.n.], 1875
·
Optometric management of nearpoint vision disorders. Author: Martin H. Birnbaum; Year: 1993; Boston: Butterworth-Heinemann, c1993; ISBN: 075069193X (alk. paper) http://www.amazon.com/exec/obidos/ASIN/075069193X/icongroupi nterna
·
Orthokeratology handbook. Author: Todd D. Winkler, Rodger T. Kame; Year: 1995; Boston: Butterworth-Heinemann, c1995; ISBN: 0750695951 (alk. paper) http://www.amazon.com/exec/obidos/ASIN/0750695951/icongroupin terna
·
Personalizing RK. Author: Paul S. Koch, David M. Dillman; Year: 1996; Thorofare, NJ: Slack, c1996; ISBN: 1556422768 http://www.amazon.com/exec/obidos/ASIN/1556422768/icongroupin terna
·
Proceedings of the Fifth International Conference on Myopia: Toronto, June 22, 23, and 24, 1994. Author: Myopia International Research Foundation, Inc; Year: 1995; New York: The Foundation, c1995
·
Proceedings of the Third International Conference on Myopia. Author: sponsored by Myopia International Research Foundation. Inc; Year: 1987; New York, N.Y., U.S.A. (1265 Broadway, New York 10001): The Foundation, c1987
Books 115
·
Proceedings. Author: Second International Conference on Myopia, October 28, 29, and 30, 1982; Year: 1983; New York, N.Y.: Myopia International Research Foundation, c1983
·
Radial keratotomy: surgical techniques. Author: Robert F. Hofmann ... [et al.]; edited by Donald R. Sanders; Year: 1986; Thorofare, N.J.: Slack, c1986; ISBN: 0943432987 http://www.amazon.com/exec/obidos/ASIN/0943432987/icongroupin terna
·
Refractive anomalies: research and clinical applications. Author: edited by Theodore Grosvenor, Merton C. Flom; with 27 contributors; Year: 1991; Boston: Butterworth-Heinemann, c1991; ISBN: 0409901490 (alk. paper) http://www.amazon.com/exec/obidos/ASIN/0409901490/icongroupin terna
·
Refractive keratotomy for myopia and astigmatism. Author: George O. Waring III; Year: 1992; St. Louis: Mosby Year Book, c1992; ISBN: 0801653495 http://www.amazon.com/exec/obidos/ASIN/0801653495/icongroupin terna
·
Refractive lamellar keratoplasty. Author: [edited by] George W. Rozakis; Year: 1994; Thorofare, NJ: Slack Inc., 1994; ISBN: 1556422296 http://www.amazon.com/exec/obidos/ASIN/1556422296/icongroupin terna
Chapters on Myopia Frequently, myopia will be discussed within a book, perhaps within a specific chapter. In order to find chapters that are specifically dealing with myopia, an excellent source of abstracts is the Combined Health Information Database. You will need to limit your search to book chapters and myopia using the “Detailed Search” option. Go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find book chapters, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Book Chapter.” By making these selections and typing in “myopia” (or synonyms) into the “For these words:” box, you will only receive results on chapters in books. The following is a typical result when searching for book chapters on myopia:
116 Myopia
·
Genetic Hearing Loss Associated with Eye Disorders Source: in Gorlin, R.J.; Toriello, H.V.; Cohen, M.M., Jr., eds. Hereditary Hearing Loss and Its Syndromes. New York, NY: Oxford University Press. 1995. p. 105-140. Contact: Available from Oxford University Press. 200 Madison Avenue, New York, NY 10016. (800) 334-4249 or (212) 679-7300. PRICE: $195.00 plus shipping and handling. ISBN: 0195065522. Summary: This chapter, from a text on hereditary hearing loss and its syndromes, discusses genetic hearing loss associated with eye disorders. Conditions covered include Usher syndrome (retinitis pigmentosis and sensorineural hearing loss); Alstrom syndrome; Edwards syndrome; retinitis pigmentosa, nystagmus, hemiplegic migraine, and sensorineural hearing loss; retinitis pigmentosa, vitiligo, and sensorineural hearing loss; Hersh syndrome; choroideremia, obesity, and congenital sensorineural hearing loss; Refsum syndrome; infantile Refsum syndrome; inverse retinitis pigmentosa, hypogonadism, and sensorineural hearing loss; miscellaneous disorders of pigmentary retinopathy and sensorineural hearing loss; myopia and congenital sensorineural hearing loss; Marshall syndrome; Holmes-Schepens syndrome; Harboyan syndrome; familial band keratopathy, abnormal calcium metabolism, and hearing loss; Ehlers-Danlos syndrome, type IV; corneal anesthesia, retinal abnormalities, mental retardation, unusual facies, and sensorineural hearing loss; DeHauwere syndrome; Abruzzo-Erickson syndrome; aniridia and sensorineural hearing loss; congenital total color blindness, cataracts, hyperinsulinism, and sensorineural hearing loss; total color blindness, liver degeneration, endocrine dysfunction, and sensorineural hearing loss; rod-cone dystrophy, renal dysfunction, and sensorineural hearing loss; OHAHA syndrome; IVIC syndrome; cataracts and progressive sensorineural hearing loss; Ohdo syndrome; Michels syndrome; Fraser syndrome; ocular albinism with late-onset sensorineural hearing loss; Norrie syndrome; Gernet syndrome; Jensen syndrome; Berk-Tabatznik syndrome; and Mohr-Mageroy syndrome. For each condition discussed, the author covers the ocular system involvement, the auditory system, laboratory findings, pathology, heredity, diagnosis, and prognosis. References are included in each section. 23 figures. 4 tables. 346 references.
·
Common Refractive Errors (Ametropias) and Deafness Source: in Johnson, D.D. Deafness and Vision Disorders: Anatomy and Physiology, Assessment Procedures, Ocular Anomalies, and Educational
Books 117
Implications. Springfield, IL: Charles C. Thomas Publisher, Ltd. 1999. p. 224-264. Contact: Available from Charles C. Thomas Publisher, Ltd. 2600 South First Street, Springfield, IL 62794-9265. (800) 258-8980 or (217) 789-8980. Fax (217) 789-9130. PRICE: $74.95 plus shipping and handling. ISBN: 039806945X. Summary: Refractive errors are functional optical (eye) defects in which the parallel light rays from the environment, after passing through the eye's transparent substances, are not brought to a sharp focus precisely on the retina when the eye is unaccommodated; hence, the retinal images are blurred. This chapter on refractive errors (ametropias) is from a textbook written to help students preparing for work in the field of deafness to understand and incorporate an awareness of vision disorders in the deaf population. The information concerning the congenital anomalies, functional defects, and pathologic ocular conditions most often found within a deaf student population was obtained from eleven years of research unobtrusively conducted within the NTID Eye and Ear Clinic between August 1984 and May 1995 (at the National Technical Institute for the Deaf, one of the eight colleges of the Rochester Institute of Technology). This chapter deals specifically with those refractive errors common in this population: myopia (nearsightedness), hyperopia (farsightedness), astigmatism, or a combination thereof. For each condition, the author provides definitions and general comments, classification issues, etiology, and the statistics for the condition in the NTID population. Refractive errors were by far the most common ocular disorders found among NTID deaf students, ranging from approximately 40 percent of the total population of students (n = 3190) entering NTID to about 85 percent of those 756 students seen in the NTID Eye and Ear Clinic. 12 tables. 57 references.
General Home References In addition to references for myopia, you may want a general home medical guide that spans all aspects of home healthcare. The following list is a recent sample of such guides (sorted alphabetically by title; hyperlinks provide rankings, information, and reviews at Amazon.com): · American College of Physicians Complete Home Medical Guide (with Interactive Human Anatomy CD-ROM) by David R. Goldmann (Editor), American College of Physicians; Hardcover - 1104 pages, Book & CD-Rom edition (1999), DK Publishing; ISBN: 0789444127; http://www.amazon.com/exec/obidos/ASIN/0789444127/icongroupinterna
118 Myopia
· The American Medical Association Guide to Home Caregiving by the American Medical Association (Editor); Paperback - 256 pages 1 edition (2001), John Wiley & Sons; ISBN: 0471414093; http://www.amazon.com/exec/obidos/ASIN/0471414093/icongroupinterna · Anatomica : The Complete Home Medical Reference by Peter Forrestal (Editor); Hardcover (2000), Book Sales; ISBN: 1740480309; http://www.amazon.com/exec/obidos/ASIN/1740480309/icongroupinterna · The HarperCollins Illustrated Medical Dictionary : The Complete Home Medical Dictionary by Ida G. Dox, et al; Paperback - 656 pages 4th edition (2001), Harper Resource; ISBN: 0062736469; http://www.amazon.com/exec/obidos/ASIN/0062736469/icongroupinterna · Mayo Clinic Guide to Self-Care: Answers for Everyday Health Problems by Philip Hagen, M.D. (Editor), et al; Paperback - 279 pages, 2nd edition (December 15, 1999), Kensington Publishing Corp.; ISBN: 0962786578; http://www.amazon.com/exec/obidos/ASIN/0962786578/icongroupinterna · The Merck Manual of Medical Information : Home Edition (Merck Manual of Medical Information Home Edition (Trade Paper) by Robert Berkow (Editor), Mark H. Beers, M.D. (Editor); Paperback - 1536 pages (2000), Pocket Books; ISBN: 0671027263; http://www.amazon.com/exec/obidos/ASIN/0671027263/icongroupinterna
Vocabulary Builder Albinism: General term for a number of inherited defects of amino acid metabolism in which there is a deficiency or absence of pigment in the eyes, skin, or hair. [NIH] Anesthesia: A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures. [NIH]
Aniridia: A congenital abnormality in which there is only a rudimentary iris. This is due to the failure of the optic cup to grow. Aniridia also occurs in a hereditary form, usually autosomal dominant. [NIH] Auditory: Pertaining to the sense of hearing. [EU] Choroideremia: An X chromosome-linked abnormality characterized by atrophy of the choroid and degeneration of the retinal pigment epithelium causing night blindness. [NIH] Dystrophy: Any disorder arising from defective or faulty nutrition, especially the muscular dystrophies. [EU]
Books 119
Fundus: The interior lining of the eyeball, including the retina, optic disc, and macula; portion of the inner eye that can be seen during an eye examination by looking through the pupil. [NIH] Hypogonadism: A condition resulting from or characterized by abnormally decreased functional activity of the gonads, with retardation of growth and sexual development. [EU] Nystagmus: An involuntary, rapid, rhythmic movement of the eyeball, which may be horizontal, vertical, rotatory, or mixed, i.e., of two varieties. [EU]
Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached. [NIH]
Multimedia 121
CHAPTER 7. MULTIMEDIA ON MYOPIA Overview Information on myopia can come in a variety of formats. Among multimedia sources, video productions, slides, audiotapes, and computer databases are often available. In this chapter, we show you how to keep current on multimedia sources of information on myopia. We start with sources that have been summarized by federal agencies, and then show you how to find bibliographic information catalogued by the National Library of Medicine. If you see an interesting item, visit your local medical library to check on the availability of the title.
Bibliography: Multimedia on Myopia The National Library of Medicine is a rich source of information on healthcare-related multimedia productions including slides, computer software, and databases. To access the multimedia database, go to the following Web site: http://locatorplus.gov/. Select “Search LOCATORplus.” Once in the search area, simply type in myopia (or synonyms). Then, in the option box provided below the search box, select “Audiovisuals and Computer Files.” From there, you can choose to sort results by publication date, author, or relevance. The following multimedia has been indexed on myopia. For more information, follow the hyperlink indicated: ·
Before we are six : pre-school vision screening. Source: sponsored by the National Society for the Prevention of Blindness; United States Productions; Year: 1979; Format: Motion picture; [United States]: United States Productions, [197-?]
122 Myopia
·
Contact lenses. Source: University of the Witwatersrand Dept. of Ophthalmology, the Contact Lens Clinic at the Johannesburg General Hospital; Year: 1970; Format: Motion picture; Johannesburg: The University; [Jersey City, N. J.: for sale by Conrad Berens International Eye Film Library, 1970]
·
Evolution in LASIK. Source: produced by Ophthalmology Interactive in conjunction with ASCRS; Year: 1998; Format: Electronic resource; Boston, MA: Ophthalmology Interactive, c1998
·
Eye surgery for refractive errors . Year: 1986; Format: Slide; [Columbus, Ohio]: Center for Continuing Medical Education, the Ohio State University College of Medicine, [1986]
·
Highlights of the XVIIth Congress of the ESCRS, Vienna '99. Source: produced by Ophthalmology Interactive in conjunction with the European Society of Cataract & Refractive Surgeons; Year: 1999; Format: Electronic resource; Boston, MA: Ophthalmology Interactive, c1999
·
Otolaryngology and refractive surgery : breakthroughs and treatments. Source: a presentation of Films for the Humanities & Sciences; ITV, Information Television Network; Year: 2000; Format: Videorecording; Princeton, N.J.: Films for the Humanities and Sciences, c2000
·
Primary care ophthalmology. Source: American Medical Association; Year: 1997; Format: Electronic resource; Newton, MA: SilverPlatter Education, 1997
·
Progressive intercalary staphyloma : 5 year old female with Marfan's syndrome and high myopia (-2500 sph d.): surgical repair with preserved human sclera. Source: Morton F. Goldberg; Year: 1969; Format: Videorecording; [Baltimore]: Goldberg; [Jersey City, N. J.: for loan by Conrad Berens International Eye Film Library, inc., 196-?]
·
Refractive errors and optical aberrations. Source: produced by Medical Illustration and Audiovisual Education, Baylor College of Medicine, Texas Medical Center, Houston, Tex; Year: 1975; Format: Videorecording; Houston, Tex.: Institute of Ophthalmology, c1975
·
Refractive errors. Source: University of Michigan, Medical Center, Independent Study Unit, Dept. of Postgraduate Medicine and Health Professions Education; Year: 1976; Format: Slide; Ann Arbor: The University: [for loan or sale by its Medical Center, Media Library], c1976
·
Refractive surgery in the new millennium : clinical and practice management issues. Source: edited by Marguerite B. McDonald; produced by Ophthalmology Interactive, in cooperation with the American Society of Cataract and Refractive Surger; Year: 1998; Format: Electronic resource; Boston, MA: Ophthalmology Interactive, c1998
Multimedia 123
·
Visual defects in man. Source: David J. Gerrick; Year: 1979; Format: Slide; Lorain, OH: Dayton Lab, c1979
Physician Guidelines and Databases 125
CHAPTER 8. PHYSICIAN GUIDELINES AND DATABASES Overview Doctors and medical researchers rely on a number of information sources to help patients with their conditions. Many will subscribe to journals or newsletters published by their professional associations or refer to specialized textbooks or clinical guides published for the medical profession. In this chapter, we focus on databases and Internet-based guidelines created or written for this professional audience.
NIH Guidelines For the more common diseases, The National Institutes of Health publish guidelines that are frequently consulted by physicians. Publications are typically written by one or more of the various NIH Institutes. For physician guidelines, commonly referred to as “clinical” or “professional” guidelines, you can visit the following Institutes: ·
Office of the Director (OD); guidelines consolidated across agencies available at http://www.nih.gov/health/consumer/conkey.htm
·
National Institute of General Medical Sciences (NIGMS); fact sheets available at http://www.nigms.nih.gov/news/facts/
·
National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines: http://www.nlm.nih.gov/medlineplus/healthtopics.html
·
National Eye Institute (NEI); guidelines available at http://www.nei.nih.gov/publications/publications.htm
126 Myopia
NIH Databases In addition to the various Institutes of Health that publish professional guidelines, the NIH has designed a number of databases for professionals.26 Physician-oriented resources provide a wide variety of information related to the biomedical and health sciences, both past and present. The format of these resources varies. Searchable databases, bibliographic citations, full text articles (when available), archival collections, and images are all available. The following are referenced by the National Library of Medicine:27 ·
Bioethics: Access to published literature on the ethical, legal and public policy issues surrounding healthcare and biomedical research. This information is provided in conjunction with the Kennedy Institute of Ethics located at Georgetown University, Washington, D.C.: http://www.nlm.nih.gov/databases/databases_bioethics.html
·
HIV/AIDS Resources: Describes various links and databases dedicated to HIV/AIDS research: http://www.nlm.nih.gov/pubs/factsheets/aidsinfs.html
·
NLM Online Exhibitions: Describes “Exhibitions in the History of Medicine”: http://www.nlm.nih.gov/exhibition/exhibition.html. Additional resources for historical scholarship in medicine: http://www.nlm.nih.gov/hmd/hmd.html
·
Biotechnology Information: Access to public databases. The National Center for Biotechnology Information conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease: http://www.ncbi.nlm.nih.gov/
·
Population Information: The National Library of Medicine provides access to worldwide coverage of population, family planning, and related health issues, including family planning technology and programs, fertility, and population law and policy: http://www.nlm.nih.gov/databases/databases_population.html
·
Cancer Information: Access to caner-oriented databases: http://www.nlm.nih.gov/databases/databases_cancer.html
Remember, for the general public, the National Library of Medicine recommends the databases referenced in MEDLINEplus (http://medlineplus.gov/ or http://www.nlm.nih.gov/medlineplus/databases.html). 27 See http://www.nlm.nih.gov/databases/databases.html. 26
Physician Guidelines and Databases 127
·
Profiles in Science: Offering the archival collections of prominent twentieth-century biomedical scientists to the public through modern digital technology: http://www.profiles.nlm.nih.gov/
·
Chemical Information: Provides links to various chemical databases and references: http://sis.nlm.nih.gov/Chem/ChemMain.html
·
Clinical Alerts: Reports the release of findings from the NIH-funded clinical trials where such release could significantly affect morbidity and mortality: http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html
·
Space Life Sciences: Provides links and information to space-based research (including NASA): http://www.nlm.nih.gov/databases/databases_space.html
·
MEDLINE: Bibliographic database covering the fields of medicine, nursing, dentistry, veterinary medicine, the healthcare system, and the pre-clinical sciences: http://www.nlm.nih.gov/databases/databases_medline.html
·
Toxicology and Environmental Health Information (TOXNET): Databases covering toxicology and environmental health: http://sis.nlm.nih.gov/Tox/ToxMain.html
·
Visible Human Interface: Anatomically detailed, three-dimensional representations of normal male and female human bodies: http://www.nlm.nih.gov/research/visible/visible_human.html
While all of the above references may be of interest to physicians who study and treat myopia, the following are particularly noteworthy.
The NLM Gateway28 The NLM (National Library of Medicine) Gateway is a Web-based system that lets users search simultaneously in multiple retrieval systems at the U.S. National Library of Medicine (NLM). It allows users of NLM services to initiate searches from one Web interface, providing “one-stop searching” for many of NLM's information resources or databases.29 One target audience for the Gateway is the Internet user who is new to NLM's online resources and does not know what information is available or how best to search for it. This audience may include physicians and other healthcare providers, Adapted from NLM: http://gateway.nlm.nih.gov/gw/Cmd?Overview.x. The NLM Gateway is currently being developed by the Lister Hill National Center for Biomedical Communications (LHNCBC) at the National Library of Medicine (NLM) of the National Institutes of Health (NIH).
28 29
128 Myopia
researchers, librarians, students, and, increasingly, patients, their families, and the public.30 To use the NLM Gateway, simply go to the search site at http://gateway.nlm.nih.gov/gw/Cmd. Type “myopia” (or synonyms) into the search box and click “Search.” The results will be presented in a tabular form, indicating the number of references in each database category. Results Summary Category Items Found Journal Articles 8405 Books / Periodicals / Audio Visual 124 Consumer Health 6 Meeting Abstracts 6 Other Collections 1 Total 8542
HSTAT31 HSTAT is a free, Web-based resource that provides access to full-text documents used in healthcare decision-making.32 HSTAT's audience includes healthcare providers, health service researchers, policy makers, insurance companies, consumers, and the information professionals who serve these groups. HSTAT provides access to a wide variety of publications, including clinical practice guidelines, quick-reference guides for clinicians, consumer health brochures, evidence reports and technology assessments from the Agency for Healthcare Research and Quality (AHRQ), as well as AHRQ's Put Prevention Into Practice.33 Simply search by “myopia” (or synonyms) at the following Web site: http://text.nlm.nih.gov. Other users may find the Gateway useful for an overall search of NLM's information resources. Some searchers may locate what they need immediately, while others will utilize the Gateway as an adjunct tool to other NLM search services such as PubMed® and MEDLINEplus®. The Gateway connects users with multiple NLM retrieval systems while also providing a search interface for its own collections. These collections include various types of information that do not logically belong in PubMed, LOCATORplus, or other established NLM retrieval systems (e.g., meeting announcements and pre-1966 journal citations). The Gateway will provide access to the information found in an increasing number of NLM retrieval systems in several phases. 31 Adapted from HSTAT: http://www.nlm.nih.gov/pubs/factsheets/hstat.html. 32 The HSTAT URL is http://hstat.nlm.nih.gov/. 33 Other important documents in HSTAT include: the National Institutes of Health (NIH) Consensus Conference Reports and Technology Assessment Reports; the HIV/AIDS Treatment Information Service (ATIS) resource documents; the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Treatment (SAMHSA/CSAT) 30
Physician Guidelines and Databases 129
Coffee Break: Tutorials for Biologists34 Some patients may wish to have access to a general healthcare site that takes a scientific view of the news and covers recent breakthroughs in biology that may one day assist physicians in developing treatments. To this end, we recommend “Coffee Break,” a collection of short reports on recent biological discoveries. Each report incorporates interactive tutorials that demonstrate how bioinformatics tools are used as a part of the research process. Currently, all Coffee Breaks are written by NCBI staff.35 Each report is about 400 words and is usually based on a discovery reported in one or more articles from recently published, peer-reviewed literature.36 This site has new articles every few weeks, so it can be considered an online magazine of sorts, and intended for general background information. You can access the Coffee Break Web site at the following hyperlink: http://www.ncbi.nlm.nih.gov/Coffeebreak/.
Other Commercial Databases In addition to resources maintained by official agencies, other databases exist that are commercial ventures addressing medical professionals. Here are a few examples that may interest you: ·
CliniWeb International: Index and table of contents to selected clinical information on the Internet; see http://www.ohsu.edu/cliniweb/.
·
Image Engine: Multimedia electronic medical record system that integrates a wide range of digitized clinical images with textual data stored in the University of Pittsburgh Medical Center's MARS electronic
Treatment Improvement Protocols (TIP) and Center for Substance Abuse Prevention (SAMHSA/CSAP) Prevention Enhancement Protocols System (PEPS); the Public Health Service (PHS) Preventive Services Task Force's Guide to Clinical Preventive Services; the independent, nonfederal Task Force on Community Services Guide to Community Preventive Services; and the Health Technology Advisory Committee (HTAC) of the Minnesota Health Care Commission (MHCC) health technology evaluations. 34 Adapted from http://www.ncbi.nlm.nih.gov/Coffeebreak/Archive/FAQ.html. 35 The figure that accompanies each article is frequently supplied by an expert external to NCBI, in which case the source of the figure is cited. The result is an interactive tutorial that tells a biological story. 36 After a brief introduction that sets the work described into a broader context, the report focuses on how a molecular understanding can provide explanations of observed biology and lead to therapies for diseases. Each vignette is accompanied by a figure and hypertext links that lead to a series of pages that interactively show how NCBI tools and resources are used in the research process.
130 Myopia
medical record system; see the following Web http://www.cml.upmc.edu/cml/imageengine/imageEngine.html.
site:
·
Medical World Search: Searches full text from thousands of selected medical sites on the Internet; see http://www.mwsearch.com/.
·
MedWeaver: Prototype system that allows users to search differential diagnoses for any list of signs and symptoms, to search medical literature, and to explore relevant Web sites; see http://www.med.virginia.edu/~wmd4n/medweaver.html.
·
Metaphrase: Middleware component intended for use by both caregivers and medical records personnel. It converts the informal language generally used by caregivers into terms from formal, controlled vocabularies; see the following Web site: http://www.lexical.com/Metaphrase.html.
The Genome Project and Myopia With all the discussion in the press about the Human Genome Project, it is only natural that physicians, researchers, and patients want to know about how human genes relate to myopia. In the following section, we will discuss databases and references used by physicians and scientists who work in this area.
Online Mendelian Inheritance in Man (OMIM) The Online Mendelian Inheritance in Man (OMIM) database is a catalog of human genes and genetic disorders authored and edited by Dr. Victor A. McKusick and his colleagues at Johns Hopkins and elsewhere. OMIM was developed for the World Wide Web by the National Center for Biotechnology Information (NCBI).37 The database contains textual information, pictures, and reference information. It also contains copious links to NCBI's Entrez database of MEDLINE articles and sequence information. To search the database, go to http://www.ncbi.nlm.nih.gov/Omim/searchomim.html. Type “myopia” (or Adapted from http://www.ncbi.nlm.nih.gov/. Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information--all for the better understanding of molecular processes affecting human health and disease.
37
Physician Guidelines and Databases 131
synonyms) in the search box, and click “Submit Search.” If too many results appear, you can narrow the search by adding the word “clinical.” Each report will have additional links to related research and databases. By following these links, especially the link titled “Database Links,” you will be exposed to numerous specialized databases that are largely used by the scientific community. These databases are overly technical and seldom used by the general public, but offer an abundance of information. The following is an example of the results you can obtain from the OMIM for myopia: ·
Aplasia Cutis Congenita, High Myopia, and Cone-rod Dysfunction Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?601075
·
Blepharoptosis, Myopia, and Ectopia Lentis Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?110150
·
Camptodactyly, Myopia, and Fibrosis of the Medial Rectus Muscle of Eye Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?602612
·
Dandy-walker Malformation with Mental Retardation, Macrocephaly, Myopia, and Brachytelephalangy Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?220219
·
Deafness, Cochlear, with Myopia and Intellectual Impairment Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?221200
·
Diaphragmatic Hernia, Exomphalos, Absent Corpus Hypertelorism, Myopia, and Sensorineural Deafness Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?222448
·
Epiphyseal Dysplasia of Femoral Head, Myopia, and Deafness Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?226950
·
Epiphyseal Dysplasia, Multiple, with Myopia and Conductive Deafness Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?132450
·
Microphthalmos with Myopia and Corectopia Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?156900
Callosum,
132 Myopia
·
Myopia 1 Web site: http://www.ncbi.nlm.nih.gov/htbinpost/Omim/dispmim?310460
Genes and Disease (NCBI - Map) The Genes and Disease database is produced by the National Center for Biotechnology Information of the National Library of Medicine at the National Institutes of Health. This Web site categorizes each disorder by the system of the body associated with it. Go to http://www.ncbi.nlm.nih.gov/disease/, and browse the system pages to have a full view of important conditions linked to human genes. Since this site is regularly updated, you may wish to re-visit it from time to time. The following systems and associated disorders are addressed: ·
Cancer: Uncontrolled cell division. Examples: Breast And Ovarian Cancer, Burkitt lymphoma, chronic myeloid leukemia, colon cancer, lung cancer, malignant melanoma, multiple endocrine neoplasia, neurofibromatosis, p53 tumor suppressor, pancreatic cancer, prostate cancer, Ras oncogene, RB: retinoblastoma, von Hippel-Lindau syndrome. Web site: http://www.ncbi.nlm.nih.gov/disease/Cancer.html
·
Immune System: Fights invaders. Examples: Asthma, autoimmune polyglandular syndrome, Crohn's disease, DiGeorge syndrome, familial Mediterranean fever, immunodeficiency with Hyper-IgM, severe combined immunodeficiency. Web site: http://www.ncbi.nlm.nih.gov/disease/Immune.html
·
Metabolism: Food and energy. Examples: Adreno-leukodystrophy, Atherosclerosis, Best disease, Gaucher disease, Glucose galactose malabsorption, Gyrate atrophy, Juvenile onset diabetes, Obesity, Paroxysmal nocturnal hemoglobinuria, Phenylketonuria, Refsum disease, Tangier disease, Tay-Sachs disease. Web site: http://www.ncbi.nlm.nih.gov/disease/Metabolism.html
·
Nervous System: Mind and body. Examples: Alzheimer disease, Amyotrophic lateral sclerosis, Angelman syndrome, Charcot-Marie-Tooth disease, epilepsy, essential tremor, Fragile X syndrome, Friedreich's ataxia, Huntington disease, NiemannPick disease, Parkinson disease, Prader-Willi syndrome, Rett syndrome, Spinocerebellar atrophy, Williams syndrome. Web site: http://www.ncbi.nlm.nih.gov/disease/Brain.html
Physician Guidelines and Databases 133
·
Signals: Cellular messages. Examples: Ataxia telangiectasia, Baldness, Cockayne syndrome, Glaucoma, SRY: sex determination, Tuberous sclerosis, Waardenburg syndrome, Werner syndrome. Web site: http://www.ncbi.nlm.nih.gov/disease/Signals.html Entrez
Entrez is a search and retrieval system that integrates several linked databases at the National Center for Biotechnology Information (NCBI). These databases include nucleotide sequences, protein sequences, macromolecular structures, whole genomes, and MEDLINE through PubMed. Entrez provides access to the following databases: ·
PubMed: Biomedical literature (PubMed), Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
·
Nucleotide Sequence Database (Genbank): Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide
·
Protein Sequence Database: Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Protein
·
Structure: Three-dimensional macromolecular structures, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Structure
·
Genome: Complete genome assemblies, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Genome
·
PopSet: Population study data sets, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Popset
·
OMIM: Online Mendelian Inheritance in Man, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM
·
Taxonomy: Organisms in GenBank, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Taxonomy
·
Books: Online books, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=books
·
ProbeSet: Gene Expression Omnibus (GEO), Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=geo
·
3D Domains: Domains from Entrez Structure, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=geo
134 Myopia
·
NCBI's Protein Sequence Information Survey Results: Web site: http://www.ncbi.nlm.nih.gov/About/proteinsurvey/
To access the Entrez system at the National Center for Biotechnology Information, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=genom e, and then select the database that you would like to search. The databases available are listed in the drop box next to “Search.” In the box next to “for,” enter “myopia” (or synonyms) and click “Go.”
Jablonski's Multiple Congenital Anomaly/Mental Retardation (MCA/MR) Syndromes Database38 This online resource can be quite useful. It has been developed to facilitate the identification and differentiation of syndromic entities. Special attention is given to the type of information that is usually limited or completely omitted in existing reference sources due to space limitations of the printed form. At the following Web site you can also search across syndromes using an index: http://www.nlm.nih.gov/mesh/jablonski/syndrome_toc/toc_a.html. You can search by keywords at this Web site: http://www.nlm.nih.gov/mesh/jablonski/syndrome_db.html. The Genome Database39 Established at Johns Hopkins University in Baltimore, Maryland in 1990, the Genome Database (GDB) is the official central repository for genomic mapping data resulting from the Human Genome Initiative. In the spring of 1999, the Bioinformatics Supercomputing Centre (BiSC) at the Hospital for Sick Children in Toronto, Ontario assumed the management of GDB. The Human Genome Initiative is a worldwide research effort focusing on structural analysis of human DNA to determine the location and sequence of the estimated 100,000 human genes. In support of this project, GDB stores and curates data generated by researchers worldwide who are engaged in the mapping effort of the Human Genome Project (HGP). GDB's mission is to provide scientists with an encyclopedia of the human genome which is Adapted from the National Library of Medicine: http://www.nlm.nih.gov/mesh/jablonski/about_syndrome.html. 39 Adapted from the Genome Database: http://gdbwww.gdb.org/gdb/aboutGDB.html#mission. 38
Physician Guidelines and Databases 135
continually revised and updated to reflect the current state of scientific knowledge. Although GDB has historically focused on gene mapping, its focus will broaden as the Genome Project moves from mapping to sequence, and finally, to functional analysis. To access the GDB, simply go to the following hyperlink: http://www.gdb.org/. Search “All Biological Data” by “Keyword.” Type “myopia” (or synonyms) into the search box, and review the results. If more than one word is used in the search box, then separate each one with the word “and” or “or” (using “or” might be useful when using synonyms). This database is extremely technical as it was created for specialists. The articles are the results which are the most accessible to non-professionals and often listed under the heading “Citations.” The contact names are also accessible to non-professionals.
Specialized References The following books are specialized references written for professionals interested in myopia (sorted alphabetically by title, hyperlinks provide rankings, information, and reviews at Amazon.com): ·
Clinical Ophthalmic Pathology: Test Yourself by John Harry, Gary Misson; Paperback (January 2004); Butterworth-Heinemann; ISBN: 0750622644; http://www.amazon.com/exec/obidos/ASIN/007137325X/icongroupinterna
·
Dictionary of Ophthalmology by Michel Millodot, Ph.D., Daniel Laby, MD; Paperback, 1st edition (January 15, 2002), Butterworth-Heinemann Medical; ISBN: 0750647973; http://www.amazon.com/exec/obidos/ASIN/0750647973/icongroupinterna
·
Emergency Ophthalmology by Kenneth C. Chern (Editor); Hardcover (October 2002), McGraw Hill Text; ISBN: 007137325X; http://www.amazon.com/exec/obidos/ASIN/007137325X/icongroupinterna
·
The Epidemiology of Eye Disease by Gordon Johnson, et al; Hardcover (January 1999), Lippincott Williams & Wilkins Publishers; ISBN: 0412643103; http://www.amazon.com/exec/obidos/ASIN/0412643103/icongroupinterna
·
The Epidemiology of Eye Disease by Gordon Johnson, et al; Paperback 436 pages, 1st edition (March 15, 1998), Lippincott, Williams & Wilkins Publishers; ISBN: 0412845008; http://www.amazon.com/exec/obidos/ASIN/0412845008/icongroupinterna
136 Myopia
·
External Eye Disease : A Systematic Approach by Ian A. MacKie; Hardcover, Illustrated edition (January 1999), Butterworth-Heinemann; ISBN: 0750617446; http://www.amazon.com/exec/obidos/ASIN/0750617446/icongroupinterna
·
External Eye Disease (Clinical Ophthalmology Slide Set , Vol 2) by Jack J. Kanski; Hardcover, Vol 2 (September 1997), Butterworth-Heinemann Medical; ISBN: 0750626461; http://www.amazon.com/exec/obidos/ASIN/0750626461/icongroupinterna
·
External Eye Disease (Clinical Ophthalmology Photo CD Set , Vol 2) by Jack J. Kanski; Unknown Binding (September 1997), ButterworthHeinemann Medical; ISBN: 0750626941; http://www.amazon.com/exec/obidos/ASIN/0750626941/icongroupinterna
·
The Eye Book: A Complete Guide to Eye Disorders and Health (Large Print) by Gary H. Cassel, M.D., et al; Paperback - 528 pages, 1st edition (February 15, 2001), Johns Hopkins University Press; ISBN: 0801865204; http://www.amazon.com/exec/obidos/ASIN/0801865204/icongroupinterna
·
The Eye: Basic Sciences in Practice by John V. Forrester (Editor), et al; Hardcover - 447 pages, 2nd edition (January 15, 2002), W B Saunders Co; ISBN: 0702025410; http://www.amazon.com/exec/obidos/ASIN/0702025410/icongroupinterna
·
Functional Anatomy and Histology of the Eye by Gordon Ruskell; Hardcover, Illustrate edition (April 2002), Butterworth-Heinemann; ISBN: 0750637749; http://www.amazon.com/exec/obidos/ASIN/0750637749/icongroupinterna
·
The Little Eye Book: A Pupil's Guide to Understanding Ophthalmology by Janice K. Comt Ledford, Roberto Pineda, MD; Paperback - 149 pages, 1st edition (January 15, 2002) Slack, Inc.; ISBN: 1556425600; http://www.amazon.com/exec/obidos/ASIN/1556425600/icongroupinterna
·
Ophthalmic Pocket Companion by Dean Dornic; Paperback, 6th edition (March 15, 2002); Butterworth-Heinemann; ISBN: 0750673818; http://www.amazon.com/exec/obidos/ASIN/0750673818/icongroupinterna
·
Ophthalmology Review Manual by Kenneth C. Chern, Michael E. Zegans (Editors); Paperback (550 pages), 1st edition (2000); Lippincott, Williams & Wilkins; ISBN: 0683303643; http://www.amazon.com/exec/obidos/ASIN/0683303643/icongroupinterna
·
Ophthalmic Research and Epidemiology: Evaluation and Application by Stanley W. Hatch (Editor), Paperback - 298 pages, 1st edition (1998), Butterworth-Heinemann Medical; ISBN: 0750699140; http://www.amazon.com/exec/obidos/ASIN/0750699140/icongroupinterna
Physician Guidelines and Databases 137
·
Ophthalmic Surgery: Principles & Practice by George L. Spaeth; Hardcover (January 2002), W B Saunders Co; ISBN: 0721669727; http://www.amazon.com/exec/obidos/ASIN/0721669727/icongroupinterna
·
Review Questions for Treatment and Management of Ocular Disease (Review Questions) by Gurwood; Paperback (2001), Parthenon Pub Group; ISBN: 1850707502; http://www.amazon.com/exec/obidos/ASIN/1850707502/icongroupinterna
·
The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease by Douglas J. Rhee (Editor), et al; Paperback 563 pages, 3rd edition (March 15, 1999), Lippincott, Williams & Wilkins Publishers; ISBN: 0781716020; http://www.amazon.com/exec/obidos/ASIN/0781716020/icongroupinterna
Vocabulary Builder Aplasia: Lack of development of an organ or tissue, or of the cellular products from an organ or tissue. [EU] Blepharoptosis: Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle. [NIH] Femoral: Pertaining to the femur, or to the thigh. [EU] Fibrosis: The formation of fibrous tissue; fibroid or fibrous degeneration [EU] Hernia: (he protrusion of a loop or knuckle of an organ or tissue through an abnormal opening. [EU] Hypertelorism: Abnormal increase in the interorbital distance due to overdevelopment of the lesser wings of the sphenoid. [NIH] Malformation: A morphologic defect resulting from an intrinsically abnormal developmental process. [EU] Microphthalmos: Congenital or developmental anomaly in which the eyeballs are abnormally small. [NIH]
Dissertations 139
CHAPTER 9. DISSERTATIONS ON MYOPIA Overview University researchers are active in studying almost all known diseases. The result of research is often published in the form of Doctoral or Master's dissertations. You should understand, therefore, that applied diagnostic procedures and/or therapies can take many years to develop after the thesis that proposed the new technique or approach was written. In this chapter, we will give you a bibliography on recent dissertations relating to myopia. You can read about these in more detail using the Internet or your local medical library. We will also provide you with information on how to use the Internet to stay current on dissertations.
Dissertations on Myopia ProQuest Digital Dissertations is the largest archive of academic dissertations available. From this archive, we have compiled the following list covering dissertations devoted to myopia. You will see that the information provided includes the dissertation’s title, its author, and the author’s institution. To read more about the following, simply use the Internet address indicated. The following covers recent dissertations dealing with myopia: ·
Assessing Near Work As a Risk for Myopia: the Better Evaluation of Eye Performance (beep) Study by Jeandervin, Marjorie Kay; Phd from The Ohio State University, 2000, 219 pages http://wwwlib.umi.com/dissertations/fullcit/9971575
140 Myopia
·
Corporate Investment with Myopic Noise Traders (investor Myopia) by Bange, Mary Marguerite, Phd from The University of Wisconsin Madison, 1991, 233 pages http://wwwlib.umi.com/dissertations/fullcit/9128894
·
Corporate Myopia and Firm Performance: an International Comparison by Beldona, Sriram, Phd from Temple University, 1994, 113 pages http://wwwlib.umi.com/dissertations/fullcit/9512805
·
Family Characteristics Related to the Development of Myopia. by Grigsby, Eugene Howard, Phd from Washington State University, 1979, 90 pages http://wwwlib.umi.com/dissertations/fullcit/7915127
·
Financial Management and the 1966 Credit Crunch: a Study of Financial Myopia by Roden, Peyton Foster, Phd from University of North Texas, 1970, 237 pages http://wwwlib.umi.com/dissertations/fullcit/7017985
·
Identity, Appearance, and Corrective Lenswear: Predictors of College Students' Interest in Vision-correcting Myopia Surgery by Stratton, Terry Dean; Phd from University of Kentucky, 1999, 286 pages http://wwwlib.umi.com/dissertations/fullcit/9957056
·
Institutional Investor Myopia, Ownership, Earnings, and Returns by Eames, Michael Joseph, Phd from University of Washington, 1995, 122 pages http://wwwlib.umi.com/dissertations/fullcit/9609635
·
Myopia and Competitive Reputations in De-escalating Promotional Competition: Game Theoretic Intuition Versus Naive Decision-making by Kallianpur, Amy (shanti), Phd from University of Pennsylvania, 1999, 119 pages http://wwwlib.umi.com/dissertations/fullcit/9926149
·
Peak Load with 'too-high' Metering Costs: Optimal Pricing under Myopia. by Oliu, Josep, Phd from University of Minnesota, 1978, 201 pages http://wwwlib.umi.com/dissertations/fullcit/7912059
·
Resolution Preference, Managerial Myopia, and Market Valuation: an Empirical Test by Ryan, Harley Eulin, Jr., Phd from Georgia State University, 1994, 104 pages http://wwwlib.umi.com/dissertations/fullcit/9526899
Dissertations 141
Keeping Current As previously mentioned, an effective way to stay current on dissertations dedicated to myopia is to use the database called ProQuest Digital Dissertations via the Internet, located at the following Web address: http://wwwlib.umi.com/dissertations. The site allows you to freely access the last two years of citations and abstracts. Ask your medical librarian if the library has full and unlimited access to this database. From the library, you should be able to do more complete searches than with the limited 2-year access available to the general public.
143
PART III. APPENDICES
ABOUT PART III Part III is a collection of appendices on general medical topics which may be of interest to patients with myopia and related conditions.
Researching Your Medications 145
APPENDIX A. RESEARCHING YOUR MEDICATIONS Overview There are a number of sources available on new or existing medications which could be prescribed to patients with myopia. While a number of hard copy or CD-Rom resources are available to patients and physicians for research purposes, a more flexible method is to use Internet-based databases. In this chapter, we will begin with a general overview of medications. We will then proceed to outline official recommendations on how you should view your medications. You may also want to research medications that you are currently taking for other conditions as they may interact with medications for myopia. Research can give you information on the side effects, interactions, and limitations of prescription drugs used in the treatment of myopia. Broadly speaking, there are two sources of information on approved medications: public sources and private sources. We will emphasize free-to-use public sources.
Your Medications: The Basics40 The Agency for Health Care Research and Quality has published extremely useful guidelines on how you can best participate in the medication aspects of myopia. Taking medicines is not always as simple as swallowing a pill. It can involve many steps and decisions each day. The AHCRQ recommends that patients with myopia take part in treatment decisions. Do not be afraid to ask questions and talk about your concerns. By taking a moment to ask questions early, you may avoid problems later. Here are some points to cover each time a new medicine is prescribed: 40
This section is adapted from AHCRQ: http://www.ahcpr.gov/consumer/ncpiebro.htm.
146 Myopia
·
Ask about all parts of your treatment, including diet changes, exercise, and medicines.
·
Ask about the risks and benefits of each medicine or other treatment you might receive.
·
Ask how often you or your doctor will check for side effects from a given medication.
Do not hesitate to ask what is important to you about your medicines. You may want a medicine with the fewest side effects, or the fewest doses to take each day. You may care most about cost, or how the medicine might affect how you live or work. Or, you may want the medicine your doctor believes will work the best. Telling your doctor will help him or her select the best treatment for you. Do not be afraid to “bother” your doctor with your concerns and questions about medications for myopia. You can also talk to a nurse or a pharmacist. They can help you better understand your treatment plan. Feel free to bring a friend or family member with you when you visit your doctor. Talking over your options with someone you trust can help you make better choices, especially if you are not feeling well. Specifically, ask your doctor the following: ·
The name of the medicine and what it is supposed to do.
·
How and when to take the medicine, how much to take, and for how long.
·
What food, drinks, other medicines, or activities you should avoid while taking the medicine.
·
What side effects the medicine may have, and what to do if they occur.
·
If you can get a refill, and how often.
·
About any terms or directions you do not understand.
·
What to do if you miss a dose.
·
If there is written information you can take home (most pharmacies have information sheets on your prescription medicines; some even offer large-print or Spanish versions).
Do not forget to tell your doctor about all the medicines you are currently taking (not just those for myopia). This includes prescription medicines and the medicines that you buy over the counter. Then your doctor can avoid giving you a new medicine that may not work well with the medications you take now. When talking to your doctor, you may wish to prepare a list of
Researching Your Medications 147
medicines you currently take, the reason you take them, and how you take them. Be sure to include the following information for each: ·
Name of medicine
·
Reason taken
·
Dosage
·
Time(s) of day
Also include any over-the-counter medicines, such as: ·
Laxatives
·
Diet pills
·
Vitamins
·
Cold medicine
·
Aspirin or other pain, headache, or fever medicine
·
Cough medicine
·
Allergy relief medicine
·
Antacids
·
Sleeping pills
·
Others (include names)
Learning More about Your Medications Because of historical investments by various organizations and the emergence of the Internet, it has become rather simple to learn about the medications your doctor has recommended for myopia. One such source is the United States Pharmacopeia. In 1820, eleven physicians met in Washington, D.C. to establish the first compendium of standard drugs for the United States. They called this compendium the “U.S. Pharmacopeia (USP).” Today, the USP is a non-profit organization consisting of 800 volunteer scientists, eleven elected officials, and 400 representatives of state associations and colleges of medicine and pharmacy. The USP is located in Rockville, Maryland, and its home page is located at www.usp.org. The USP currently provides standards for over 3,700 medications. The resulting USP DIÒ Advice for the PatientÒ can be accessed through the National Library of Medicine of the National Institutes of Health. The database is partially
148 Myopia
derived from lists of federally approved medications in the Food and Drug Administration's (FDA) Drug Approvals database.41 While the FDA database is rather large and difficult to navigate, the Phamacopeia is both user-friendly and free to use. It covers more than 9,000 prescription and over-the-counter medications. To access this database, simply type the following hyperlink into your Web browser: http://www.nlm.nih.gov/medlineplus/druginformation.html. To view examples of a given medication (brand names, category, description, preparation, proper use, precautions, side effects, etc.), simply follow the hyperlinks indicated within the United States Pharmacopoeia (USP). It is important to read the disclaimer by the USP (http://www.nlm.nih.gov/medlineplus/drugdisclaimer.html) before using the information provided. Of course, we as editors cannot be certain as to what medications you are taking. Therefore, we have compiled a list of medications associated with the treatment of myopia. Once again, due to space limitations, we only list a sample of medications and provide hyperlinks to ample documentation (e.g. typical dosage, side effects, drug-interaction risks, etc.). The following drugs have been mentioned in the Pharmacopeia and other sources as being potentially applicable to myopia: Vitamin D and Related Compounds ·
Systemic - U.S. Brands: Calciferol; Calciferol Drops; Calcijex; Calderol; DHT; DHT Intensol; Drisdol; Drisdol Drops; Hectorol; Hytakerol; Rocaltrol; Zemplar http://www.nlm.nih.gov/medlineplus/druginfo/vitamindandrel atedcompoundssys202597.html
Commercial Databases In addition to the medications listed in the USP above, a number of commercial sites are available by subscription to physicians and their institution